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11Introduction and thesis outline
Introduction
Prostate cancer
Prostate cancer (PC) has the highest prevalence of all cancers among men, and is 
responsible for 22% of all newly diagnosed cancers in the Netherlands. The risk of 
developing PC before the age of 80 in the western world is 10%. Although non-me-
tastasized PC has a very good prognosis, PC still is the second leading cause of can-
cer-related death for men in the Western world (6%). In the last two decades, incidence 
of PC has risen remarkably, due to enlarged awareness of the disease, ageing of 
the population, the possibility to locate the tumor with ultrasound and MRI, and the 
introduction of the Prostate Specific Antigen (PSA) test [1]. When detected early, when 
the disease is still localized only in the prostate gland itself, the 5-year survival rate is 
nearly 99%. However, once the cancer has spread beyond the prostate gland, survival 
rates drop dramatically [2]. This highlights the need for sensitive diagnostic and effective 
therapeutic methods for PC.
Diagnosis of prostate cancer
Primary diagnosis
In several countries such as the USA, PSA levels together with digital rectal ultrasound 
exam are used as screening method for PC. However, PSA biomarker measurement 
has several drawbacks, i.e. low sensitivity and specificity, and the lack of distinction 
between localized and metastatic disease. In 80% of cases, patient complaints 
together with elevated PSA are not related to PC, but to benign prostate disease such 
as benign prostate hypertrophy (BPH) or prostatitis. Both age and a family history for 
PC are risk factors for developing this disease, although the latter has been the subject 
of debate lately [3]. Prostate cancer is usually diagnosed using transrectal ultrasound 
(TRUS) or MRI combined with biopsies. These modalities are generally able to detect 
and localize primary prostate cancer, but are less effective for clinical staging and 
therapy management. Due to the type of tissue of the prostate gland, accurate imaging 
by means of CT is currently not possible. An overview of current and future radionuclide 
imaging methods is given in chapter 2.
New developments in imaging of prostate cancer 
Currently, more advanced functional multi-modality MR imaging techniques are 
under clinical development, such as Dynamic Contrast Enhanced MRI (DCE-MRI), 
that visualizes perfusion and enhances specificity of MRI, and Magnetic Resonance 
Spectroscopy (MRS) that uses levels of cellular metabolites like choline and citrate to 
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increase tumor detection rate [4]. Furthermore, MRI can be combined with intravenous 
injection of ultrasmall paramagnetic iron particles (USPIO) for better detection of small 
lymph node metastases. After intravenous administration, USPIO are retained in the 
lymph nodes where they are phagocytized by macrophages, which produces the 
hypointense signal in T2 weighted MRIs. In malignant lymph nodes, the macrophages 
are replaced by tumor cells, and the lymph nodes will appear hyperintense. With this 
technique, even small metastases in normal sized lymph nodes can be detected [5, 6]
Next to advances in MR imaging, radionuclide imaging of PC is rapidly emerging. 
Positron emission tomography (PET) imaging using 18F-FDG is a widely used imaging 
modality to detect metastatic disease in several cancers, making use of trapping of 
18F-FDG in metabolically active cells. Unfortunately, 18F-FDG PET/CT is inadequate 
for (re)staging of PC, as a large fraction of PC expresses only low numbers of glucose 
transporters such as Glut-1, which limits the 18F-FDG uptake. In addition, 18F-FDG is 
excreted mainly via the urinary system, which further limits the sensitivity and specificity of 
18F-FDG-PET/CT in the genitourinary region [4, 5, 7]. Several other radiotracers have been 
developed and tested for imaging metastatic PC, such as the radiolabeled metabolite 
tracers 11C-choline and 18F-fluorocholine. Both agents are based on choline as key 
precursor for cell membrane biosynthesis. For imaging of recurrent prostate tumors, 
lymph node metastases and bone metastases, 11C-choline or 18F-fluorocholine is now 
more and more included in everyday clinical practice [8]. Several studies have shown 
that choline imaging is useful in patients with short PSA-doubling times (<6 months) and 
high PSA serum levels (>2-10 ng/ml) as well as high-risk Gleason scores (7-10). A 
limitation of the use of choline-tracers in recurrent disease is their poor detection rate in 
patients with low PSA levels (<2.5 ng/ml). Unfortunately, clinical relevance of imaging 
of recurrent disease is the highest in patients with low PSA levels. At PSA values below 
1 ng/ml, detection rates are less than 20%, increasing to >70% at PSA values >2.5 
ng/ml [9]. Since biochemical relapse is already considered in patients with PSA levels 
of 0.2 ng/ml, there is an urgent need for more sensitive radiotracers [10]. 
In a systematic review based on 37 studies in 1244 PC patients, Bauman et al. 
described recommendations for the use of 18F-fluorocholine for imaging of PC. While 
initial staging with 18F-fluorocholine should be restricted to intermediate to high-risk 
populations with PSA levels of >10 ng/ml or Gleason scores of ≥7, restaging of 
recurrent and castrate-resistant disease with 18F-fluorocholine is recommended in 
patients with PSA levels of >2 ng/ml [11]. In addition, the use of 18F-fluorocholine for 
the definition of dominant intra-prostatic foci or limited lymph node recurrence was 
recommended for focal therapy escalation or focal salvage therapy. Moreover, 18F-fluo-
rocholine imaging was recommended for treatment monitoring of hormone or radiation 
therapy [5]. 11C-acetate is another metabolite tracer, that was developed based on 
incorporation of acetate in membrane lipids of tumor cells due to the overexpression of 
fatty-acid synthase particularly in PC cells. 11C-acetate has been clinically evaluated for 
detection of recurrent prostate cancer, showing a sensitivity of 64% and specificity of 
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93%, making this a less promising tracer [12].
Capromab pendetide (Prostascint®), an 111In-labeled monoclonal antibody targeting 
the PSMA receptor has been approved by the FDA in 1996 as a diagnosing imaging 
agent in newly diagnosed patients with biopsy-proven PC, who are thought to be 
clinically localized and at high risk for pelvic lymph node metastases. In addition, 111In-
capromab pendetide was approved in post prostatectomy patients with a rising PSA 
and a negative metastatic evaluation with high clinical suspicion of occult metastatic 
disease. Imaging using radiolabeled capromab pendetide however is not performed 
regularly. Due to its non-specific uptake, possibly enhanced by biopsy-related 
inflammation, and the relatively poor tumor-to-background ratios, the usefulness of 111In-
capromab pendetide for imaging prostatic malignancies remains rather limited. An 
important disadvantage of capromab pendetide is the fact that it binds to an intracellular 
domain of PSMA. Therefore, capromab pendetide only binds to viable tumor cells 
following internalization or to dead cells with disrupted cellular membranes [5].
Promising developments are seen with J591, that is directed against an epitope on the 
extracellular domain of the PSMA receptor. This monoclonal antibody has been labeled 
with 111In and 89Zr for immunoSPECT/PET [13], as well as with 177Lu for radioimmuno-
therapy [14]. 
Another group of tracers undergoing clinical investigation for PC consists of the 
radiolabeled bombesin-analogues targeting the gastrin releasing peptide receptor 
(GRPR). GRPR is overexpressed in prostate cancer in general and in 86% of PC lymph 
nodes and 53% of PC bone metastasis [15]. Kahkonen et al. showed a sensitivity and 
specificity of 81% and 88%, respectively, for detection of primary prostate cancer, and 
a sensitivity of 70% for detection of metastatic lymph nodes. It is deemed unsuitable 
for detecting bone lesions, due to its low sensitivity for detecting bone metastases [16]. 
There is evidence that GRPR in PC is less abundantly expressed in advanced stages of 
the disease, making the GRPR receptor less suitable as a target [17].
A new class of promising tracers currently under clinical development consists of 
radiolabeled PSMA-ligands targeting the prostate specific membrane antigen (PSMA). 
PSMA is an enzyme, NAALADase, expressed on the vast majority of PC. A series 
of radiolabeled PSMA inhibitors has been developed, such as 99mTc-MIP-1404 
(Trofolastat®), 123I-MIP-1072, 123I-MIP-1095 [18, 19] and 68Ga-HBED-CC-PSMA (Figure 1).
123I-MIP-1072 and 123I-MIP-1095 have been clinically evaluated for their potential 
to visualize prostate, bone and soft-tissue PC lesions. Early results show potential for 
123I-MIP-1072 in imaging of (primary) PC, whilst MIP-1095 radiolabeled with 131I will 
be further investigated for its therapeutic potential [18].
99mTc-MIP-1404 is currently evaluated in a multicenter phase II trial. Next to its high 
clinical potential and excellent sensitivity for imaging PC metastases, 99mTc-MIP-1404 
has several other advantages over current imaging agents, such as the short time 
between injection and imaging, and the easy radiolabeling procedure enabling use of 
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the tracer in nuclear medicine departments without specialized facilities [20]. 
68Ga-HBED-CC-PSMA is another PSMA ligand currently under investigation for PET. The 
first clinical studies indicate that this tracer may have considerable advantages in detecting 
PC lesions in patients with recurrent disease, even in patients with low PSA levels [10, 21, 
22]. Based on promising preclinical results, Afshar-Oromieh et al. investigated the role 
of 68Ga-HBED-CC-PSMA in PET/CT imaging in a cohort of 37 patients. In 84% of the 
patients, PC-specific lesions could be identified. At PSA levels <2.2 ng/ml, PC-specific 
lesions were found in 60% of the patients. At PSA levels >2.2 ng/ml, PC-specific 
lesions were found in all patients. Afshar et al. have also shown superiority of this tracer 
over 18F-choline in detecting PC lesions in patients with biochemical relapse. In this 
study, 86.5% of the patients showed at least one PC-specific lesion with 68Ga-HBED-
CC-PSMA PET/CT, whereas this was the case in only 70.3% when 18F-fluorocholine 
was used as a tracer. At PSA values higher than 2.82 ng/ml, 68Ga-HBED-CC-PSMA 
could detect at least one lesion in each patient, while 18F-fluorocholine missed lesions 
in 10% of the patients. At PSA levels below 2.82 ng/ml at least one lesion could be 
detected in 68.8% and 43.8% of the patients using 68Ga-HBED-CC-PSMA and 18F-
fluorocholine, respectively. Most importantly, all lesions visible in 18F-fluorocholine-PET/
CT were also visible using 68Ga-HBED-CC-PSMA PET/CT, indicating that 68Ga-HBED-
CC-PSMA PET/CT can replace 18F-fluorocholine PET/CT in these patients. No false-
positives were found. Overall, this study suggests a significantly improved sensitivity of 
68Ga-HBED-CC-PSMA PET/CT compared to 18F-fluorocholine PET/CT, especially at 
low PSA levels [22]. Recently, Eiber et al. reported the detection of PC lesions with 68Ga-
HBED-CC-PSMA-PET/CT in 248 patients with biochemical recurrence after radical 
prostatectomy. 68Ga-HBED-CC-PSMA-PET/CT showed substantial higher detection 
rates than reported for other imaging modalities. Most importantly, a high number of 
positive findings in the clinically important range of low PSA values (<0.5 ng/ml) was 
Figure 1. Structure of MIP-1072, MIP-1095 and HBED-CC-PSMA.
MIP-1072 MIP-1095 HBED-CC-PSMA
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identified [23].
Recently, the 18F-labeled 
PSMA-ligands 18F-DCFBC and 
18F-DCFPyl were developed 
at Johns Hopkins University 
(Baltimore, MD, USA), enabling 
centralized production, thus 
eliminating the need for on-site 
manufacturing (Figure 2). This 
could markedly improve the 
accessibility of radiolabeled 
PSMA-ligands. Rowe at al. compared the first generation 18F-PSMA ligand 18F-DCFBC 
to conventional imaging modalities in both hormone naïve and castration resistant 
PC. In a lesion-by-lesion analysis, detection of lymph nodes, bone lesions and visceral 
lesions by 18F-DCFBC was superior to conventional imaging, with superior sensitivity 
for the 18F-ligand (92% vs 71%) [24]. Based on the positive results with 18F-DCFBC, the 
second generation 18F-PSMA ligand 18F-DCFPyl was developed, with the advantage 
of lower blood pool activity most likely caused by binding of 18F-DCFBC to plasma 
proteins. Dietlein et al. described a direct comparison between 68Ga-HBED-CC-PSMA-
PET/CT and 18F-DCFPyL-PET/CT. In this study, 14 patients underwent both 68Ga-HBED-
CC-PSMA-PET/CT (1 h p.i.) and 18F-DCFPyL-PET/CT (2 h p.i.). All lesions detected 
by 68Ga-HBED-CC-PSMA-PET/CT were also detected by 18F-DCFPyL-PET/CT. 18F-
DCFPyL-PET/CT detected additional lesions suspicious for PC in 3 out of 14 patients, 
suggesting a higher sensitivity using 18F-DCFPyL. Furthermore, SUVmax and tumor-to-back-
ground lesions were significantly higher with 18F-DCFPyL-PET/CT, possibly due to later 
acquisition times (with better signal-to-noise ratios) and faster clearance of the 18F-PSMA 
ligand [25]. This highlights the potential of 18F-labeled PSMA ligands in diagnosis of PC.
Therapy of prostate cancer 
Dependent on the stage of the disease, determined by PSA levels and by means of 
Gleason score based on prostate biopsies, therapeutic options differ significantly. In 
patients with low risk PC, there is often no (direct) need for treatment. In pT1a-b patients, 
“watchfull waiting” is advised, whilst in T1c-2a (Gleason score <7, pretreatment PSA 
<10 ng/ml and <2 positive biopsies), “active surveillance” is indicated. In patients 
with localized or locally advanced prostate cancer, treatment options consist of 
(external) radiation therapy or radical prostatectomy. Treatment in this phase has a 
curative intent, but is accompanied with significant morbidity, such as relatively high 
risks for urinary incontinence and impotence. When PC has metastasized, treatment is 
no longer curative, but is aimed at slowing spread of the disease and optimal quality 
of life. Bilateral orchidectomy or hormonal therapy with LHRH antagonists and LHRH 
Figure 2. Structure of 18F-DCFPyL and 18F-DCFBC.
18F-DCFPyL 18F-DCFBC
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agonists (with or without anti-androgens) are therapeutic options of choice in this phase 
of PC, although accompanied with severe side-effects. Eventually, the disease will 
progress to castration-resistant prostate cancer (CRPC), a phase in which progression 
occurs even though serum testosterone is at castration level. Therapeutic options in 
this phase are limited. A relatively new therapy for asymptomatic metastatic CRPC 
is sipuleucel-T (Provenge®), which is EMA approved since 2013. Sipuleucel-T is a 
dendritic cell vaccine manufactured from autologous leukocytes, activating the immune 
system of the patient to selectively kill PC cells. Although prolonged survival has been 
shown using this vaccine, it is not reimbursed in The Netherlands due to the negative 
advice of the Dutch Medicine Evaluation Board considering effectiveness.
First line chemotherapy in CRPC consists of docetaxel combined with prednisone. 
Second line options are chemotherapy using cabazitaxel and prednisone, or 
abiraterone. Abiraterone is a relatively new agent that inhibits CYP17, thus blocking 
testosterone synthesis entirely. Even in CRPC, complete testosterone blockade results in 
therapeutic effect comparable to that of cabazitaxel, but with less side-effects and the 
possibility of oral dosing. Third option is enzalutamide, an oral non-steroïd androgen 
receptor antagonist that prevents binding of activated androgen receptors to DNA. 
Painful bone metastases may be palliatively treated with α-emitting radionuclide 223Ra 
(Xofigo®), which has also shown overall survival benefit in a phase III clinical trial [26]. 
Prevention of Skeletal Related Events is done by means of bisphosphonate therapy or 
denosumab, an IgG2 monoclonal antibody that inhibits osteoclastic activity.
As is shown above, therapeutic options once the disease has spread beyond the 
prostate are limited, highlighting the need for new systemic therapies. One of the most 
promising class of therapeutic agents currently investigated in clinical trials consists 
of 177Lu-labeled PSMA ligands. In these trials, new PSMA ligands are investigated 
which can be radiolabeled with both radionuclides used for diagnostic purposes 
(111In/68Ga), and nuclides suitable for therapy of PC, such as 177Lu and 90Y. The first 
clinical trials were performed with DOTA-conjugated PSMA, followed by DOTAGA-
conjugated PSMA ligands with favourable tumor uptake compared to the DOTA-conju-
gated ligands. Baum et al. evaluated the therapeutic effects of DOTAGA conjugated 
PSMA ligand 177Lu-DOTAGA-(ly)fk(Sub-KuE) (177Lu-PSMA-I&T) in a group of 56 mCRPC 
patients. Of all patients, 33.3% reported significant improvement in pain after treatment 
with 1-5 cycles of therapy (5.7 ± 0.8 GBq/cycle), whereas the therapy was very well 
tolerated, showing no significant side effects nor hematological or renal toxicity. Of 25 
patients included in this study, that were followed up at least 6 months after 2 or more 
cycles of therapy, 14 patients were reported to have partial remission. Stable disease 
was reported in 2 patients, and 9 patients revealed progressive disease according 
to EORTC response criteria [27]. A PSA decline of >50% was observed in 58.9% of 
patients.
These results of the first clinical studies indicate that PSMA ligands will have a high 
impact on both diagnostic and therapeutic procedures in PC patients in the near future.
17Introduction and thesis outline
Monoclonal antibodies 
Monoclonal antibodies (mAbs) are antibodies that bind to the same epitope, and are 
currently used in the treatment of a wide range of malignancies. The first monoclonal 
antibodies were generated in 1975, and the first license for clinical use of a mAb was 
granted in 1986. Since then, development of mAb-based pharmacotherapy has risen 
to about 30 licensed mAb-based drugs. Humanized mAbs are nowadays the fastest 
growing group of biotechnology-derived molecules used in clinical trials [28]. The huge 
advantage of this class of pharmaceuticals is their specific targeting.
Next to the regular therapeutic use of mAbs, these pharmaceuticals can be radiolabeled 
in order to enable visualization of the target cells by means of immunoPET or 
immunoSPECT. In case of successful targeting of malignant tissue, these mAbs may also 
be used in RadioImmunoTherapy (RIT), when labeled with the β-emitting radionuclides 
177Lu or 90Y. These are capable of destruction of malignant cells and, dependent on 
their specific properties, the cell layers surrounding the targeted tissue.
Currently, only two radiolabeled therapeutic antibodies are FDA approved, i.e. 
90Y-ibritumomab-tiuxetan (Zevalin®) and 131I-tositumomab (Bexxar®) for the treatment of 
chemotherapy-refractive NHL. For the treatment of prostate cancer, the 177Lu-labeled 
anti-PSMA mAb J591 was investigated in a phase II clinical trial [14], showing promising 
results that are further investigated in a phase III clinical trial.
Several antigens are overexpressed in prostate cancer cells, and are therefore potentially 
suitable for targeting prostate cancer using mAbs. We investigated the expression of 
4 of the most common antigens in PC: PSMA, PSCA, MUC1 and TROP-2 in human 
prostate cancer tissue samples by means of immunohistochemical analysis. We 
investigated frozen samples of normal human prostate tissue, BPH tissue and prostate 
cancer tissue with increasing Gleason grades (n=2-3). All samples were stained with 
mAbs directed against the PC-associated antigens mentioned above. Sections were 
stained with diaminobenzidine and counterstained with hematoxylin. Gleason grade 
of the samples was scored. Intensity of staining was scored as - (no staining), ± (very 
weak staining), + (weak staining), ++ (moderate staining), +++ (strong staining) and 
++++ (very strong staining). Staining intensity can be compared within samples from 
the same Ab, but not between different Abs, due to the inequality in sensitivity of the 
antibodies for their respective antigens. Tissue samples were collected according to 
national and institutional guidelines. Results are summarized in Table 1.
PSMA
PSMA is by far the most well-known target in PC imaging. PSMA is an integral, 
membrane glycoprotein (84 kD) that is highly expressed on prostate epithelial cells. It is 
a homologue of the protein N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I or 
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folate hydrolase I), a protein which is active in the central nervous system. In malignant 
tissue, PSMA has been suggested to be involved in angiogenesis, as PSMA was 
found to be expressed in the endothelial cells lining the neovasculature of solid tumors, 
next to its expression in prostate cancer cells [5]. In our immunohistochemical studies, 
although with a limited number of prostate tissue samples, a clear intense staining of all 
prostate cancer samples was observed, with a trend of higher expression in PC with 
a higher Gleason score (Table 1, Figure 3). This is in accordance with other studies, 
which conclude that PSMA is strongly upregulated in prostate cancer (95% expression 
in PC cells and 100% in tumor positive lymph nodes and bone metastasis) [15]. PSMA 
expression levels are directly correlated to PC progression, expression increases with 
androgen independence, metastasis and cancer progression [29].
PSCA
PSCA (Prostate Stem Cell Antigen) is a small (10-24 kDa), anchored cell-surface 
glycoprotein, that is expressed on several epithelial cells among which epithelial 
cells of the prostate. It is expressed mainly in differentiating cells rather than in stem 
cells, contradictory to the suggestion of its name. Table 1 shows limited expression of 
PSCA in normal tissue, that increases with Gleason grade (Figure 3) which is in line 
with literature findings. PSCA is expressed extensively in PC: 90% in primary prostate 
cancer [30] and 95% in lymph node and bone metastasis [15]. Its expression increases 
with increasing Gleason score, tumor invasion, androgen independence and is related 
to poor prognosis. Expression is limited by androgen deprivation [29].
TROP-2
TROP-2, also known as EGP-1 (epithelial glycoprotein-1), GA733-1, gp50/T16, 
TACSTD2 (tumor-associated calcium signal transducer 2), is a 46 kDa transmembrane 
glycoprotein expressed in carcinomas of the lung, bladder, breast, cervix, ovary, 
stomach and prostate. Most normal human tissues do not express TROP-2, but it is found 
Table 1. Intensity of immunohistochemical staining of normal human prostate tissue and prostate cancer Gleason grade 8 
samples using 4 different antibodies (PSMA, PSCA, TROP-2 and MUC1).
PSMA PSCA TROP-2 MUC1
Normal* + / +++ - / + ++ / +++ -
BPH* ± / +++ - / ± ++ / +++ -
Gleason < 6** ++ / +++ - + / ++ -
Gleason 6* ++ / +++ - + / +++ - / ±
Gleason 7-8* ++ / ++++ - / ± ++ / +++ - / ±
Gleason 9-10* +++ / ++++ - / ++ ++ / +++ - / ±
*n=3, **n=2
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Normal prostate tissue
Figure 3. Immunohistochemical staining of normal human prostate tissue and prostate cancer Gleason grade 8 samples 
using 4 different antibodies (PSMA, PSCA, TROP-2 and MUC1).
Gleason 8
TROP-2
MUC1
PSMA
PSCA
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in epithelial tissue and at low levels in several normal glandular cells, including glands 
in the bronchus, breast, prostate and skin, and ducts and acini of the pancreas [31]. 
Immunohistochemical analysis of the different samples of prostate tissue shows relatively 
high expression in normal prostate tissue and BPH as well as prostate cancer samples 
with different Gleason scores, without obvious increase with increasing Gleason scores 
(Table 1, Figure 3).
MUC1
MUC1 is a large mucin (122 kDa) expressed on the surface of most epithelial tissues. 
In PC tissue MUC1 is expressed equally over the tumor cell surface, as opposed to its 
apical expression in normal epithelial cells. Table 1 shows virtually no expression in 
healthy prostate tissue and BPH, together with limited expression in higher PC grades 
(Figure 3). Overexpression of MUC1 is seen in several cancer types such as ovarian, 
lung, pancreatic, colon and some types of prostate cancer, and has been related to 
tumor angiogenesis, proliferation, signal transduction, invasion, metastasis, and immu-
nosuppression. 
Due to their specificity, monoclonal antibodies can be used for cancer imaging and 
targeted therapy. However, there are several drawbacks to the use of mAbs in radio-
immunoimaging and -therapy. Due to the long circulatory half-lives of intact antibodies 
(IgG), lesions can only be depicted several days after injection when the radiolabeled 
antibody has cleared from the background tissues. This is inconvenient for patients and 
for clinical practice. Next, this limits the use of this imaging modality when imaging 
is required directly before and after treatment [32]. In addition, monoclonal antibodies 
show nonspecific localization in tumors and inflamed tissues due to the Enhanced 
Permeability and Retention (EPR) effect.
Furthermore, in radioimmunotherapy, the long circulatory half-life of mAbs causes 
relatively high radiation doses to well-perfused tissues such as liver, spleen and bone 
marrow. The long exposure to the therapeutic radionuclide results in clinically relevant 
myelotoxicity limiting the activity dose that can be safely administered. To avoid toxicity 
related to slow clearance of radiolabeled antibodies from the circulation, various 
approaches can be applied. One of these approaches consists of the use of antibody 
fragments, because antibody fragments are cleared much faster from the blood. In 
general, tumor uptake of antibody fragments is lower than that of the intact antibody, 
while kidney uptake is higher. Another strategy to use the excellent targeting capability 
of mAbs and to overcome their disadvantages in imaging and RIT is pretargeting.
Pretargeting
In pretargeting, tumors are targeted by a non-radiolabeled targeting agent, allowing 
the unbound agent to clear from the circulation, followed by a second injection of a 
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radiolabeled small molecule that is recognized by the targeting agent. The unbound 
radiolabeled compound then rapidly accumulates in the tumor or clears quickly from 
the circulation (Figure 4). This concept was first published in 1984 by Goodwin et al. 
Two pretargeting approaches can be distinguished. The first approach is based on 
the ultra-high binding affinity (10-15 M) [33] of biotin to mammalian avidin or bacterial 
streptavidin. The biotin-avidin pretargeting system has been applied clinically, but is 
hampered by the inherent immunogenicity of (strept)avidin being a nonhuman protein. 
Next to that, due to the high affinity of biotin and (strept)avidin, both agents also 
complex in the circulation, thus causing longer circulatory half-life of the radiolabeled 
compound.
The second strategy uses bispecific antibodies (bsAbs) as targeting agents. Initially, 
these bispecific antibodies were developed by chemically coupling anti-tumor-antibody 
Fab-fragments with an anti-chelator antibody. Injection of this bsAb was followed by a 
radiolabeled chelator. Salaun et al [34] performed a phase II clinical trial in patients with 
metastatic medullary thyroid carcinoma (MTC) using an anti-CEA x anti-DTPA bsAb, 
followed by injection of an 131I-di-DTPA-indium bivalent hapten. This pretargeted ra-
dioimmunotherapy approach showed antitumor activity, accompanied by severe but 
manageable toxicity in progressive MTC. 
This system was improved by replacing the chelator by an HSG (Histamine-Succi-
nyl-Glycine) hapten-peptide containing a DOTA moiety, which was suitable for 
Figure 4. Pretargeting.
This figure was originally published in: Borrmann A, van Hest JCM. Bioorthogonal chemistry in living organisms. Chem Sci 
2014; 5(6):2123–34. © by Chem Sci.
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labeling with different radionuclides. The bsAb was further optimized by introducing 
the Dock-and-Lock (DNL) method developed by Rossi et al., efficiently joining two 
anti-tumor Fab fragments covalently with one anti-HSG-Fab fragment [35]. This trivalent 
bsAb provided higher tumor uptake and retention than Fab’- Fab’conjugates, and 
relatively rapid clearance from the circulation. The combination of one anti-HSG-Fab-
fragment on the bsAb together with two HSG residues on the hapten-peptide provided 
optimal tumor retention of the radiolabeled peptide-hapten, a phenomenon referred 
to as affinity enhancement [33, 36]. Radiolabeled compounds bearing two haptens are 
more avidly bound at the tumor cell surface, since they can cross-link between two 
adjacent bsAbs at the tumor cell surface (Figure 5) [37]. This system allowed for high 
tumor-to-blood ratios within 1 h after injection of the radiolabeled peptide.
Using the DNL method, several recombinant bsAbs were produced including an anti-CEA 
bsAb (TF2), an anti-CD20 bsAb (TF4), an anti-EGP-1 bsAb (TF12) and an anti-MUC1 
bsAb (bsPAM4) [38]. In a phase I/II clinical trial Schoffelen et al. have demonstrated 
the potential of such an approach to target colorectal carcinoma (CRC) in patients. 
The results showed rapid and specific tumor targeting of the 111In- or 177Lu-labeled 
hapten-peptide IMP288 after pretargeting with TF2. The study demonstrated that PRIT 
in CEA expressing CRC is feasible and safe [39].
Figure 5. Pretargeting with TF12 and IMP288.
This figure was originally published in: Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional 
antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008; 
49(1):158-63. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.
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For pretargeting of human 
carcinomas, the bsAb TF12 (Figure 
5) was developed using the DNL 
method, based on the monoclonal 
antibody hRS7 in combination 
with the anti-HSG mAb. hRS7 is 
a humanized IgG1 monoclonal 
antibody directed against TROP-2, 
which is overexpressed in prostate 
cancer. The studies described in this 
thesis, aimed to provide proof-of-
concept for pretargeting of prostate 
cancer, using TF12 together with the 
di-HSG-hapten IMP288 (Figure 6).
Aim of the studies
The aim of the studies described in this thesis was to investigate the potential of (pre)
targeted radioimmunoimaging and radioimmunotherapy of prostate cancer using a 
radiolabeled humanized anti-TROP-2 monoclonal antibody (hRS7) and an anti-TROP-2 
x anti-HSG bispecific monoclonal antibody (TF12) in combination with a radiolabeled 
di-HSG hapten-peptide (IMP288). 
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Thesis outline
Substantial progress has been made in the development of functional and molecular 
imaging modalities for prostate cancer, such as positron emission tomography using 
radiolabeled metabolic tracers, receptor-binding ligands, amino acids, peptides 
and antibodies. In chapter 2, the value of these novel radionuclide based molecular 
imaging techniques in the assessment of prostate cancer is reviewed.
In chapter 3, the characteristics of the anti-TROP-2 monoclonal antibody hRS7 for 
targeting prostate cancer are assessed. Its potential in both immunoSPECT and 
Figure 6. Structural formula of IMP288.
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immunoPET is investigated in nude mice with human prostate cancer xenografts.
In chapter 4, the internalizing properties of the anti-TROP-2 bispecific antibody TF12 
are evaluated both in vitro and in vivo, to determine whether its internalizing properties 
would hamper its use in pretargeting.
In chapter 5, pretargeting of PC with anti-TROP-2 x anti-HSG bsAb TF12 and the 
radiolabeled di-HSG peptide IMP288 is investigated in mice with human prostate 
tumors. The optimal dose of both agents and optimal dose interval are determined, as 
well as the retention of the radiolabeled hapten-peptide in the tumor. After optimization, 
the potential for pretargeted radioimmunoimaging and radioimmunotherapy is assessed 
in the same mouse model.
Chapter 6 describes our studies investigating radioimmunoPET using TF12 and 
68Ga-IMP288 in mice with s.c. and i.p. human PC xenografts using 18F-FDG as a 
reference.
In chapter 7, the efficacy of pretargeted radioimmunotherapy with multiple cycles 
of TF12 and 177Lu-labeled IMP288 in mice with PC xenografts is investigated and 
compared with that of conventional radioimmunotherapy with 177Lu-labeled hRS7.
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Abstract
Prostate cancer is the most common malignancy in men in the Western world 
and represents a major health problem with substantial morbidity and mortality. 
Sensitivity and specificity of digital rectal examination (DRE) and evaluation of 
prostate specific antigen (PSA) are excellent methods for diagnosis of prostate 
cancer, but have limited value for staging. Imaging of prostate cancer has 
become increasingly important to improve staging and management of prostate 
cancer patients. Conventional imaging modalities, such as transrectal ultrasound 
and computed tomography, show limited accuracy for a reliable assessment of 
prostate cancer. Diagnostic value of magnetic resonance imaging has improved 
by dynamic contrast enhancement (DCE-MRI) and diffusion-weighted magnetic 
resonance imaging (DWI). Recently, substantial progress has been made in the 
development of functional and molecular imaging modalities, such as positron 
emission tomography using radiolabeled metabolic tracers, receptor-binding 
ligands, amino acids, peptides, or antibodies. Here, we review the value of 
these novel radionuclide imaging techniques in the assessment of prostate cancer.
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Introduction
Prostate cancer remains the most common malignancy in men in Europe, with an 
incidence of 382,000 cases and a mortality rate of 89,000 in 2008 [1]. In early 
stages of the disease, neoplastically transformed prostate cells are confined to the 
prostate gland. In later stages malignant cells metastasize to other parts of the body, 
typically including bones and lymphnodes. Currently, metastatic prostate cancer is 
essentially incurable. Therefore, early diagnosis represents the most effective strategy 
with a change for curative treatment options and consequently minimizes prostate can-
cer-related mortality [2].
At present, in the US screening for prostate cancer is advisable for men above 40 years 
of age by evaluation of the prostate-specific antigen levels (PSA) and by digital rectal 
examination (DRE). When abnormalities are found or suspected, further evaluation is 
commenced, typically by taking transrectal ultrasound (TRUS)-guided biopsy [3]. The most 
commonly used histopathological grading system for prostate cancer is the Gleason 
score. Together with other patient parameters, like age, health state, PSA levels, and 
biopsy pathology, the Gleason grading system predicts prognosis and helps to guide 
therapeutic management. Patients with a low Gleason score have well-to-moderate-
ly differentiated prostate cancer histology and usually have localized disease. These 
early-stage patients can have a very indolent course of the disease with low mortality 
rates and can be monitored by watchful waiting to prevent overtreatment and related 
morbidity.
Curative treatment of confined prostate cancer includes radical prostatectomy performed 
either as an open conventional procedure or by (robot-assisted) laparoscopic surgery and 
may be combined with various forms of radiation therapy (RT), including 3-dimensional 
conformal RT, intensity-modulated RT, or proton beam RT [4]. Other curative treatment 
options include brachytherapy combined with external- beam RT, high-intensity focused 
ultrasound, and cryosurgery. However, in a substantial proportion of prostate cancer 
patients, primary curative treatment fails, as becomes evident by frequent recurrences 
of the disease. In general, the first sign indicating treatment failure is a shorter doubling 
time of PSA serum levels that may occur months or even years before development of 
clinical symptoms or radiographic indications for recurrent disease.
However, the diagnostic use of PSA levels has several important drawbacks. Due to 
low sensitivity and specificity, the diagnostic value of PSA levels is limited and may 
yield both false-negative and false-positive results, leading to under- and overtreatment, 
respectively. Most notably, evaluation of PSA levels fails to differentiate between local 
and metastatic disease, which is in fact a prerequisite for appropriate management 
of the disease [5]. Therefore, new highly sensitive and specific imaging modalities for 
accurate visualization of prostate cancer and reliable monitoring of therapy response 
are urgently needed. Radionuclide imaging techniques such as PET and SPECT are 
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very sensitive imaging modalities as picomolar amounts of the tracer can be detected. 
Depending on the radiotracer used, these techniques can visualize specific molecular 
processes. 
Here, we review conventional and novel imaging modalities in prostate cancer and 
discuss the new developments in radionuclide imaging of prostate cancer in more 
detail.
Conventional imaging methods
Transrectal Ultrasound
Today, transrectal ultrasound (TRUS) is the most commonly used technique for further 
clinical evaluation of size and anatomy of the prostate gland. TRUS has several 
advantages including high level of safety, favorable portability, relatively low costs, 
ease of use, and the possibility to perform real-time imaging. However, several 
disadvantages like low resolution, sensitivity, and specificity limit the reliability of TRUS. 
In particular, TRUS has a limited ability to delineate small cancer foci which usually are 
isoechoic and therefore cannot be detected. Moreover, the majority of hypoechoic foci 
detected by TRUS are not malignant, but rather represent conditions such as benign 
prostatic hyperplasia (BPH), atrophy, or inflammatory processes in the prostate gland 
[6].
Currently, several modulations of TRUS are clinically available, including Doppler 
TRUS and contrast-enhanced TRUS with microbubbles. Using Doppler TRUS, regions of 
tumors with hypervascularity can be detected. However, since many small tumors are 
not angiogenic, the sensitivity of Doppler TRUS is not significantly increased compared 
to TRUS [7]. In contrast-enhanced TRUS with microbubbles, sensitivity to detect tumor 
foci is higher than in conventional TRUS, still, imaging does not reliably discriminate 
between inflammatory and malignant processes in the prostate [8].
Computed Tomography
Due to its soft-tissue type tissue architecture, the prostate gland can only be visualized 
poorly by computed tomography (CT). An accurate distinction between neoplastic and 
healthy tissue by CT is currently not feasible. Therefore, the use of CT in prostate cancer 
is limited to providing an anatomic reference for functional imaging modalities and for 
the detection of metastatic bone involvement.
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Magnetic Resonance Imaging
The soft-tissue resolution of Magnetic Resonance Imaging (MRI) is superior to CT. MRI 
accurately visualizes the anatomy of the prostate, which allows a more reliable detection 
of prostate cancer. Moreover, with innovative techniques such as diffusion weighted 
MRI (DWI), MR spectroscopy (MRS), and dynamic contrast-enhanced MRI (DCE-MRI), 
functional assessment of the disease is also possible, resulting in a more precise staging 
and follow-up of prostate cancer.
In malignant tumors with high cellular density diffusion of water molecules is restricted, a 
process that can be visualized by DWI [9]. Typically, prostate cancers have relatively tight 
glandular elements with increased cellular density and decreased extracellular space, 
producing high-signal-intensity foci on DWI [8]. Unfortunately, the specificity of this modality 
is relatively low since benign hyperplastic changes can also show low water diffusion [8].
MRS is a technique that provides information on aberrant levels of cellular metabolites. 
Prostate cancer is associated with locally elevated levels of choline and polyamine and 
decreased levels of citrate that can be evaluated by MRS. Recent reports indicate that 
MRS appears to be a promising functional imaging modality for the detection of prostate 
cancer [10, 11, 12]. Unfortunately, to obtain increased tumor detection rate MRS needs to be 
combined with MRI, which is technically challenging and therefore currently not widely 
available [13].
With DCE-MRI, tumor vascularization can be visualized by quantitative kinetic parameters 
that reflect blood flow and the vascular permeability [8]. DCE-MRI has higher specificity 
than MRI alone [14]. However, small low-grade tumors might be missed due to lack of 
angiogenesis. Furthermore, there is a concern regarding gadolinium-based contrast agents 
due to the risk for induction of nephrogenic systemic fibrosis in patients with renal failure [8].
More advanced imaging techniques include high-resolution MRI combined with 
lymphotropic superparamagnetic (ultra) small particles of iron oxide, (U)SPIO. 
Administered intravenously, (U)SPIO penetrate the vascular endothelium and enter the 
interstitial space and lymph vessels, finally reaching the lymph nodes. In the lymph nodes, 
the particles are phagocytised by macrophages which produces signal variations. In 
case of malignant involvement of the lymph node, absence of macrophage activity leads 
to signal modification. Consequently, affected lymph nodes will appear hyperintense 
on T2-weighted MRIs [15]. It has been found that USPIO-MRI has a significantly higher 
sensitivity than conventional MRI [16]. However, several disadvantages may limit the clinical 
use of USPIO-MRI, such as the requirement for particular expertise, its time-consuming 
nature, and the limited sensitivity of USPIO-MRI in small lymph nodes (<5 mm). Recently, 
the uptake of bombesin-functionalized iron oxide nanoparticles in PC3 prostate cancer 
cells has been evaluated and preclinical data indicate that this approach may yield a 
prostate cancer-selective imaging probe [17].
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Figure 1. PET/CT image acquired after injection of 11C-choline in a 
patient with prostate cancer. This image shows metastatic involvement 
of a lymph node (white arrow) and vertebra (green arrow).
Radionuclide imaging
Positron Emission Tomography
Radiolabeled metabolite tracers
Today, positron emission tomography (PET) is emerging as an important functional 
imaging modality in various malignancies. Using PET, specific cellular and molecular 
processes, such as glucose metabolism and cell proliferation can be functionally 
visualized. The most commonly used tracer for PET imaging is 18F-fluorodeoxyglucose 
(18F-FDG). Tumor cells can be depicted by this technique by exploiting their enhanced 
glucose demand that is mainly due to increased aerobic glycolysis in malignant cells, 
allowing them to be distinguished from normal cells [18]. 18F-FDG is taken up via glucose 
transporters. Intracellularly, 18F-FDG is rapidly phosphorylated after which it cannot 
be metabolized any further. 
Consequently, 18F-FDG is 
trapped inside metabolically 
active cells and can be 
visualized with PET.
For anatomic reference for 
the functional PET images, 
integrated PET/CT has become 
the standard technology. 
Unfortunately, in primary 
prostate cancer 18F-FDG-PET 
with or without integration of 
CT has only limited sensitivity. 
A large fraction of prostate 
cancers expresses only low 
numbers of glucose transporters 
such as Glut-1, which limits 
18F-FDG uptake [19]. In addition, 
sensitivity of 18F-FDG-PET is 
also limited since 18F-FDG is 
excreted mainly via the urinary 
tract, obscuring the prostate 
gland, and restricting the iden-
tification of pelvic lymph node 
metastases [20].
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3-Deoxy-3-18F-fluorothymidine (FLT) 
radiolabeled with 18F is another 
potential tracer for monitoring early 
effects of treatment of hormone-re-
fractory prostate cancer. FLT has 
been introduced as a radiophar-
maceutical for assessing tumor 
proliferation with PET imaging. 
Oyama et al. [21] demonstrated a 
significant decrease of FLT uptake 
in tumors after administration of 
docetaxel, while the changes 
of FDG uptake were minimal. 
Immunohistochemical analysis 
revealed that the changes of FLT 
uptake were correlated with those 
of proliferation activity. 
Currently, choline radiolabeled 
with 11C (Figure 1) or 18F (Figure 
2) is routinely used as PET tracer 
to image prostate cancer [22]. The 
use of choline is based on the 
fact that it is a key precursor in the 
biosynthesis of phosphatidylcho-
line, a major component of the 
cell membrane.
An explanation for increased 
choline uptake in prostate 
cancer might be the increased 
proliferation rate in tumors [23]. 
Another possible explanation is 
upregulation of choline kinase in cancer cells [24].
The major advantage of 11C-choline PET is the limited excretion rate via the urinary 
system, which minimizes obscuring of the prostate and therefore enables imaging of 
the pelvis without confounding bladder activity [25]. Rinnab and coworkers [26] evaluated 
11C-choline PET/CT in 50 patients with biochemical recurrence and reported a sensitivity 
of 91% at PSA concentrations below 2.5 ng/ml and a specificity of 50%. Besides low 
specificity, the use of the tracer 11C-choline is limited by the short half-life of 11C (t½ 
20 min), which requires the availability of an on-site cyclotron [22]. With a half-life of 
110 min, 18F-labeled choline (18F-FCH) overcomes this limitation. However, urinary 
excretion of 18F-FCH is higher than that of 11C-choline and might confound image 
Figure 2. Transaxial slices of18F-choline PET/CT images of a patient 
with metastasized prostate cancer. Panel (A) shows local recurrence 
of prostate cancer in the left retrovesical area. Panels (B-H) show 
metastatic involvement of lymph nodes.
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interpretation. Eschmann et al. [27] compared 11C-choline PET/CT with conventional 
whole-body MRI and reported a better overall diagnostic performance with 11C-choline 
PET/CT due to higher detection rate of lymph node metastases and other local disease 
related alterations. However, for detection of bone metastases, the authors recommend 
a combination of both techniques to improve diagnostic accuracy. 
Acetate is another commonly used tracer for PET imaging of prostate cancer. Intra-
cellularly, acetate is converted into acetyl-CoA and incorporated into cholesterol and 
fatty acids, which finally form the cellular membrane. Recently, fatty acid synthesis was 
shown to be increased in prostate cancer with fatty-acid synthase being overexpressed 
[28]. Since acetate is excreted mainly via the pancreas [8], confounding bias through 
bladder activity is prevented which enables accurate imaging of the pelvis. Therefore, 
11C-acetate PET has been clinically evaluated for detection and follow-up of prostate 
cancer. A clinical trial by Albrecht et al. [29] suggested that 11C-acetate PET might be 
useful for the detection of recurrent prostate cancer, especially in very early work-up 
of postoperative patients presenting with very low PSA values. Those data confirmed 
previous PET studies by Oyama et al. [30], who showed that 11C-acetate uptake in the 
prostate bed as well as in lymph nodes was superior to that of 18F-FDG. 18F-fluoroace-
tate, an 18F-labeled analogue of acetate, has also been developed for PET. Similar to 
acetate, 18F-fluoroacetate is substrate for acetyl coenzyme A synthase, but with lower 
specificity. 18F-fluoroacetate represents a new alternative for 11C-acetate in PET imaging 
of prostate cancer with the benefit of using a positron emitter with a longer half-life [31]. 
Small-animal PET series with 18F-fluoroacetate in CWR22 tumor-bearing mice showed 
clear delineation of tumor tissue compared to reference organs, suggesting that it might 
be a useful PET tracer for imaging of malignancies [31]. Matthies et al. [32] provided 
preliminary clinical data of a prostate cancer patient with rising PSA and progressive 
bone metastases. They showed that, compared to 11C-acetate, 18F-fluoroacetate PET 
offers the possibility of delayed imaging with the potential to further increase tumor 
to-background ratios.
For detection of malignant bone metastases, 18F-sodium fluoride PET (Figure 3) has 
shown high sensitivity and specificity [33]. The uptake in malignant lesions represents 
the increase in local blood flow and osteoblast activity. 18F-fluoride PET has been 
found to be more sensitive than 99mTc-methylene diphosphonate (99mTc-MDP) planar 
bone scintigraphy, especially in the early detection of metastases [33]. 18F-fluoride PET 
is characterized by a twofold higher bone uptake than 99mTc-MDP, faster clearance 
from the blood pool and a higher target-to-background ratio [33]. Unfortunately, like 
99mTc-MDP, 18F-fluoride PET is not tumor-selective and false-positive rates may be high 
[34]. However, this limitation can be overcome by integration of 18F-fluoride PET with CT, 
which provides higher specificity and sensitivity [35]. More recent data indicate 18F-FCH 
PET/CT to be more specific than 18F-fluoride PET/CT in the early detection of bone 
metastases [36].
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Another potential tracer for PET 
imaging of prostate cancer 
is 18F-fluoropropionic acid 
(18F-FPA). It is hypothesized 
that, as discussed above 
for fluoroacetate, 18F-FPA 
mimics acetate and therefore 
accumulates in tumor tissue 
[37]. Compared to 18F-FDG, 
18F-FPA showed more accurate 
delineation of CWR22 prostate 
cancer xenografts in mice. 
However, further research is 
necessary to evaluate if 18F-FPA 
offers further advantages over 
existing tracers for prostate 
cancer.
Radiolabeled androgen receptor binding ligands
Recently, the imaging agent 18F-fluoro-5-alpha-dihydrotestosterone (18F-FDHT) that binds 
to androgen receptors, has been developed. Functional androgen receptor expression is 
a key factor in anti-androgen-based treatment of prostate cancer. Consequently 18F-FDHT 
PET/CT may be exploited to monitor viable and androgen-sensitive tumor tissue and 
for the evaluation of anti-androgen therapy response [38]. The major advantage of this 
modality is that androgen-sensitive tumors can be detected whereas androgen-resistant 
tumors cannot, predicting if antiandrogen-based approaches represent a therapeutic 
option for individual patients. 18F-FDHT PET/CT seems to be more likely to be of use in 
advanced disease with metastatic bone involvement rather than in localized prostate 
cancer, since background uptake can be high [39]. However, so far, experience with 
18F-FDHT PET/CT is limited and more studies evaluating its role in prostate cancer are 
needed. 
Figure 3. Coronal and sagittal slices of a 
Na-F-18 PET scan of a patient with bone 
metastases in clavicula (green arrow), lumbal 
spine (L2, white arrow), and left femur 
(purple arrow).
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Radiolabeled bombesin- and gastrin-releasing peptide receptor binding ligands
Since bombesin- and gastrin-releasing peptide receptors (GRPR) are overexpressed 
in prostate cancer, they represent a potential target for molecular imaging. The first 
radiolabeled bombesin analog (Cu-64-DOTA-8-amino-octanoicacid-bombesin) was 
introduced by Rogers et al. [39]. In this study, specific tumor localization of 64Cu-DOTA-
Aoc-bombesin in mice with PC3 xenografts was demonstrated by microPET imaging 
and was confirmed by biodistribution studies. However, the high uptake of 64Cu-labeled 
bombesin in normal tissues prevented its clinical implementation.
In a very recent study, the values of the 111In-labeled bombesin agonists PESIN, AMBA, 
MP2346, and MP2653 and the 99mTc-labeled antagonist Demobesin-1 for SPECT/
CT imaging of prostate cancer were evaluated in SCID mice xenografted with human 
GRPR-overexpressing PC3 tumors [40]. Schroeder et al. showed that Demobesin-1 
was superior to the other agents with respect to in vivo stability, tumor uptake, and 
retention. Typically, renal and pancreatic clearance for Demobesin-1 was fast. The 
best GRPR agonists in this study were PESIN and AMBA with sufficient in vivo stability 
and relatively high tumor uptake and retention. However, further studies are needed to 
evaluate the clinical use of these agents in patients with prostate cancer.
In another study, novel series of [64Cu-NO2A-(X)-BBN(7-14)NH2] agonists for the specific 
targeting of GRPR on human PC3 cells and tumor tissue have been evaluated [41]. The 
[64Cu-NO2A-(AMBA)-BBN(7-14)NH2] conjugate exhibited the highest accumulation in 
tumor tissue and the most efficient whole-body clearance via the renal-urinary excretion 
pathway.
One of the first clinical studies for imaging androgen-dependent prostate cancer using 
99mTc-[Leu13]BN has been performed by Scopinaro and colleagues in eight patients 
with primary prostate cancer. They were able to visualize eight cancers in the prostate 
fossa with SPECT. Moreover, they reported uptake in obturator nodes which were 
proven to be cancer-specific by histopathology in three patients that were negative
on MRI and CT [42]. In another study, Vincentis et al. [43] reported detection of prostate 
cancer by 99mTc BN SPECT in 12 out of 12 patients with androgen-dependent prostate 
cancer and visualization of loco-regional lymph nodes in 4 out of 12 patients. These 
preliminary data suggest that 99mTc BN SPECT could be useful to detect primary prostate 
cancer and to evaluate loco-regional lymph node involvement. 
Other strategies focus on imaging of the heterodimeric transmembrane glycoprotein αvβ3 
integrin that plays an important role in angiogenesis, metastasis, and the development 
of bone metastases in prostate cancer [44]. To image expression of αvβ3, the PET tracer 
18F-galacto-RGD was developed. Compared to conventional bone scans, the detection 
rate of bone metastases was higher using tracer 18F-galacto-RGD PET. However, uptake 
of 18F-galacto-RGD was heterogeneous, which suggests a variation in αvβ3 expression 
in prostate cancer metastases [45].
During invasion, angiogenesis, and metastasis of GRPR-positive tumors, the endothelial 
cells around the tumor tissue are activated and express high levels of integrin αvβ3. 
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Thus, many GRPR-positive tumors are also positive for integrin αvβ3 
[45]. Due to this, 
dual-receptor targeting of αvβ3 and GRPR represents another potential approach for 
detection of prostate cancer. Therefore, a BBN-RGD peptide heterodimer has been 
developed, that recognizes GRPR through the BBN motif and integrin through the RGD 
motif. In prostate cancer xenograft models, the BBN-RGD heterodimer labeled with 18F 
exhibited excellent tumor uptake and favorable in vivo kinetics superior to the BBN and 
RGD analogues [46].
In a subsequent study, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) has been 
used as a chelator and the potential advantages of 64Cu-labeled NOTA-RGD-bombesin 
heterodimer above the monomeric analogues NOTA-RGD and NOTA-bombesin for 
imaging GRPR-positive tumors were demonstrated [47].
Radiolabeled antibody imaging
Currently, extensive research is focused on both imaging and therapy of several types 
of malignancies using radiolabeled monoclonal antibodies (mAbs) directed towards 
relevant tumor-associated cell surface antigens.
Recently, several anti-PSMA antibodies have been developed that target the prostate 
specific membrane antigen (PSMA). The first antibody used to target PSMA in prostate 
cancer is capromab (7E11). Capromab pendetide (Prostascint®) is a monoclonal 
antibody labeled with 111Indium that specifically targets an intracellular epitope of 
PSMA. Capromab pendetide was approved by the FDA for imaging of soft-tissue sites 
in metastatic prostate cancer for presurgical staging. In addition, it was approved for 
the evaluation of PSA relapse after local therapy. In a low number of presurgical patients 
with high-risk disease that show no lesions on CT or MRI scans, capromab detected 
positive nodes, thereby sparing these patients unnecessary surgical procedures [48]. 
However, as indicated above, capromab binds to the intracellular domain of PSMA. 
Therefore, binding to viable tumor cells first requires internalization. Alternatively, 
capromab may only bind to dead cells with disrupted cellular membranes. In addition, 
localization of capromab uptake is limited by nonspecific binding and high activity in 
the blood [8]. However, due to the relatively long half-life of 111Indium (2.8 days), SPECT 
images can be obtained several days after injection, allowing washout of background 
activity from blood and bowel. Using capromab, detection of recurrence of disease, 
lymph node metastases, and other metastatic involvement is possible and combination 
with CT to improve anatomical resolution increases its specificity. One of the major 
limitations of imaging with radiolabeled capromab is the poor penetration in bone, 
limiting the detection of metastatic bone involvement [49].
To overcome limitations due to intracellular binding of capromab, antibodies binding 
to the epitopes on the extracellular domain of PSMA, such as J591, J415, and J533, 
have been developed that show high affinity binding to viable PSMA-expressing 
LNCaP cells [50]. In a preclinical study, mice were treated with J591 radiolabeled 
with 131Iodine, 177Lutetium, and 90Yttrium. 177Lu and 90Y provide better dosimetry due 
40 Chapter 2
to their longer biological half-lives [51]. However, due to development of human-an-
ti-mouse antibody (HAMA) responses, repetitive dosing was restricted. Meanwhile, a 
humanized form of J591 has been developed, which was well-tolerated and showed 
high tumor targeting capacity [52]. The first clinical studies with 111In-, 90Y, and 177Lu-ra-
diolabeled humanized mAb J591 have been performed by Bander et al. [53]. Tumor 
targeting results of 53 patients that received radiolabeled humanized J591 in phase 
I trials have been analyzed. In 43 evaluable patients, J591 accurately targeted bone 
lesions in 94% and soft-tissue lesions in 72% of the patients, respectively. They also 
showed that the humanized antibody is less immunogenic and can be administered 
several times to the same patient with persistently accurate tumor targeting activity. 
More recently, a phase-II clinical trial with 177Lu-J591 for metastatic castration-resistant 
prostate cancer has been completed with excellent targeting of CT or MRI proven 
sites of prostate cancer metastases in 94% of the patients [54]. During this study, throm-
bocytopenia was the most commonly seen hematologic toxicity and limited the dose 
of 177Lu-J591. Also, 90Y-J591 is known for its hematologic toxicity causing significant 
myelosuppression. 
Recently, three other antibodies were identified that are directed against alternative 
epitopes on PSMA that appear to have diagnostic potential for prostate cancer [55]. 
Wolf et al. characterized monoclonal antibodies 3/A12, 3/E7, and 3/F11 in vitro 
and demonstrated a high affinity binding to PSMA-positive C4-2 cells for all three 
antibodies. A subsequent study focused on in vivo behavior, biodistribution, and tumor 
uptake of the 64Cu-DOTA-labeled antibodies 3/F11 and 3/E7 and fragments of 
3/A12 [52]. PET imaging demonstrated specific tumor uptake of these monoclonal 
antibodies in PSMA-positive C4-2 tumors in SCID mouse xenografts models, which 
further confirmed possible use of those antibodies in imaging of prostate cancer. Very 
recently, another group studied the potential targeting ability of the humanized IgG1 
mAb hRS7 which is directed against EGP-1. The epithelial glycoprotein-1 (EGP-1) 
is a pancarcinoma marker that is expressed at high levels on virtually all prostate 
carcinomas. They evaluated the biodistribution of 111In-, 125I-, and 89Zr-labeled hRS7 
and performed immunoPET and immunoSPECT with 111In-hRS7 and 89Zr-hRS7 in mice 
with s.c. and intraprostatic PC3 xenografts. They showed that specific tumor uptake of 
hRS7 is high with high tumor-to- blood ratios, which allowed excellent immunoPET/CT 
and immunoSPECT imaging of the PC3 xenografts [56]. 
Another recent study developed a pretargeting approach for localizing advanced 
prostate cancer based on an anti-EGP-1 antibody in subcutaneous and orthotopic PC3 
mouse models [57]. The pretargeting approach resulted in high uptake in the tumor, 
rapid blood clearance, and excellent tumor-to-blood ratios for 111In-IMP288 in the PC3 
tumors. Already 1 h after injection of the radiolabeled peptide, pretargeted immunoPET 
images clearly visualized the subcutaneous and orthotopic tumors with minimal activity 
in the kidneys. Van Rij et al. showed that pretargeting with TF12 in combination with 
radiolabeled IMP288 is an excellent approach for specific, fast, high-contrast imaging 
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of prostate cancer.
Another important cell surface target for molecular imaging of prostate cancer is the 
prostate stem cell antigen (PSCA), which is over-expressed in a majority of prostate 
cancers and has low levels of expression in a very limited number of normal tissues. 
PSCA has been detected in approximately 60% of lymph node and liver metastases 
[58] and strong PSCA staining has been observed in 87–100% of bone metastases 
[56]. Elevated PSCA expression has also been shown to correlate with increased tumor 
stage, grade, and progression to androgen independence. Olafsen et al. studied a 
humanized anti-PSCA monoclonal antibody 1G8 (hu1G8) in preclinical models [59] and 
showed that PET evaluation in LAPC-9-xenografted mice following radioiodination with 
the positron emitter 124I provided high contrast PET images. Due to the slow clearance 
kinetics of the antibody, enhanced target-to-background images were not obtained until 
1 week after administration of 124I-hu1G8. To facilitate and accelerate clearance from 
blood, antibody fragments of various sizes were used in subsequent studies.
Leyton et al. evaluated the role of the from hu1G8 antibody derived minibody 2B3 
labeled with 131I or 124I for imaging prostate cancer xenograft-bearing mice. The 2B3 
minibody showed fast blood clearance in comparison to the intact hu1G8 monoclonal 
antibody, which resulted in the ability to image prostate cancer xenografts within 
21 h in contrast to 168 h with the intact antibody [60]. Remarkably, the 2B3 minibody 
mimicked the tumor uptake of the intact hu1G8 monoclonal antibody in the LAPC-9 
model despite its rapid elimination from the circulation. Due to the ability of the 2B3 
antibody to image androgen-independent as well as androgen-dependent xenografts, 
2B3 has promising potential as a rapid imaging agent for high-risk prostate cancer 
patients [60].
Another recent study evaluated the tumor targeting activity of an internalizing human 
single-chain antibody fragment (scFv) UA20 that is directed against a still unknown 
antigen. UA20 was labeled with 99mTc to target human prostate carcinoma in DU145 
xenograft mouse models [61]. In this study, UA20 scFv showed rapid and specific inter-
nalization in prostate tumor cells in vitro and accumulation in prostate tumor xenografts 
in vivo. SPECT/CT showed significant tumor uptake as early as 1 h after injection and 
at 3 h after injection, tumor uptake was 4.4% ID/g. In contrast, the control antibody 
N3M2 showed a tumor uptake of only 0.26% ID/g that was similar to nonspecific 
uptake in muscle and fat. These data indicated the potential of UA20 scFv for future 
development for prostate cancer imaging. 
Radiolabeled amino acid imaging
Radiolabeled amino acids may be alternative tracers for imaging of prostate cancer, 
since their uptake is frequently increased in rapidly proliferating cells [28].
A potential tracer for PET imaging of prostate cancer is the radiolabeled amino acid 
methionine. Since accumulation of 11C-methionine in tumor cells reflects transport of 
amino acids and protein synthesis, enhanced metabolism of tumors can be visualized 
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with 11C-methionine. Methionine is mainly metabolized in liver and pancreas, without 
excretion via the urinary tract [3].
The few studies available that investigated the role of 11C-methionine PET in prostate 
cancer indicate superiority of 11C-methionine PET over 18F-FDG PET in the detection 
of metastatic bone and soft-tissue lesions [62]. Nunez et al. obtained a relatively high 
sensitivity (72.1%) of 11C-methionine PET for the detection of bone and soft-tissue 
metastases, which compared favorably with the sensitivity of 48% for 18F-FDG PET. A 
possible explanation for this difference in sensitivity of detection of metastatic lesions 
might be the relatively high activity of 18F-FDG in the bladder, interfering with the 
evaluation of the prostate and nearby tissues. In contrast, only a minimal amount of 11C-
methionine is excreted via the urinary system allowing more reliable evaluation of pelvic 
structures. As a consequence 18F-FDG may have limited ability to detect abdominal 
retroperitoneal metastases [37]. Nunez et al. also found that the agreement between 
11C-methionine PET and conventional imaging methods exceeds the agreement of 
conventional methods with 18F-FDG PET.
In a pilot study, L-leucine analogue anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid 
(anti-18F-FACBC) showed uptake in primary and metastatic prostate cancer. Bladder 
excretion of anti-18F-FACBC was found to be low and data indicate a potential role for 
anti-18F-FACBC in the differentiation between BPH and malignant transformation of the 
prostate gland [63]. However, anti-18F-FACBC needs to be further evaluated in clinical 
studies.
Since tumors express specific antigens, radiolabeled antibodies can target the antigens 
and can be of diagnostic value. However, due to the long circulatory half-life of 
radiolabeled antibodies high target to background ratios are only obtained several 
days after injection. Therefore, peptides that target those antigens represent alternatives 
for imaging of prostate cancer [64]. PET imaging of xenografted tumors overexpressing 
PSMA was achieved with the PSMA inhibitor labeled with 11C. This 11C-DCMC 
compound specifically binds with high affinity to the extracellular domain of PSMA [65]. 
11C-DCMC showed clear delineation of the tumor at 30 min after injection. This PSMA 
inhibitor was also labeled with 18F. High uptake of 18F-DCFBC was observed in the 
PSMA-positive tumors whereas uptake in PSMA-negative tumors was low [66].
Conclusion and future perspectives
Since conventional approaches have limited value in the early detection, staging, and 
follow-up of prostate cancer, extensive research currently focuses on the development 
of highly sensitive and specific imaging modalities for accurate visualization of prostate 
cancer.
Improvements on conventional MR imaging have yielded promising new approaches 
such as DWI, MRS, or DCE-MRI, which allows for more accurate disease staging and 
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follow-up of prostate cancer.
Substantial progress has been made in the development of radionuclide imaging 
techniques and the value of numerous radioactive tracers for the detection of prostate 
cancer has been evaluated. Since sensitivity of 18F-FDG-PET for imaging of prostate 
cancer is limited, tracers like 11C-choline, 18F-FCH, 11C-acetate, and 11C-methionine 
represent more appropriate alternatives. 11C-methionine PET is superior to 18F-FDG-PET 
in both the detection of soft-tissue lesions and the early detection of bone metastases. 
For evaluation of tumor bed and lymph nodes, 11C-acetate PET was superior to 
18F-FDG-PET. However, in progressive disease and detection of bone metastases, 18F-flu-
oroacetate might be superior to 11C-acetate. In this case, 18F-fluoride PET represents 
another appropriate tracer for detection of bone involvement with high sensitivity and 
specificity. The relatively novel tracer 18F-FPA appears to be superior to 18F-FDG in the 
detection of prostate cancer; however, more preclinical and clinical data are needed 
for further evaluation. Receptor binding ligands like 18F-FDHT may have a value in the 
detection of androgen-sensitivity of the tumor, which would direct therapeutic strategies 
towards anti-androgen-based approaches. During the last decade, a wide range of 
antibodies and antibody fragments, such as capromab, 3/A12, 3/E7, 3/F11, 2B3, 
and UA20 have been developed which show promising potential for targeted imaging 
of prostate cancer.
More studies are necessary to accurately compare novel imaging modalities and 
their tracers for optimal suitability in the early detection of (recurrent) prostate cancer, 
metastatic manifestations, and response to therapy.
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Abstract
hRS7 is a humanized IgG1 monoclonal antibody directed against the Epithelial 
Glycoprotein-1 (EGP-1; also known as TROP-2). This antigen is found in many 
epithelial cancers, including prostate cancer, and therefore this antibody could be 
suitable for targeting this cancer. In this study, the characteristics of hRS7 to target 
prostate cancer were examined. The potential for immunoPET with 89Zr-hRS7 
and immunoSPECT with 111In-hRS7 was assessed using nude mice with human 
prostate cancer xenografts.
Methods
EGP-1 expression was assessed by immunohistology in human primary and 
metastatic prostate cancer samples and in PC3 xenografts. The optimal antibody 
protein dose for prostate cancer targeting was examined in nude mice with s.c. 
PC3 xenografts and then the biodistribution of 111In-, 125I- and 89Zr-labeled hRS7 
was determined in s.c. PC3 xenografts at 1, 3 and 7 days p.i. ImmunoPET and 
immunoSPECT were performed with 89Zr-hRS7 and 111In-hRS7 in mice with s.c. 
and intraprostatic PC3 xenografts, respectively.
Results
Immunohistochemical analysis showed abundant EGP-1 expression in human 
primary and metastatic prostate cancers and in PC3 xenografts. 111In-hRS7 and 
89Zr-hRS7 preferentially and specifically accumulated in PC3 xenografts, with 
tumor uptake as high as 60% ID/g at a protein dose of 0.1 µg per mouse. PC3 
tumors in nude mice were clearly visualized with both tracers with immunoPET 
and immunoSPECT.
Conclusion
hRS7 shows excellent in vivo tumor targeting in human PC xenografts. Therefore, 
hRS7 is a potent vehicle for targeting PC. 
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Introduction
Despite ongoing improvement in both detection and treatment of prostate cancer (PC), 
it is the second leading cause of cancer-related deaths in men in the Western world. PC 
causes significant morbidity, especially when metastasized. While treatable in early, 
hormone-dependent stages, PC can only be managed palliatively in the later, hor-
mone-refractory phase of the disease.
At diagnosis, imaging of PC aims at differentiating between malignant and non-malignant 
tissue. Diagnosis is usually performed effectively with imaging modalities like Trans 
Rectal Ultrasound (TRUS) combined with biopsies or Magnetic Resonance Imaging 
(MRI), which are usually able to adequately detect and localize primary PC [1]. In 
advanced PC, however, it is essential to differentiate between metastatic and non-met-
astatic disease, to predict disease outcome, and to determine treatment options. TRUS 
and conventional MRI are less effective in detecting metastatic spread.
Positron Emission Tomography (PET) imaging is a useful imaging modality to detect 
metastatic disease in several cancers. 18F-FDG-PET is not suitable for staging patients 
with PC, since sensitivity is low due to poor 18F-FDG uptake in most well-differentiat-
ed PC lesions and due to the elimination of 18F-FDG via the kidneys and the urinary 
bladder [2,3]. 18F-Fluorocholine has been investigated extensively, but also has a low 
sensitivity for detecting PC metastases [2,3]. 11C-acetate is a promising radiotracer for 
PC, but it requires an on-site cyclotron [1,2,3].
 
Several radiolabeled monoclonal antibodies (mAbs) have been developed and tested 
for PC imaging. The anti-PSMA antibody, 111In-capromab pendetide (Prostascint®, EUSA 
Pharma, Oxford, UK), has been approved for pre-surgical staging and evaluation of 
recurrence after focal therapy of PC, but has several limitations. These include the 
suboptimal visualization of bone metastases and the inability to discern viable from 
non-viable cancer cells, most likely because this antibody is directed against an 
intracellular epitope [3]. However, the use of 111In-capromab pendetide in combination 
with SPECT/CT showed improved results [4]. J591, a humanized anti-PSMA monoclonal 
antibody, has been reported to have better characteristics to detect bone metastases [3].
hRS7 is a humanized IgG1 monoclonal antibody directed against the Epithelial 
Glycoprotein-1 (EGP-1; also known as TROP-2). EGP-1 is a transmembrane glycoprotein 
with a molecular mass of approximately 46 kDa [5]. hRS7 was originally raised against 
human non-small cell carcinoma of the lung [6], and was found to be reactive with 
carcinomas of the lung, bladder, breast, cervix, ovary, stomach and prostate. Most 
normal human tissues do not express EGP-1, including lymph nodes, heart, connective 
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tissues, blood vessels, stomach, jejunum and duodenum, but it is found at low levels in 
several normal glandular cells, including glands in the bronchus, breast, prostate and 
skin, and ducts and acini of the pancreas [6]. Given its expression in prostate cancer, 
we studied the potential targeting ability of hRS7 IgG in a nude mouse-human prostate 
cancer model, examining the antibody radiolabeled with radioiodine or radiometals, 
and applying SPECT and PET imaging modalities.
Materials and methods
The monoclonal antibody hRS7 
The production and characterization of hRS7 (the humanized version of the murine 
monoclonal antibody RS7-3G11) have been described previously [7]. As a control 
antibody the humanized anti-CD22 antibody, hLL2 (not reactive with prostate cancer), 
was used. Both antibodies were supplied by Immunomedics, Inc. (Morris Plains, NJ, 
USA).
Cell culture
The human prostate cancer cell line, PC3, is an androgen-independent cell line, 
originally derived from a PC bone metastasis. Cells were obtained from ATCC 
(CRL-1435) and grown in complete RPMI 1640 medium, supplemented with 10% FCS 
(fetal calf serum, Life Technologies, Grand Island, NY). Before s.c. inoculation of mice to 
induce PC3 xenografts, tumor cells were washed with 0.9% NaCl, disaggregated with 
trypsin, and resuspended in 67% complete RPMI 1640 medium with 33% Matrigel (BD 
Biosciences, San Jose, CA) to the appropriate concentration (3 x 106 cells/200 µL).
Murine models
Nude mice (Central Animal Facility, Radboud University Medical Center Nijmegen, 
The Netherlands), 8–9 weeks old, were adapted to laboratory conditions for at least 
one week before experimental use. They were housed under non-sterile standard 
conditions in filter-topped cages (5 mice per cage), with free access to animal chow 
(Sniff Voer®) and water.
Male BALB/c nude mice were inoculated s.c. in the shoulder with 3 x 106 PC3 cells 
suspended in 200 µL of 67% complete RPMI 1640 medium with 33% Matrigel (BD 
Biosciences, San Jose, CA). The s.c. PC3 tumors grew to approximately 0.1 g in 
10 days after tumor cell inoculation as determined by caliper measurements in three 
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dimensions using the formula: V =4/3π (length/2 x width/2 x height/2), assuming 
that the density of tumor tissue is 1 g/cm3. For an orthotopic mouse model, NMRI-foxn1 
nude mice (Charles River) were used, because their prostate is larger and allows 
injection of 20 µL of cell suspension. NMRI-foxn1 mice were anesthetized and the 
abdomen was opened via a 1-cm midline mini-laparotomy. The prostate was gently 
lifted out of the abdomen and placed on gauze. Using a 29-G needle and a 1-ml 
syringe, 20 µL of a cell suspension containing 2 × 106 PC3 cells in Matrigel was 
injected into one of the dorsal lobes of the prostate. After 7-21 days, palpable tumors 
developed in the prostate.
All experiments were approved by the national Animal Welfare Committee through the 
institutional Animal Welfare Committee of the Radboud University Medical Center, and 
were conducted in accordance with the principles set forth by the Revised Dutch Act on 
Animal Experimentation.
Radiolabeling of hRS7
mAb hRS7 was radioiodinated according to the iodogen method [8]. Ten µL of 0.5 
mol/L phosphate buffer, pH 7.4, 86 µL 50 mmol/L phosphate buffer, pH 7.4, 3.5 
µL hRS7 (5.8 mg/mL), and 3.7 MBq Na125I (GE Healthcare Europe, Den Bosch, 
The Netherlands) were added to an Eppendorf vial coated with 50 µg of iodogen 
(1,3,4,6-tetrachloro-3,6-diphenylglycoluril; Pierce Biotechnology, Inc.). The mixture 
was incubated for 10 min at room temperature, immediately followed by purification on 
a PD-10 column (GE Healthcare) eluted with PBS, 0.5% bovine serum albumin (BSA). 
Conjugation of hRS7 with p-isothiocyanatobenzyl-DTPA (Macrocyclics, Dallas, TX) was 
done essentially as described by Ruegg et al. [9]. Briefly, 0.5 mL mAb hRS7 (10 mg/
mL) was mixed with 50 µL 1.0 M NaHCO3, pH 9.5, and a 50-fold molar excess 
of p-isothiocyanatobenzyl-DTPA (1.1 mg). Following incubation at room temperature 
for 1 h, the reaction mixture was dialyzed for 3 days in a Slide-A-Lyzer (20 kDa 
cutoff, Pierce, Rockford, IL) against 0.25 M NH4Ac, pH 5.4. Determination of the 
substitution ratio, as described by Hnatowich et al. [10], revealed that 2 DTPA chelates 
were conjugated per hRS7 antibody molecule. Subsequently, the hRS7-DTPA conjugate 
was diluted in 0.25 M NH4Ac, pH 5.4, to 1 mg/mL, and aliquots were
 stored at 
–20°C. hRS7-DTPA was labeled with 111InCl3 by adding 0.37 MBq/µg hRS7-DTPA in 
0.25 M NH4Ac, pH 5.4. The mixture was incubated at room temperature for 30 min. 
The radiolabeled hRS7 preparation was purified by gel filtration on a PD-10 column. 
The radiochemical purity was determined by Instant Thin Layer Chromatography (ITLC) 
using 0.1 M sodium citrate, pH 6, as the mobile phase.
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hRS7 was conjugated with desferrioxamine (Df) (Novartis, Basel, Switzerland) via 
an amide linkage and labeled with 89Zr as described previously [11]. The antibody 
and N-succinyldesferrioxamine-tetrafluorphenol (VU Medical Center, Amsterdam, The 
Netherlands) were conjugated at room temperature for 30 min. On average, one 
Df-chelate per mAb molecule was conjugated. After conjugation, the pH was adjusted 
to 4.4 by adding 4 µl of 0.25 M H2SO4 and the iron was removed from the chelator 
by adding 50 µl of a 25 mg/ml EDTA solution and incubation for 30 min at 35°C. 
The hRS7-Df conjugate was purified on a PD-10 column that was eluted with 5 mg/
mL gentisic acid in 0.9% NaCl pH 5. hRS7-Df was radiolabeled using 120 MBq 
89Zr oxalate (IBA Molecular, Louvain-le-Neuve, Belgium). The pH of the 89Zr oxalate 
solution was adjusted to 4.1 using a 2.0 M Na2CO3 solution. After 3 min the pH of 
the 89Zr oxalate solution was adjusted to 6.9 using a 0.5 M HEPES solution and the 
purified hRS7-Df was added. The solution was incubated for 90 min at 37 oC. Labeling 
efficiency was 60%, as determined by ITLC. The radiolabeled hRS7 preparation was 
purified by gel filtration on a PD-10 column and the radiochemical purity (>95%) was 
determined by ITLC using 20 mM citrate buffer, pH 6 as the mobile phase. Labeling 
efficiency varied considerably (15-80%), depending on the batch 89Zr oxalate used. 
The desired amount of 89Zr-hRS7-desferal (20 µg hRS7-Df labeled with 11 MBq 89Zr) 
was diluted in 5 mg/mL gentisic acid, pH 5, to a volume of 200 µL. The control 
antibody hLL2, an anti-CD22 monoclonal antibody was conjugated with desferrioxam-
ine and labeled with 89Zr as described above.
Immunoreactivity
The immunoreactive fraction of the radiolabeled hRS7 was determined using freshly 
trypsinized PC3 cells, as described by Lindmo et al. [12] with minor modifications. Briefly, 
a fixed amount of radiolabeled antibody (200 Bq) was incubated with increasing con-
centrations of PC3 tumor cells in 0.5 mL binding buffer (RPMI 1640 medium, 0.5% 
BSA). A duplicate of the lowest cell concentration was incubated in the presence of an 
excess of unlabeled antibody to correct for nonspecific binding. After 1 h at 37°C, the 
activity in the total vial was determined in a gamma counter (Wallac wizard 3’’ 1480 
automatic gamma counter). Cells were spun down and washed once with 500 µL of 
binding buffer and the activity in the cell pellet was determined in the gamma counter. 
The immunoreactive fractions of all radiolabeled preparations used in the experiments 
exceeded 80%.
Immunohistochemical studies
Frozen 5-µm sections of PC3 tumor xenografts were air-dried and fixed in cold acetone 
for 10 minutes. After fixation, the slides were dried overnight and incubated with 4 µg/
ml hRS7 in PBS, 1% BSA, for 1 h at room temperature. Slides were rinsed with PBS, and 
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were incubated with rabbit-anti-human-IgG-peroxidase (DAKO, Glostrup, Denmark) in 
PBS, 1% BSA (preincubated in 10% Normal Mouse Serum) for 30 min. After washing 
with PBS, the sections were stained with 3,3’-diaminobenzidine (Powervision DAB, 
Immunologic, Duiven, The Netherlands). All slides were counterstained with Mayer’s 
hematoxylin (Fluka Chemie, Buchs, Switzerland) and mounted in Permount (Fisher 
Scientific, Breda, The Netherlands). Human tumor sections were stained similarly 
except that these sections were incubated with the murine RS7 antibody, and rab-
bit-anti-mouse-IgG-peroxidase was used as the second antibody. Tissue samples were 
collected according to national and institutional guidelines.
Biodistribution studies 
The effect of the antibody dose on the biodistribution of 111In-hRS7 in mice with s.c. 
PC3 tumors was determined in groups of 5 mice that received escalating protein doses 
of 111In-hRS7 (0.1, 1, 10, 30 and 100 µg hRS7/mouse, 0.4 MBq). Three days after 
injection of the radiolabeled mAb, mice were euthanized by CO2/O2 asphyxiation 
and a blood sample was obtained by heart puncture. Tissues (tumor, muscle, femur, 
lung, spleen, kidney, liver, duodenum and colon) were dissected, weighed, and the 
radioactivity content was determined in a gamma counter (Wallac wizard 3’’ 1480 
automatic gamma counter). To permit calculation of the radioactive uptake in each 
organ as a fraction of the injected dose, an aliquot of the injection dose was counted 
simultaneously.
In another study,111In-hRS7 (0.4 MBq, 5 µg) and 125I-hRS7 (0.2 MBq, 5 µg of hRS7) 
were coinjected in groups of 5 mice that were killed by CO2 asphyxiation and dissected 
at 3 days p.i. (post injection). Tissue samples were counted in a gamma counter for 
111In and 125I activity. 125I activity was corrected for crossover with 111In activity. To 
check the accuracy of the 125I activity in the samples, samples were counted again one 
month later. Results of the biodistribution experiments were expressed as a percentage 
of the injected dose per gram of tissue (% ID/g).
ImmunoPET and ImmunoSPECT imaging
Groups of 5 mice with s.c. PC3 tumors were injected with 11 MBq (20 µg) 89Zr-hRS7. 
Although optimal protein dose was established at ≤10 µg hRS7, a higher amount was 
chosen due to the higher activity that is needed for imaging. At 1, 3 or 7 days after 
injection, mice underwent immunoPET using a small-animal PET/CT scanner (Inveon®, 
Preclinical Solutions, Siemens Healthcare Molecular Imaging, Knoxville, TN, USA), 
while anesthetized with a mixture of isoflurane, N2O and oxygen. One additional 
group was coinjected with an excess of 500 µg of unlabeled hRS7 and one group 
received 89Zr-labeled hLL2 (20 µg, 6 MBq) to determine the nonspecific uptake in the 
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tissues. Animals were placed in a supine position in the PET/CT scanner. Emission 
scans were acquired over 15 (day 1), 20 (day 3) or 30 minutes (day 7), followed 
by a CT scan for anatomical reference (spatial resolution 113 µm, 80 kV, 500 µA). 
Scans were reconstructed using Inveon Acquisition Workplace software version 1.2, 
with an ordered set expectation maximization-3D/maximum a posteriori (OSEM3D/
MAP) algorithm having the following parameters: matrix 256 x 256 x 159, pixel size 
0.43 x 0.43 x 0.8 mm3 and a beta-value of 0.1. Images were analyzed quantitatively 
by drawing regions of interest and tumor-to-liver ratios were calculated. After imaging, 
mice were killed by CO2 asphyxiation and dissected to determine tissue uptake by 
gamma counting.
Orthotopically implanted mice were scanned using a U-SPECT II microSPECT scanner 
(Milabs, Utrecht, The Netherlands). All mice were injected with 111In-hRS7 (37 MBq, 
10 µg) 3 days before the SPECT images were acquired. Four groups of 5 mice 
were imaged at 10, 13, 17 and 24 days after intraprostatic PC3 cell inoculation. 
A control group of 3 mice without surgery and without PC3 tumor was imaged simul-
taneously. The second control group of mice with PC3 tumors received 500 µg of 
unlabeled hRS7 along with the injection of 111In-hRS7 on day 17, in order to block 
specific uptake of the radiolabeled antibody. Thirty min before scanning, the mice 
received 0.5 mg of furosemide s.c. to promote voiding of the bladder. Mice were 
killed and scanned for 30 min using the 1.0 mm diameter pinhole collimator tube. After 
scanning, biodistribution of the 111In-label was determined as described above. Scans 
were reconstructed with MILabs reconstruction software, which uses an ordered-subset 
expectation maximization algorithm, with a voxel size of 0.375 mm. Tumor-to-liver 
ratios were calculated with the PMOD software (version 3.15, PMOD technologies 
Ltd, Zürich, Switzerland).
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 4.00 and InStat 
version 3.05 (San Diego, CA) for Windows®. Differences in uptake of radiolabeled 
RS7 were tested for significance using the nonparametric Mann Whitney test for two 
groups. A P-value below 0.05 was considered significant. For multiple comparisons 
the Bonferroni correction was applied.
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Results
Immunohistochemical studies
Figure 1 shows that EGP-1 was expressed heterogeneously throughout the PC3 tumor 
(A, B). EGP-1 expression was membranous and cytoplasmic. Immunohistochemical 
analysis of three human primary prostate tumors with varying Gleason scores showed 
high homogeneous and consistent expression of EGP-1 in all three PC tumors analyzed 
(D, E and F). Normal human prostate (C) showed EGP-1 expression of the glandular 
epithelium. Immunohistochemistry also showed abundant expression of EGP-1 in PC 
metastases in a lymph node (G, H) and in the liver (I).
Figure 1A-B. hRS7 staining of PC3 mouse xenografts, magnified 100x (A) and 400x (B).
Figure 1C-F. mRS7 staining of human prostate tissue with different Gleason scores: normal prostate (C), Gleason 6 (D), 
Gleason 7-8 (E) and Gleason 9-10 (F) (magnified 100x).
Figure 1G-I. mRS7 staining of two human lymph node (G,H) and one liver (I) metastases (magnified 100x).
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Biodistribution studies
A protein dose study showed maximum tumor uptake (>50% ID/g) following injection 
of ≤10 µg of 111In-hRS7 at 3 days after injection (Figure 2A). Tumor uptake of 111In-hRS7 
decreased significantly with increasing doses of mAb from 60.8 ± 14.8% ID/g at 
0.1 µg/mouse to 22.2 ± 7.1% ID/g at 100 µg/mouse (P=0.004). Protein dose did 
not affect concentrations in the blood or normal tissues. Tumor-to-blood ratios ranged 
from 3.0 (at 100 µg/mouse) to 7.2 (at 0.1 µg/mouse). Tumor weights were 0.08 ± 
0.043 g and did not differ significantly between groups.
Figure 2A. Biodistribution of escalating 111In-hRS7 doses (0.1-100 µg, 0.4 MBq) in BALB/c nude mice with a subcutane-
ous PC3 xenograft at 3 days after injection (n=5).
Figure 2B. Biodistribution of 125I-hRS7 (5 µg, 0.2 MBq) and 111In-hRS7 (5 µg, 0.4 MBq) in BALB/c nude mice with a 
subcutaneous PC3 xenograft at 3 days after injection (n=5).
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Figure 2B shows that uptake of 111In-hRS7 in tumor tissue at 3 days after injection was 
significantly higher than that of 125I-hRS7 (36.5 ± 13.3% ID/g vs 7.3 ± 2.3%ID/g, 
P=0.0003, weight of the tumors 0.28 ± 0.11 g), yet normal tissue uptake was similar. 
This confirmed earlier studies with the murine RS7 antibody that showed residualizing 
radionuclides would be better retained with this internalizing antibody [13]. The bio-
distribution of 89Zr-hRS7 was determined at 1, 3 and 7 days p.i. Figure 3 shows that 
tumor uptake of 89Zr-hRS7 at 3 days after injection was comparable to that of 10 µg of 
111In-hRS7 (46.7 ± 2.7% ID/g vs 44.8 ± 11.0% ID/g). The same applies for the tissue 
uptake in all other organs (<9% ID/g for 89Zr-hRS7), except for femur uptake which is 
significantly higher for 89Zr-hRS7 (6.9 ± 0.9% vs 1.0 ± 0.2% ID/g, P<0.0001). Tumor 
uptake increased significantly with time from 30.1 ± 2.8% ID/g at 1 day p.i. to 54.3 ± 
7.0% ID/g at 7 days p.i., consequently the tumor-to-blood ratio increased with time to a 
ratio exceeding 8 at 7 days after injection (P=0.0001). Tumor uptake was blocked by 
coinjection of an excess of unlabeled antibody, resulting in nonspecific (non-antigen-me-
diated) tumor uptake of 11.2 ± 0.8% ID/g at 3 days p.i. Tumor uptake of 89Zr-labeled 
control anti-CD22 antibody at 3 days p.i. was low as well: 10.1 ± 2.1% ID/g.
Figure 3. Biodistribution of 89Zr-hRS7 (20 µg, 11 MBq) in BALB/c nude mice with a subcutaneous PC3 xenograft at 
increasing time after injection (1, 3 and 7 days after injection, n=5). One group of mice was coinjected with an excess 
of 500 µg of unlabeled hRS7, one group received 20 µg (6 MBq) of a control antibody not reactive with prostate cancer 
(89Zr-hLL2).
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Figure 4 shows that tumor uptake of 111In-hRS7 in the orthotopic mouse model at 3 days 
after injection was constant in the time period investigated and on average was slightly 
lower than that detected in the s.c. model (31.7 ± 9.8% ID/g at 10 days, 23.6 ± 3.8 
at 13 days, 32.0 ± 12.9% ID/g at 17 days and 19.3 ± 8.5% ID/g at 24 days after 
inoculation). Tissue uptake in all other organs was low (<7% ID/g). Tumor uptake could 
be blocked by coinjection of an excess of unlabeled antibody, resulting in nonspecific 
tumor uptake of 6.1 ± 1.7% ID/g. Mean weight of the tumors in this experiment was 
0.042 ± 0.026 g, there was no significant tumor weight difference between the 
experimental groups. 
ImmunoPET/CT and immunoSPECT imaging 
MicroPET/CT imaging of 89Zr-hRS7 was performed in mice with s.c. PC3 tumors at 
1, 3 and 7 days p.i. One day after injection of the radiolabeled antibody, the PET/
CT image showed high activity in blood. At 3 days p.i., blood levels were lower and 
Figure 4. Biodistribution of 111In-hRS7 (10 µg, 37 MBq) in NMRI nude mice with an orthotopic PC3 xenograft at increas-
ing time after cell inoculation (10, 13, 17 and 24 days p.i, n=5). One group of mice without PC3 xenograft received 
the same amount of 111In-hRS7. The second control group of mice with an orthotopic PC3 tumor additionally received an 
excess of 500 µg of unlabeled hRS7 (n=3).
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Figure 5. Anterior 3D volume-rendering projections of PET/CT scans of mice with a subcutaneous PC3 tumor on the 
shoulder injected with 89Zr-hRS7 (20 µg, 11 MBq) acquired 1 (A), 3 (B,D,E) or 7 (C) days after injection. One control 
group was coinjected with an excess of 500 µg of unlabeled hRS7 (D), a second control group (E) received the same 
dose of an antibody not reactive with prostate cancer (89Zr-hLL2, 20 µg, 6 MBq). Arrows indicate tumor. 
A B C D E
the tumor was clearly visible. At 7 days p.i., 89Zr-hRS7 was retained in the tumor and 
had cleared from the rest of the body, with some activity in the skeleton (Figure 5). 
PET/CT imaging at 7 days after injection showed high uptake of the 89Zr-labeled hRS7 
antibody in the PC3 tumor. There was no accumulation of radioactivity in the other 
organs, and some uptake in the skeleton (nose, the joints of the knees and shoulders 
and the spine) was observed. Accumulation of 89Zr-hRS7 in the tumor was significantly 
reduced when an excess of unlabeled hRS7 was coinjected (Fig. 5D). The same low 
uptake in the tumor was observed after injection of the 89Zr-labeled control antibody 
hLL2 (Figure 5E). Tumor-to-liver ratios were determined by ROI analysis at each time 
point: the tumor-to-liver ratio was 2.9 ± 0.2, 6.5 ± 0.6 and 7.7 ± 1.3 at 1, 3 and 7 
days after injection, respectively. The tumor-to-liver ratio increased significantly between 
1 and 3 days after injection (P<0.0001).
MicroSPECT imaging of 111In-hRS7 was performed in mice at 10, 13, 17, and 24 
days after inoculation of tumor cells in the prostate. Representative coronal sections 
through the center of the tumor are displayed in Figure 6. The mice in the control group 
without PC3 tumors showed no uptake of 111In-hRS7. Uptake in PC3 tumors in the 
prostate could be blocked by coinjection of an excess of unlabeled hRS7. Tumors were 
clearly visualized in the prostate in all mice. There was no visual difference in SPECT 
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images acquired 10, 13, 17, or 24 days after tumor cell inoculation. Tumor-to-liver 
ratios were determined by ROI analysis at each time point. The tumor-to-liver ratio at 
10 days after inoculation was 6.9 ± 0.3, 4.4 ± 0.6 at 13 days, 7.3 ± 3.8 at 17 
days, and 7.5 ± 3.5 at 24 days. There was no significant increase in tumor-to-liver 
ratio with time. Tumors weights were 0.047 ± 0.017 g at 10 days, 0.028 ± 0.015 
g at 13 days, 0.046 ± 0.012 g at 17 days, and 0.067 ± 0.042 g at 24 days 
after intraprostatic cell injection, and there was no significant tumor weight difference 
between the experimental groups.
Discussion
In the present study, the potential of hRS7 for radioimmunoimaging of PC was 
investigated. Immunohistochemical analysis showed that EGP-1 is expressed on the 
epithelial cells of the normal prostate and is abundantly expressed on human primary 
prostate tumors and human PC metastases, indicating that EGP-1 is a potential target 
for PC imaging. Expression of EGP-1 in normal prostate tissue does not necessarily 
disqualify the use of hRS7 for specific imaging of PC. Firstly, in situations where distant 
Figure 6. Anterior projections of SPECT scans of NMRI nude mice with an orthotopic PC3 tumor in the prostate injected 
with 111In-hRS7 (10 µg, 37 MBq) at 10 (A), 13(B), 17(C) and 24(D) days after tumor cell inoculation respectively. One 
control group of mice with an orthotopic PC3 tumor was coinjected with an excess of 500 µg of unlabeled hRS7 (E). The 
second control group received 111In-hRS7 and consisted of mice without PC3 xenograft (F). Arrows indicate tumor. Scans 
were acquired 3 days after injection.
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metastases are being examined, EGP-1 expression in the normal prostate is irrelevant. 
Secondly, it has yet to be determined whether EGP-1 would be accessible to the 
antibody in the intact tissue architecture of the normal prostate, as has been described 
for other antibodies [14]. Since EGP-1 is not expressed in the prostate of mice, we could 
not assess this issue.
The antibody protein dose escalation study with 111In-hRS7 revealed that the highest 
tumor uptake was obtained at ≤10 µg, with progressively less uptake as the dose was 
increased to 100 µg. This likely reflects a gradual saturation of antigen. The antigen 
was not fully saturated at the 100 µg dose, because when a 500 µg blocking dose 
was administered, tumor uptake was as low as 10% ID/g (vs 20% ID/g at 100 µg). 
Uptake in normal tissue was low (<6%), as expected, since murine tissues do not 
express cross-reactive antigen, and was not affected by the protein dose.
Simultaneous injection of 111In-hRS7 and 125I-hRS7 showed a much higher tumor uptake 
of 111In-hRS7 compared to the 125I-labeled mAb (36.5 ± 13.3% ID/g vs 7.3 ± 2.3% 
ID/g, P=0.0003). This is in agreement with previous reports that show murine RS7 
internalization [15]. Internalization causes catabolism of the labeled antibody in the 
lysosomes with subsequent wash-out of the 125I-labeled metabolite. Upon internaliza-
tion, the 111In- and 89Zr-labeled metabolites are retained intracellularily in the lysosomes. 
Uptake of 111In-hRS7 and 125I-hRS7 in normal tissues was relatively low (all <6%).
The biodistribution of 89Zr-hRS7 in mice with s.c. PC3 xenografts was similar to that of 
111In-hRS7, except for femur uptake which was significantly higher for the 89Zr-labeled 
hRS7. Tumor uptake increased significantly from 24 to 72 h p.i. (from 26.6 ± 7.9% 
ID/g to 43.6 ± 11.5% ID/g, P=0.0003). Between 3 and 7 days p.i., tumor uptake 
stabilized (54.3 ± 7.0% ID/g at 7 days p.i.), but due to the blood clearance of the 
radiolabeled mAb, tumor-to-blood ratios increased from 2 at 24 h to >8 at 7 days p.i. 
Tumor uptake was specific, as blocking the EGP-1 antigens in vivo with an excess of 
unlabeled hRS7 resulted in a much lower uptake of the radiolabeled hRS7 antibody in 
the tumor (11.2 ± 0.8% ID/g, 3 days p.i.). The same low nonspecific uptake (10.1 ± 
2.1% ID/g) was observed when 89Zr-hLL2 was injected. The specific accumulation of 
89Zr-hRS7 could be clearly visualized with PET/CT. Some 89Zr activity in the skeleton 
was observed, most likely due to incorporation of released 89Zr from the internalized 
and catabolized antibody into the bone, as has been described for a 89Zr-anti-EGFR 
antibody [16]. ROI analysis of the PET images revealed a significant increase of the 
tumor-to-liver ratio between 1 and 3 days after injection of 89Zr-hRS7 (2.9 ± 0.2% vs 
6.5 ± 0.6% ID/g).
SPECT imaging of PC3 tumors in the mouse prostate clearly visualized the intraprostatic 
tumors with very low background activity levels. Metastatic spread of the tumor was 
not observed. Both imaging and biodistribution results showed that uptake could be 
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blocked by an excess of unlabeled antibody. A few mice showed accelerated mAb 
clearance from the blood, which occurs occasionally in BALB/c mice, as described 
previously [17]. Tumor uptake in the intraprostatic tumors was slightly lower than that in 
the s.c. tumors and was not affected by time after tumor inoculation.
Previous studies with hRS7 have demonstrated high antigen expression on a wide 
range of human tumor types, including breast and lung tumors [18,19]. Our studies 
suggest that radiolabeled hRS7 may also be a useful agent for targeting prostate 
cancer. To further improve PC imaging, a pretargeting strategy with an EGP-1 targeted 
bispecific antibody would be desirable. Future experiments will be aimed at the use of 
this bispecific antibody.
Conclusion
hRS7 showed high and specific accumulation in PC3 xenografts in nude mice. Immu-
nohistochemical staining of human prostate tumor samples disclosed abundant EGP-1 
expression in primary prostate tumors and PC metastases. Biodistribution studies showed 
high and specific tumor uptake and high tumor-to-blood ratios, especially at later time 
points. These properties of hRS7 result in excellent immunoPET and immunoSPECT 
images of PC3 xenograft mouse models. hRS7 is a promising candidate for imaging 
of EGP-1 expressing prostate tumors.
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Abstract
RS7 is an internalizing anti-TROP-2 pancarcinoma antibody capable of targeting 
most epithelial cancers. Since pretargeting strategies could improve tumor 
localization of radionuclides, a new anti-TROP-2 x anti-hapten bispecific antibody 
(bsAb) for pretargeting, based on humanized RS7 (hRS7) was prepared and 
evaluated with a radiolabeled hapten-peptide in vitro and in vivo to determine if 
its internalization properties would interfere with pretargeting. 
Methods
The anti-TROP-2 x anti-hapten bsAb, TF12, was prepared using the 
modular Dock-and-Lock method. TF12 and hRS7 binding was assessed 
by cell binding assays and FACScan in a variety of human carcinoma 
cell lines. TF12’s internalization was evaluated in vitro using a fluorescent 
TF12 conjugate or hapten-peptide, as well as 111In-labeled TF12 and 
RS7. TF12’s biodistribution and use as a pretargeting agent with an 
111In-labeled hapten-peptide were assessed in several human epithelial 
cancer xenografts. Dose optimization was examined in 2 cell lines. 
Results
TF12 internalizes, but a substantial fraction remained accessible on 
the tumor surface. FACScan analysis showed only a minor change in 
fluorescent signal when probed with a fluorescent hapten-peptide over 4 h, 
and microscopy showed substantial membrane staining when reassessed 
24 hours after TF12 exposure. Only 40.1% of 111In-TF12 was internalized 
after 24 h. In vivo, excellent tumor localization of the 111In-labeled peptide 
was observed in several tumor models.
Conclusion
TF12 was retained sufficiently on the cell surface in a number of epithelial 
cancers, thereby making it suitable for pretargeted imaging and therapy 
of various TROP-2-expressing carcinomas.
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Introduction
Radioimmunotherapy is an effective therapeutic option for follicular non-Hodgkin 
lymphoma [1-3], but with challenges in solid tumors, efforts continue to search for new 
targets and procedures to improve imaging and therapeutic prospects [3]. In the search 
for new targets, TROP-2 (also known as EGP-1, epithelial glycoprotein-1; GA733-1, 
gastric antigen 733-1; and TACSTD2, tumor-associated calcium signal transducer 2) 
is of interest [4]. TROP-2 is a 47.8-kD integral membrane glycoprotein that is highly 
expressed on the majority of epithelial cancers originating from the breast, prostate, 
lungs, ovaries, gastrointestinal tract, pancreas, and skin, as well as selective expression 
in some normal tissues [5, 6]. TROP-2 expression is associated with poor prognosis, tumor 
aggressiveness and metastasis [4]. RS7 is an anti-TROP-2 monoclonal IgG antibody 
that targets epithelial cancers, including lung, breast, colon, pancreas, and prostate 
cancers [6-13]. Previous studies showed RS7 is internalized rapidly after binding TROP-2 
on the target cell surface, with an estimate of 50% internalized within 70 min in a 
breast cancer cell line, while even faster internalization rates were determined in a 
lung cancer cell line [6, 8]. In vitro and in vivo studies showing that radiometal-labeled 
RS7 (e.g., 111In or 90Y) is retained at a much higher level than radioiodinated RS7 
also are consistent with RS7’s internalization [10, 11]. More recently, this property led 
to an evaluation of RS7 as a targeting agent for drugs [14]. However, unconjugated 
humanized RS7 (hRS7) showed potent ADCC (antibody-dependent cell-mediated 
cytotoxicity) activity in gynecological cancers, suggesting that some portion of hRS7 is 
retained on the surface to allow immune effector cell interaction.
Numerous studies have shown various pretargeting strategies are superior to directly 
radiolabeled antibodies in generating high tumor/non-tumor ratios quickly, with 
tumor uptake frequently rivaling that of a directly radiolabeled F(ab’)2 or even an IgG 
[15]. With its pancarcinoma targeting capability, the anti-TROP-2 antibody, RS7, is 
an interesting antibody for pretargeting, but with previous reports indicating RS7 is 
internalized [6, 8], its utility in pretargeting, where the primary targeting agent must 
remain accessible for some time to allow binding of the secondary compound, was in 
question. Nevertheless, with the ease of making bispecific antibodies (bsAb) with the 
Dock-and-Lock technology [16], an RS7-based anti-TROP-2 x anti-hapten Tri-Fab bsAb, 
designated TF12, was prepared (Figure 1). In this report, the potential for using TF12 
in a pretargeting setting with a radiolabeled hapten-peptide was evaluated in vitro 
and in vivo in various epithelial cancer cell lines. The results show TF12 provides 
excellent localization of the radiolabeled hapten-peptide in vivo, illustrating the internal-
ization properties of this bsAb/target combination do not impede its development for 
pretargeting applications. 
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Materials and methods
Cell Lines 
MDA-MB-468 (breast cancer), SK-OV-3 (ovarian cancer), PC3 (prostate cancer), Calu-3 
(lung cancer), HT29 (colon cancer), LS174T (colon cancer), Capan-1 (pancreatic 
cancer), and Raji (Burkitt lymphoma) were purchased from American Type Culture 
Collection (Manassas, VA).
Figure 1. Schematic representation of the TF12 DNL construct (A). The hRS7-Fab-DDD2 (DDD, dimerization and docking 
domain) module forms homodimers (B). The h679 anti-HSG Fab is fused with the AD2 sequence (AD, anchoring domain) 
(C). When these 2 proteins are brought together, the AD2 portion docks to the docking domain of the DDD2 module, 
forming the tri-Fab anti TROP-2 x anti HSG bsAb TF12 (D). Disulfide bridges form between the strategically placed 
cysteines to link the 2 modules covalently.
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Antibodies and Other Agents
The TF12 Tri-Fab bsAb (molecular weight 157 kDa) was prepared by the Dock-and-Lock 
procedure [16], using a humanized version of the murine RS7 as the partner with the 
humanized anti-HSG (histamine-succinyl-glycine) hapten antibody, 679 [17] (Figure 1). 
Purified TF12 and hRS7, as well as other antibodies that were used as controls, 
including veltuzumab [Vmab; humanized anti-CD20 IgG [18]] and TF8 (humanized 
anti-CD22 [based on epratuzumab [19]] x anti-HSG DNL Tri-Fab bsAb construct), were 
all provided by Immunomedics Inc., or IBC Pharmaceuticals, Inc., Morris Plains, NJ.
Unconjugated AffiniPure goat-anti-human (GAH) IgG (heavy and light chain specific) 
and FITC-conjugated AffiniPure GAH IgG (Fc-specific; FITC-GAH IgG) were purchased 
from Jackson ImmunoResearch, West Grove, PA. GAH IgG, TF12, hRS7, and Vmab, 
were conjugated with AlexaFluor® 488 (Invitrogen, Carlsbad, CA) according to manu-
facturer’s instructions. The AlexaFluor® conjugates were designated AF-[antibody name].
IMP288, the di-HSG hapten-peptide (DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2; 
MW: 1,453 Da), was prepared and radiolabeled with 111In as described previously 
[20]. Radioiodinated TF12 and hRS7 were made by the iodogen method [21]. 125I and 
111In were provided by either Perkin Elmer (Waltham, MA, USA) or Covidien (Petten, The 
Netherlands). Instant thin-layer chromatography showed <5% unbound radionuclide. 
Immunoreactivity of radiolabeled TF12 or hRS7 was determined by Lindmo assays 
[22] or by size-exclusion high performance liquid chromatography (SE-HPLC) using an 
excess of an anti-hRS7 idiotype antibody, as described previously [17].
A fluorescent-conjugated peptide, designated RDC017, was used to assess the 
accessibility of the bsAb bound to the surface of several cell lines. RDC017 was 
prepared from a thiol-containing derivative of the IMP288 (see Supplemental Data*).
Fluorescence-Activated Cell Sorting (FACS) Analysis
FACS analysis was performed to determine hRS7 and TF12 binding to TROP-2 
expressing tumor cell lines. Cell suspensions were incubated with 5 µg/mL of RS7 and 
TF12 AF-conjugates for 30 min at room temperature (RT), and were analyzed by FACS 
(BD FACSCalibur, Becton Dickinson, San Jose, CA) after washing and fixing with 10% 
formalin. For each cell line, AF-Vmab was used as a negative control with the same 
procedures.
*http://jnm.snmjournals.org/content/suppl/2012/09/12/53.10.1625.DC1/104364_Supplemental_
Data.pdf
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Internalization Assays
MDA-MB-468 and PC3 were incubated with TF12 (5 µg/mL) for 1 h at 4°C. After 
washing to remove the unbound antibody, fresh medium was added and incubation 
was continued at 37°C. At 1, 2, and 4 h, the presence of surface-bound TF12 
was then probed using a molar excess RDC017 for 30 min at 4°C before being 
washed and then fixed with 10% buffered formalin. As an internalizing control, Raji 
cells were incubated with the Tri-Fab bsAb, TF8 (anti-CD22 x anti-HSG), using the 
same procedure and probing with the RDC017 peptide. Non-specific binding was 
examined by incubating samples only with the fluorescent agent.
In a second approach, internalization assays using 111In-radiolabeled RS7 and TF12 
with PC3 cells in culture were performed as described previously [23, 24]. Briefly, cells 
were grown to confluence in 6-well plates, and incubated in triplicate with either 
6.15 ng 111In-radiolabeled hRS7, 4.02 ng 111In-TF12, or a combination of 4.02 ng 
of 111In-TF12 and 1.74 ng of unlabeled IMP288 in 2 mL of media plus 0.5% bovine 
serum albumin (all wells received 50,000 cpm in 100 µl PBS). As a control, separate 
wells were incubated in triplicate in the presence of 2 µg of unlabeled antibody before 
adding the radiolabeled product. After 1, 2, 4, 9 and 24 h incubation at 37°C, the 
cells were washed twice with cold PBS. To remove the membrane-associated fraction, 
the cells were incubated with an acid-buffer (0.1 M acetic acid, 154 nM NaCl, pH 
2.6) for 10 min. Then, after washing the cells twice with PBS, they were removed 
from the plate with a cotton swab. The percentage of radioactivity in the two fractions, 
the membrane-associated and internalized fractions, with and without the addition of 
excess unlabeled antibody, was determined in triplicate.
Microscopic Evaluation of Internalization
An assessment of internalization of TF12 by fluorescent microscopy was performed 
in MDA-MB-468 cells following the procedure by Pirker et al. [25]. Briefly, 5 x 105 
MDA-MB-468 cells were incubated with 5 µg/mL of TF12 or control TF8 anti-CD22 
for 1 h at 4°C. CD22-expressing Raji human Burkitt lymphoma cells incubated with TF8 
served as a positive control for internalization, since TF8 was based on epratuzumab, 
a rapidly internalizing, humanized anti-CD22 antibody [19]. After washing cells with 
ice-cold PBS, 0.1% BSA, 0.1% NaN3 to remove excess unbound bsAb, the cells were 
re-suspended in fresh media, and a T0 sample was collected, with the remaining cells 
allowed to incubate at 37°C for 1 or 24 h. At the prescribed times, the cells were 
washed with cold media, then probed using either the fluorescent di-HSG-peptide RDC 
017 (3.2 nmoles/mL) or AF-conjugated AffiniPure GAH IgG (AF-GAH IgG). The set 
of cells probed with AF-GAH IgG were first fixed with 4% formalin in PBS and then 
permeabilized with 0.1% Triton-X-100 (5 min, RT) before adding the AF-GAH IgG. 
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This allowed the secondary agent to localize both surface and internalized TF12. Both 
the RDC017 and AF-GAH IgG were incubated for 30 min at 4°C before the cells 
underwent a final wash in PBS, followed by a brief fixation in PBS/formalin, and then 
a sample was placed on a slide for microscopic examination.
Biodistribution Studies
Studies were performed at either the Radboud University Medical Centre (Nijmegen, 
The Netherlands) or the Center for Molecular Medicine and Immunology (CMMI, 
United States) after receiving approval from their respective animal welfare committees. 
Mice were obtained from either Taconic (Hudson, NY, USA) or Janvier (Le Genest 
Saint Isle, France), and were acclimated to laboratory conditions for at least 1 week 
before implantation of tumors. They were housed under non-sterile standard conditions 
in cages with free access to food and water. 
A typical study involved nude mice that were inoculated subcutaneously with 1 x 106 
– 1 x 107 MDA-MB-468, SK-OV-3, PC3 or Capan-1 cells for assessment of targeting 
with radiolabeled TF12 or hRS7 IgG, or pretargeting with TF12. Pretargeting was 
also assessed using TF8 anti-CD22 bsAb with subcutaneously-grown Raji human 
Burkitt lymphoma cells. Once tumors were palpable, the studies were initiated (tumors 
generally averaged 0.1 to 0.3 g at the time of necropsy). The specific details for each 
study are given in the RESULTS. Animals were anesthetized and bled intracardially 
before euthanizing by CO2/O2 asphyxiation at various time points. After necropsy, 
tumors and organs of interest were excised, weighed, and counted in a scintillation 
counter. The percentage-injected dose per gram (% ID/g) was calculated based on a 
standard of the injected product co-counted with the tissues.
Results
In Vitro Characterization of TF12 Binding
The molecular characterization and binding properties of TF12 are given in Supplemental 
Figure 1.* Size-exclusion HPLC, SDS-PAGE confirmed purity, and its binding properties 
using Biacore to anti-rat hRS7 idiotype antibody as a surrogate for TROP-2 and the 
hapten, HSG, were confirmed. Binding analysis to MDA-MB-231 and SK-OV-3 breast 
and ovarian carcinoma cell lines showed similar affinity. By flow cytometry, TF12 and 
hRS7 bound in a similar manner to 4 cell lines of different origin shown in Table 1. 
TROP-2 expression in two other cell lines using hRS7 also is shown.
*http://jnm.snmjournals.org/content/suppl/2012/09/12/53.10.1625.DC1/104364_Supplemental_
Data.pdf
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In Vitro Assessment of Internalization
The internalization rate of murine 
RS7 in Calu-3 or MBA-MD-468 
previously indicated 50% of the bound 
antibody was internalized in ~ 1 h 
or less [6, 8]. MDA-MB-468 cells that 
were pre-incubated with TF12 at 4°C 
before being washed and incubated 
at 37°C showed continued evidence 
of binding the fluorescent hapten-pep-
tide RDC017 over 4 h (Figure 2). This 
was in sharp contrast to Raji lymphoma 
cells incubated with TF8, an anti-CD22 
bsAb. Even after just 1 h, the RDC017 
no longer bound to the cells, suggesting 
TF8 had internalized completely. It 
is important to emphasize that this 
assay does not account for bsAb that 
might otherwise be released from the 
cells into the media rather than being 
internalized. However, given the reported rapid internalization of the epratuzumab 
anti-CD22 antibody [19, 26, 27], it is reasonable to assume the inability of the peptide 
to bind to the Raji cells pre-incubated with TF8 was due to its internalization and 
not its release into the media. By microscopy, MBA-MD-468 cells pre-incubated with 
TF12 and probed with RDC017 showed intense membrane localization through 24 h, 
indicating that TF12 was still present on the surface (Figure 3). However, when the cells 
were probed with a fluorescent-conjugated anti-human IgG after fixing and permeabi-
Figure 2. Analysis of internalization of TF12 anti-TROP-2 or 
TF8 anti-CD22 bsAb in MDA-468 and Raji cells, respectively. 
Cells were probed with the fluorescent hapten-peptide RDC017 
after incubation with each bsAb. Fluorescence, as determined 
by FACScan, is expressed as Mean Fluorescent Intensity (MFI), 
normalizing data by subtracting the MFI for RDC 017 alone, 
which was minimal.
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hRS7 TF12
MDA-468 Breast 824 865
Capan-1 Pancreatic 66 71
HT29 Colonic 98 109
SK-OV-3 Ovarian 283 273
PC3 Prostate 169 ND
Calu-3 Lung 144 ND
Table 1. FACS analysis of TROP-2 expression in several epithelial cancer cell lines.*
*TROP-2 expression is given as a normalized Mean Fluorescence Intensity (MFI), subtracting corresponding negative 
controls MRI from the TF12 or hRS7 binding.
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lizing cells to allow the fluorescent conjugate to penetrate inside the cells, staining was 
seen within the cells (Figures 3D and 3E), indicating that some portion had internalized. 
Microscopic examination of Raji cells incubated with TF8 and probed with RDC017 
immediately after the 4°C incubation showed a patchy distribution that became more 
diffuse and faint (nearly absent) when probed after a 1-h incubation at 37°C, again 
suggesting that most of the anti-CD22 bsAb had internalized (not shown).
In order to provide a more quantitative estimate of how much TF12 is internalized, 
Figure 3. Visualization of TF12 internalization. MDA-MB-468 cells were incubated for 1 h at 4°C with TF12 before replac-
ing with fresh media, and raising the incubation temperature to 37°C. (A-C) The cells were then probed with fluorescent 
RDC017 immediately after the 1-h 4°C incubation (A), after 1 h at 37°C (B), or 24 h at 37°C (C). D and E represent 
specimens of the same MDA-MB-468 cells first incubated with TF12 for 1 h at 4°C, but in this case, TF12 binding was 
revealed using AF-GAH IgG after fixing and permeabilizing the cells. (D) immediately following the 1-h 4°C incubation; 
(E) after 1-h 37°C incubation. Images were brightened and the contrast enhanced using Adobe® Photoshop®.
A
C
B
E
D
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% Internalized antibody* (mean ± SD)
Time (h) RS7 TF12 TF12+IMP288
1 14.9 ± 0.97 13.6 ± 3.09 22.2 ± 9.79
2 16.6 ± 1.02 16.3 ± 1.13 22.2 ± 2.49
4 18.6 ± 0.58 22.8 ± 1.47 23.2 ± 0.46
9 25.3 ± 0.18 28.3 ± 2.54 30.2 ± 2.34
24 32.0 ± 2.09 40.1 ± 4.99 38.4 ± 4.68
*Internalized antibody is expressed as a percentage [internalize ÷ (internalized + membrane-bound) x (100)]. In the 
presence of excess unlabeled antibody, the % internalized antibody at 24 h ranged from 2.6 to 4.1%.
Table 2. Internalization of 111In-labeled RS7, TF12 and TF12 + IMP288 in PC3 cells in culture. 
Figure 4. Biodistribution of 125I-TF12 in nude mice bearing Capan-1 human pancreatic cancer xenografts. Percent injected 
dose per gram tumor and blood (A), other tissues (B). 
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TF12 and hRS7 were radiolabeled with 111In and the fractional amount internalized 
over 24 h was evaluated in the PC3 prostate cell line. One hour after cells were 
incubated with the antibodies, ~14% of the antibody had internalized (Table 2). Over 
the next 8 h, the percent internalized increased nearly 2-fold, to 25.3 ± 0.18% for the 
hRS7 IgG and to 28.3 ± 2.54% for TF12. By 24 h, 40.1 ± 4.99% of the TF12 bsAb 
had internalized, while about one-third of the hRS7 IgG was inside the cell. Thus, in 
this cell line, ~60% of the bsAb is retained on the surface of the cells. When divalent 
hapten-peptide IMP288 was co-administered with radiolabeled TF12, uptake over the 
first 2 h was higher than with the bsAb alone. These data suggest that cross-linked TF12 
initiates an earlier spurt of internalization that seems to plateau, achieving the same 
maximum uptake as TF12 alone (not cross-linked by the hapten-peptide). As expected, 
pre-incubating cells with unlabeled antibody blocked binding of the radiolabeled 
antibody to TROP-2, illustrating that internalization of the radiolabeled antibody was 
related to its binding to TROP-2.
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Biodistribution Studies with Antibody Alone
A biodistribution study performed in animals bearing the Capan-1 human pancreatic 
xenograft showed radioiodinated TF12 cleared rapidly from the blood, with 0.15 ± 
0.03% ID/g in the blood at 24 h (Figure 4), which is in agreement with the rapid 
clearance found with other tri-Fab bsAb [16]. Tumor uptake peaked at 2 h post-injection 
(5.6 ± 0.63% ID/g), falling to 1.43 ± 0.09% ID/g at 24 h. Similar levels of 125I-TF12 
were found in MBA-MD-468 breast and SK-OV-3 ovarian cancer cell lines 1 day after 
injection (0.91 ± 0.018% ID/g and 1.29 ± 0.33% ID/g, respectively), with blood 
concentrations averaging ≤0.4% ID/g. The spleen was the only tissue that showed an 
unusual early uptake, averaging ~20 to 25% ID/g at 2 and 5 h post injection, but 
like all the other normal tissues, TF12 cleared quickly, being equal to that in the liver 
(~ 0.5% ID/g) at 24 h.
The rapid clearance of the TF12 bsAb and its relatively low tumor uptake was in 
sharp contrast to the slow blood clearance of the hRS7 IgG and its higher uptake. For 
example, in PC3-bearing nude mice, tumor uptake of 125I-hRS7 on day 3 was 7.3 ± 
2.3% ID/g, while the concentration in the blood was 8.1 ± 1.1% ID/g. However, it is 
important to note that in PC3-bearing mice given 111In-hRS7, tumor uptake was 36.5 ± 
13.3% ID/g, whereas the blood concentration was similar to radioiodinated hRS7 IgG 
on day 3. These results are indicative of an internalizing antibody binding to a stable 
chelate-radiometal, where the percent uptake accounts for the cumulative binding of 
hRS7, its internalization, and entrapment of the 111In-activity over time. However, the 
uptake of radioiodinated IgG or bsAb is expected to reveal only the amount of antibody 
that remains accessible (i.e., has not been internalized and catabolized).
Pretargeting Studies
Despite in vitro evidence that some portion of TF12 is internalized, biodistribution 
studies in mice bearing different s.c. tumor xenografts and pretargeted the day before 
with TF12 showed reasonably high (~10-15% ID/g) uptake of the 111In-labeled peptide 
in the tumors (Table 3). Tissue uptake and blood concentrations were low, with tumor-to-
blood ratios ranging from ~60:1 to 1000:1.
Additional studies examined several doses of TF12 (40, 79, and 158 µg) given with 
a fixed amount of IMP288 (0.026 nmole; TF12:IMP288 mole ratios = 10, 20, and 
40:1) in the SK-OV-3 and MDB-MD-468 models (Figure 5). 111In-IMP288 uptake in 
SK-OV-3 at 3 h increased from 5.3 ± 1.2% ID/g at the 10:1 ratio to as high as 21.3 
± 6.2% ID/g at the 40:1 ratio. Tumor uptake for TF12 in these animals (as measured 
by 125I-TF12 added to TF12) was similar in the groups, ranging from 1.1 to 1.5% 
ID/g. In contrast, MDA-MB-468 uptake was only modestly increased from 11.6 ± 
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Figure 5. Optimizing IMP288 uptake in SK-OV-3 human ovarian cancer and MDA-MB-468 human breast cancer 
xenografts in nude mice. Animals (n=5/interval) were given 40, 79, or 158 µg of TF12 (containing trace 125I-TF12) and 
then 16 h later, they received 0.026 nmoles (~40 µCi) of 111In-IMP288. Animals were necropsied at 3 (A) and 24 h (B). 
Tumor and blood concentrations for the 111In-IMP288 (bars) and the 125I-TF12 (in parentheses) at the 3-h necropsy, as 
well as the 24-h tumor data. Tumors averaged between 0.1 to 0.3 g. 
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MBA-MD-468 SK-OV-3 PC3
Tumor 14.8 ± 3.4 13.6 ± 2.6 9.8 ± 1.6
Blood 0.02 ± 0.00 0.04 ± 0.02 0.16 ± 0.02
Spleen 0.17 ± 0.03 0.56 ± 0.34 0.31 ± 0.07
Kidney 2.45 ± 0.55 2.51 ± 0.64 1.49 ± 0.29
Liver 0.10 ± 0.02 0.20 ± 0.06 0.21 ± 0.03
Tumor to blood 1037 ± 303 378 ± 126 62 ± 4
Tumor weight (g) 0.06 ± 0.02 0.20 ± 0.09 0.07 ± 0.01
Table 3. Biodistribution of pretargeted 111In-IMP288 in MDA-468, SK-OV-3 and PC3 3 h after injection. 
Nude mice were injected intravenously with 79 µg (0.5 nmol) 125I-TF12 (0.37 MBq) and 0.025 nmol 111In-IMP288, with 
exception of PC3 studies, where 462 µg (~3 nmol) of 125I-TF12 and 0.11 nmol 111In-IMP288. In all cases, 111In-IMP288 
was given 16 h after the TF12 injection. Data are expressed as % ID/g (mean ± SD; n=5).
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1.9 to 15.2 ± 3.3% ID/g over this same range of TF12. Interestingly, tumor uptake 
of the 125I-TF12 was nearly 2-fold higher in the MDA-MB-468 xenografts than in the 
SK-OV-3 tumors, yet the breast cancer xenograft did not have a higher IMP288 uptake 
commensurate with the higher TF12 level. By 24 h, tumor uptake for the 111In-IMP288 
plateaued in both models, even though the uptake of the 125I-TF12 decreased nearly 
2- to 4-fold. 
These targeting results are in sharp contrast to those obtained with the TF8 anti-CD22 
bsAb in BALB/c nude mice bearing CD22-expressing Ramos or Raji tumors. In this 
study, animals were given 0.25 nmoles (40 µg) of TF8 followed 24 h later with 0.025 
nmoles of 111In-IMP288. Three hours later, uptake in Raji tumors was just 0.17 ± 
0.07% ID/g and in Ramos, 0.15 ± 0.08 (n=4 in each). The low tumor uptake was 
predicted by the earlier in vitro studies that indicated efficient internalization within 1 h. 
Thus, even though tumor/blood ratios were high (e.g., averaging 38:1 in Raji-bearing 
mice), the low tumor uptake indicated unfavorable pretargeting with this bsAb.
Discussion
Pretargeting procedures for localizing radionuclides are very attractive, because they 
are able to localize the radiolabeled product (e.g., hapten-peptide or biotin) very 
quickly, developing very high tumor/nontumor ratios rapidly, and often with tumor 
uptake that can rival a directly radiolabeled IgG or F(ab’)2 fragment 
[15]. Bispecific 
antibody pretargeting procedures have typically relied on the bsAb’s natural clearance 
from the blood and tissues, requiring a delay of several days before the hapten-pep-
tide is given [15]. It is imperative that the bsAb remain accessible in the tumor (e.g., 
not internalized) in order for the radiolabeled hapten-peptide to be localized. Thus, if 
the pretargeting agent binds an antigen that triggers internalization, this target likely 
would not be suitable for pretargeting. For example, anti-CD22 antibodies are known 
to internalize rapidly, making these antibodies attractive candidates for targeting drugs 
or toxins that exert their effects intracellularly [27-32]. Pantelias et al. [33] compared the 
pretargeting of 3 different antigens associated with hematopoietic malignancies, 
anti-CD20, CD22, and HLA-DR, finding the anti-CD22 pretargeting agent had the 
lowest uptake of the 3 conjugates. However, CD22 also had the lowest density of 
the 3 antigens in the various cell lines examined, and thus this result may have merely 
reflected the lower antigen density. Herein, we included an evaluation of the TF8 
tri-Fab bsAb that binds to CD22, suspecting its rapid internalization would affect its 
utility in pretargeting. We first noted that in vitro, the TF8 anti-CD22 bsAb was no 
longer accessible within just 1 h of its binding, and then in vivo, no appreciable 
localization of the radiolabeled hapten-peptide was observed. Thus, we agree that 
bsAbs to CD22 are not suitable for pretargeting, but not because it is insufficiently 
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expressed on target cells, but because the bsAb is efficiently internalized. Instead, 
we previously recommended the TF4 anti-CD20 tri-Fab bsAb be used for pretargeting 
B-cell malignancies [34]. It is interesting to note that in those studies, 111In-TF4 had 
substantially higher uptake in tumor xenografts than radioiodinated TF4, suggesting 
some internalization over the 1-day pretargeting interval.
While antibody-based therapeutics (unconjugated and conjugated) are widely studied 
in hematological malignancies, it has been more challenging to find suitable targets for 
epithelial cancers [3]. In this regard, TROP-2 represents a promising new target for cancer, 
being expressed on the surface of many carcinomas [4]. Early in its development, the 
anti-TROP-2 antibody, RS7, was reported to internalize, and therefore most studies have 
focused on developing targeting strategies that take advantage of RS7’s internalization 
properties [7, 10, 14, 35]. Shih et al. [8] examined internalization in MDA-MD-468 cells in 
vitro over 30 min and reported an extrapolated internalization rate of 0.0147 min-1, 
indicating that under saturating conditions, surface-bound antibody will be internalized 
over ~70 min. Other studies in the Calu-3 human lung cancer cell line suggested an 
even faster rate of internalization, with most of the antibody being internalized within 
45 min [6]. This compares to the anti-CD22 antibody, where 50% of the antibody 
was reported to be internalized within 10 min, with data indicating that nearly all the 
antibody had internalized within 2 h [27]. In vivo studies comparing RS7 labeled with 
a radiometal with RS7 labeled by the more traditional non-covalent radioiodination 
procedures showed substantially higher tumor retention when the antibody was labeled 
with a residualizing radionuclide, supporting the internalization capability of the RS7 
antibody [7, 10, 11]. Thus, these data gave pause to developing a pretargeting procedure 
for TROP-2 localization. However, given TROP-2’s presence in many carcinomas, and 
because the modular Dock-and-Lock method greatly simplifies bsAb preparation [16], 
TF12 was prepared for evaluation.
Our findings with the hRS7 IgG and the TF12 bsAb indicate that despite some initial 
internalization, sufficient residual bsAb remains on the surface of tumor cells to capture 
the hapten-peptide after ~1-day delay. Some of the in vitro studies were performed with 
the washed cells placed in fresh media before probing with the fluorescent hapten-pep-
tide. Thus, it is unlikely that re-expression of antigen with re-engagement by the bsAb 
contained in the media explained the continued presence of TF12 on the cell surface. 
Because TF12 clears so quickly from the blood, it is equally unlikely that there would be 
considerable replenishing of the bsAb after the internalization process had occurred. 
Therefore, although there have been reports that internalization is nearly complete 
within ~1 h, our studies with TF12 and hRS7 radioconjugates found a smaller portion 
of the antibody, perhaps as low as 10-20%, is internalized over the first hour, but 
thereafter, internalization proceeds at a much slower rate (i.e., it is not linear). Indeed, 
it appears that after an initial spurt of internalization, some cell lines only had ~50% of 
the antibody internalized over 24 h.
These observations are very important, because antibodies are often characterized as 
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being internalizing or non-internalizing, when in fact there are varying rates among 
antibodies that are “actively” internalized, as well as rates for those “passively” taken 
into the cell. At least in the case of TF12, the in vitro studies using the fluorescent 
hapten-peptide were helpful for illustrating the continued capacity to bind the hap-
ten-peptide after several hours and even 1 day. This type of assay should be useful for 
predicting which bsAb would have suitable surface retention for in vivo targeting, but it 
is unlikely it will be useful for predicting the actual quality of a given pretargeting agent, 
because there are other parameters that impact tumor localization [36]. With recent 
clinical studies, using the TF2 anti-CEACAM5 tri-Fab bsAb, also finding the bsAb is 
cleared sufficiently within just 1 day to allow efficient localization of the radiolabeled 
hapten-peptide [37, 38], we are encouraged to continue developing the TF12 bsAb for 
future clinical evaluation.
Conclusion
TF12 is a suitable bsAb for pretargeting different cancers that express TROP-2, primarily 
because after an initial spurt of internalization, sufficient bsAb remains on the surface to 
allow efficient capture of the hapten-peptide. With recent preclinical studies showing 
hRS7 targeting of prostate cancer [13], and with the need for developing better imaging 
procedures for this disease, this clinical indication should be considered. However, 
hRS7-SN-38 drug conjugates also have been proven to be effective in several cancer 
cell lines, including lung, pancreatic, colorectal, and breast cancers [6, 7, 12, 14, 39], and 
thus developing a highly sensitive imaging procedure for these cancers, perhaps to be 
used in concert with the therapeutic agent, is of interest as well.
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Abstract
TF12 is a trivalent bispecific antibody that consists of two anti-TROP-2 Fab 
fragments and one anti-HSG (histamine-succinyl-glycine) Fab fragment. The 
TROP-2 antigen is found in many epithelial cancers, including prostate cancer 
(PC), and therefore this bispecific antibody could be suitable for pretargeting 
in this cancer. In this study, the characteristics and the potential for pretargeted 
radioimmunoimaging and radioimmunotherapy with TF12 and the radiolabeled 
di-HSG peptide IMP288 in mice with human PC were investigated.
Methods 
The optimal TF12 protein dose, IMP288 peptide dose, and dose interval for 
prostate cancer targeting were assessed in nude mice with s.c. PC3 xenografts. 
ImmunoPET/CT was performed using TF12/68Ga-IMP288 at optimized 
conditions. The potential of pretargeted radioimmunotherapy (PRIT) using the 
TF12 pretargeted 177Lu-IMP288 was determined.
Results
TF12 and 111In-IMP288 showed high and fast accumulation in the tumor (20.4 
± 0.6% ID/g at 1 h p.i.) at optimized conditions, despite the internalizing 
properties of TF12. The potential for PRIT was shown by retention of fifty percent 
of the 111In-IMP288 in the tumor at 48 h p.i. One cycle of treatment with TF12 
and 177Lu-IMP288 showed significant improvement of survival compared to 
treatment with 177Lu-IMP288 alone (90 vs 67 days, P <0.0001) with no renal or 
hematologic toxicity.
Conclusion
TROP-2-expressing prostate cancer can be pretargeted efficiently with TF12, 
with very rapid uptake of the radiolabeled hapten-peptide, IMP288, sensitive 
immunoPET, and effective therapy.
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Introduction
Prostate cancer (PC) causes significant morbidity, and still is the second leading cause 
of cancer-related deaths in men in the Western world. Approximately 17% of American 
men will be diagnosed with PC during their lifetime, and 20% of them will die of the 
disease. While curable when diagnosed in an early stage and treatable in the hor-
mone-dependent stage, PC treatment options are limited in advanced stages. In view 
of this, it is essential to differentiate between metastatic and non-metastatic disease to 
predict disease outcome and to determine treatment options. Furthermore, an accurate 
imaging method for determining the location, extent and biological potential of PC 
could improve patient outcome by directing therapy more accurately both in surgery 
and radiation therapy. Trans Rectal Ultrasound (TRUS) and conventional Magnetic 
Resonance Imaging (MRI) are rather effective for diagnosis of the primary tumor, but 
adequate detection of metastatic spread leaves room for further improvement. Positron 
Emission Tomography (PET) imaging is a widely used imaging modality to detect 
metastatic disease in several cancers. However, 18F-FDG-PET is not suited for staging 
patients with PC, since sensitivity is low due to artifacts related to its renal excretion 
and due to the relatively low avidity of differentiated prostate cancer for 18F-FDG [1, 2]. 
Several other radiotracers have been developed for imaging metastasized PC, but all 
of them have disadvantages, such as low sensitivity or practical considerations, such as 
the need for an on-site cyclotron for the 11C-tracers. Antibody imaging in humans has 
been reported with several radiolabeled monoclonal antibodies, such as 7E11-C53 
(Prostascint®, capromab pendetide) and J591 [2]. Due to the long circulatory half-lives 
of imaging agents based on intact antibody molecules, lesions can only be depicted 
several days after injection.
hRS7 is a humanized IgG1 monoclonal antibody directed against TROP-2, also known 
as EGP-1 (epithelial glycoprotein-1), GA733-1, gp50/T16, TACSTD2 (tumor-associ-
ated calcium signal transducer 2). TROP-2 is a 46 kDa transmembrane glycoprotein 
expressed in carcinomas of the lung, bladder, breast, cervix, ovary, stomach and 
prostate [3]. Most normal human tissues do not express TROP-2, but it is found at low levels 
in several normal glandular cells, including glands in the bronchus, breast, prostate and 
skin, and ducts and acini of the pancreas [4]. Given its expression in prostate cancer, 
we studied the potential targeting ability of hRS7 IgG in a nude mouse-human prostate 
cancer model [5], showing excellent in vivo targeting of PC3 xenografts with 89Zr- and 
111In-hRS7 IgG within 3 days. The slow clearance from the circulation results in low 
tumor-to-background ratios at earlier time points after i.v. injection. For earlier imaging, 
we explored a pretargeting approach using the bispecific monoclonal antibody 
(bsAb) TF12, a trivalent bsAb that consists of two anti-TROP-2 Fab fragments and one 
anti-HSG (histamine-succinyl-glycine) Fab fragment [6]. In pretargeting, unlabeled TF12 
is injected intravenously, and when it has cleared from the blood, an HSG-substituted 
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radiolabeled hapten-peptide is injected. This hapten-peptide will be trapped in the 
tumor by the anti-HSG arm of the bsAb or is rapidly cleared from the body.
In this study, the characteristics and the potential for pretargeted radioimmunoimaging 
and radioimmunotherapy with TF12 and the radiolabeled di-HSG peptide, IMP288, 
in mice with human PC xenografts were investigated.
Materials and methods
The anti-TROP-2 x anti-HSG bsAb TF12 was produced using the Dock-and-Lock 
technology (DNL®) as described previously [7]. The production and characterization of 
the anti-TROP-2 mAb hRS7 have been described previously [3].The DOTA-conjugated 
hapten-peptide IMP288 (DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2) was prepared 
as described by McBride et al. [8]. 
Cell culture
The human prostate cancer cell line, PC3, is an androgen-independent cell line, originally 
derived from a PC bone metastasis. Cells were obtained from ATCC (CRL 1435; 
Manassas, VA) and were grown in RPMI 1640 medium (GIBCO®, Life Technologies 
Corporation, Carlsbad, CA, USA), supplemented with 10% FCS (fetal calf serum, Life 
Technologies, Grand Island, NY). Before subcutaneous inoculation of mice to induce 
PC3 xenografts, tumor cells were washed with 0.9% NaCl, disaggregated with 
trypsin and resuspended in 67% complete RPMI 1640 medium and 33% Matrigel (BD 
Biosciences, San Jose, CA) to the appropriate concentration (3 x 106 cells/200 µL). 
Mouse model
All experiments were approved by the institutional Animal Welfare Committee of the 
Radboud University Medical Center (Nijmegen, The Netherlands), and were conducted 
in accordance with the principles set forth by the Revised Dutch Act on Animal Experi-
mentation.
Male BALB/c nude mice (Janvier SAS, Le Genest Saint Isle, France), 8–9 weeks old, 
were adapted to laboratory conditions for at least one week before experimental use. 
They were housed under non-sterile standard conditions in filter-topped cages (5 mice 
per cage), with free access to animal chow (Sniff Voer®) and water.
The mice were inoculated s.c. in the flank with 200 µL of PC3 cell suspension (3 x 106 
cells). The s.c. PC3 tumors grew to approximately 0.1 g in 10 days after tumor cell 
inoculation, as determined by caliper measurements in 3 dimensions using the formula 
V = 4/3π (length/2 x width/2 x height/2), assuming that the density of tumor tissue is 
1 g/cm3. The radiolabeled preparations (0.2 mL) were injected intravenously.
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Radiolabeling of IMP288 and hRS7
The DOTA-conjugated IMP288 was radiolabeled with 111In (Covidien, Petten, The 
Netherlands), 177Lu (IDB Holland BV, The Netherlands), or with 68Ga from a TiO2-based 
68Ge/68Ga generator (Cyclotron Co, Ltd., Obninsk, Russian Federation). Radiolabeling 
was performed essentially as described previously by Schoffelen et al. [9]. For 68Ga-
labeling, 84 MBq of 68GaCl3 was added to 1 µg of IMP288 in 1 M HEPES buffer 
(50 µL, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, Sigma-Aldrich, USA). After 
incubation at 95°C for 20 minutes, 50 mM ethylenediaminetetraacetic acid (EDTA, 
Sigma-Aldrich, St. Louis, MO, USA) was added to a final concentration of 1 µM. The 
68Ga-IMP288 preparation was purified on an Oasis® HLB cartridge (Waters, Milford, 
MA, USA) and eluted with 1 mL of 25% ethanol essentially as described previously [10]. 
Before i.v. injection, the preparation was diluted at least 2.5 times with 0.5% bovine 
serum albumin (BSA, Sigma-Aldrich) in PBS.
DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed 
essentially as described previously [3, 5]. The radiochemical purity of the labeled 
IMP288 preparations was determined using instant thin-layer chromatography (ITLC) 
and reversed-phase high-performance liquid chromatography (RP-HPLC), as described 
previously [9]. ITLC was performed to determine the fraction of unbound 111In, 177Lu, or 
68Ga (mobile phase 1:1 0.1 M ammonium acetate (Merck, Darmstadt, Germany) and 
0.1 M EDTA), and the fraction of colloid (mobile phase 1:1 methanol (Merck) and 
0.25 M ammonium acetate, pH 5.5). 
For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 µm, 4.6 × 250 mm; Agilent 
Technologies, Amstelveen, The Netherlands) was eluted with a mixture of 97% of a 
0.1% trifluoroacetic acid in H2O solution (TFA, Lab-scan, Analytical Sciences, Brussels, 
Belgium) with 3% of a 0.1% TFA in acetonitrile solution (Lab-scan, Analytical Sciences, 
Brussels, Belgium) with a linear gradient to 100% of the latter solution over 10 minutes 
at a flow rate of 1 mL/min. Radiochemical purity (RCP) of all labeled IMP288 
preparations always exceeded 97%; the RCP of 177Lu-hRS7 exceeded 98%.
Radiolabeling of TF12
The bsAb TF12 was radioiodinated with 125I according to the iodogen method [11]. 
Twenty µg of TF12 and 3.7 MBq Na125I (GE Healthcare Europe, Den Bosch, The 
Netherlands) in 50 mmol/L phosphate buffer, pH 7.4, were incubated in an Eppendorf 
vial coated with 50 µg of iodogen (1,3,4,6-tetrachloro-3,6-diphenylglycoluril; Pierce 
Biotechnology, Inc.) for 10 minutes at room temperature. 125I-TF12 was purified on a 
PD-10 column (GE Healthcare, London, UK) eluted with PBS, 0.5% BSA. 
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Immunoreactivity
The anti-TROP-2 reactivity of radiolabeled TF12 and hRS7 was determined using freshly 
trypsinized PC3 cells, as described by Lindmo et al. [12] with minor modifications. The 
bispecific immunoreactivity of TF12 was demonstrated by incubating PC3 cells with 
TF12 (10 µg/mL) and subsequent incubation with 111In-IMP288 (200 Bq/ml). After 1 h 
at 37°C, the total activity and activity in the cell pellet were determined in a γ-counter. 
More than 70% of the added hapten-peptide specifically bound to the PC3 cells.
Biodistribution studies 
The effect of the TF12 dose on tumor uptake of a fixed amount (0.25 nmol = 400 ng) 
111In-labeled IMP288 in mice with s.c. PC3 tumors was determined by administering 
1.25, 2.5, 5.0 or 12.5 nmol (231, 462, 924 or 2310 µg) of TF12 i.v., and then 
16 hours later 0.4 MBq of 111In-IMP288 was injected. Two hours later, mice were 
dissected and tissue uptake determined (5 mice/group).
Subsequently, the optimal amount of IMP288 that can be given after administering 
a fixed dose of TF12 (2.5 nmol = 462 µg) was determined. Four doses of IMP288 
were examined: 25, 50, 100 and 200 nmol, each given 16 h after TF12. Two hours 
after injection of 0.4 MBq of 111In-IMP288, mice were euthanized and necropsied 
(5 mice/group). The optimal interval between TF12 and 111In-IMP288 injection was 
assessed at the pre-selected optimal TF12 (2.5 nmol) and IMP288 doses (0.1 nmol). 
The following intervals were tested: 12, 14, 18, 20, 24 and 36 h. Lastly, under 
optimized conditions (2.5 nmol TF12, 0.1 nmol IMP288, 16-h interval), the retention 
of 111In-IMP288 in the tumor was monitored over the course of 3 days.
Pretargeted immunoPET
Groups of 5 mice with s.c. PC3 tumors were injected i.v. with 2.5 nmol of TF12 and 
16 h later with 5 ± 2 MBq (0.1 nmol) of 68Ga-IMP288. One hour after injection 
of 68Ga-IMP288, mice were euthanized by O2/CO2 asphyxiation and PET/CT 
images were acquired with an Inveon® animal PET/CT scanner (Siemens Preclinical 
Solutions, Siemens Healthcare Molecular Imaging, Knoxville, TN, USA), having an 
intrinsic spatial resolution of 1.5 mm. The animals were placed in a prone position. 
PET emission scans were acquired for 20 min, preceded by CT scans for anatomic 
reference (spatial resolution, 113 µm; 80 kV; 500 µA; exposure time, 300 ms). Scans 
were reconstructed using Inveon Acquisition Workplace software (version 1.2; Siemens 
Preclinical Solutions), with an ordered set expectation maximization-3D/maximum a 
posteriori (OSEM3D/MAP) algorithm with the following parameters: matrix 256 x 256 
x 159, pixel size 0.43 x 0.43 x 0.8 mm3 and a beta-value of 0.1. After imaging, 
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tumors and organs were dissected, weighed and counted in a gamma counter to 
determine biodistribution of the radiolabel. The percent-injected dose per gram (% 
ID/g) tissue was calculated against an injection standard. 
Pretargeted radioimmunotherapy
The potential of pretargeted radioimmunotherapy (PRIT) with TF12 and 177Lu-IMP288 
was assessed in a therapy experiment in mice with PC3 xenografts (10 mice/group). 
Mice were treated with TF12/177Lu-IMP288 or 177Lu-hRS7 IgG 9 days after PC3 cell 
inoculation, when tumors weighed approximately 0.1 g.
In the mice that were treated with PRIT, tumors were pretargeted with 2.5 nmol TF12 16 
h before administration of the 177Lu-IMP288. The next day, mice received the maximum 
177Lu activity dose that could be labeled to 0.1 nmol IMP288 (13.7 MBq). Another 
group was treated with the maximum tolerable dose of 177Lu-hRS7 (11.1 MBq, 13.8 
µg). One control group of PC3 tumor-bearing mice was injected i.v. with vehicle (200 µL 
PBS, 0.5% BSA) twice instead of TF12 and IMP288. The other control group received 
vehicle instead of TF12 and was injected 16 h later with 13.7 MBq of 177Lu-IMP288.
Tumor size was measured in three dimensions with a caliper and body weight was 
determined twice weekly starting 7 days after tumor cell inoculation. Blood samples 
of 0.1 mL of all mice were collected via submandibular bleeding before therapy, and 
14, 21, 35, 42, 56, 70 and 88 days after administration of the agents to determine 
hemoglobin levels, and leukocyte and platelet counts. Blood creatinine and BUN levels 
were determined before and 4 and 7 weeks after start of the therapy. When the 
humane endpoint was reached (tumor size >2 cm3 or animal discomfort level >3), mice 
were euthanized by O2/CO2-asphyxiation and dissected. At dissection, the tumor and 
kidneys were excised and weighed. The experiment was terminated 120 days after 
injection of the radiolabeled compounds and the remaining mice were euthanized and 
dissected. 
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows® 
Survival curves were compared using the log-rank test. The level of significance was 
set at a P-value of less than 0.05.
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Results
Biodistribution studies
The optimal TF12 protein dose to pretarget the PC3 tumors was determined in a 
protein dose escalation study. Tumor uptake of 111In-IMP288 (0.25 nmol) 2 h after 
injection increased with increasing bsAb TF12 protein doses, as summarized in Figure 
1A. Highest uptake (7.5% ID/g) was obtained when the tumor was pretargeted by 
injection of 12.5 nmol of TF12. The optimal amount of TF12 was determined to be 
2.5 nmol, since there was only minor improvement of tumor uptake (1.5-fold increase) 
at the highest bsAb dose (5-fold increase) . 
Following injection of increasing amounts of IMP288 at a fixed TF12 dose of 2.5 nmol, 
tumor uptake clearly decreased (Figure 1B). Optimal uptake in the tumor (20-25% ID/g) 
was obtained at hapten-peptide doses ≤0.1 nmol IMP288. Based on these results, 0.1 
nmol of IMP288 was used in further experiments, since this amount of IMP288 could 
be labeled with activity doses required for pretargeted immunoPET imaging (68Ga) and 
for pretargeted radionuclide therapy (177Lu). 
Recently, in vitro experiments have shown that TF12 is slowly internalized by the tumor 
cell after binding to TROP-2 [6]. To estimate the kinetics of internalization of TF12 in vivo, 
Figure 1A. Biodistribution of a fixed dose of 111In-IMP288 (0.25 nmol, 0.4 MBq) injected intravenously 16 h after injec-
tion of escalating TF12 doses (1.25-12.5 nmol) in BALB/c nude mice with a subcutaneous PC3 xenograft at 2 h after 
injection (n=5).
Figure 1B. Biodistribution of escalating 111In-IMP288 doses (0.025-0.2 nmol, 0.4 MBq) injected i.v. 16 h after a fixed 
dose of TF12 (2.5 nmol) in BALB/c nude mice with a subcutaneous PC3 xenograft at 2 h days after injection (n=5).
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the biodistribution of bsAb TF12 labeled with 111In and 125I was studied in mice with s.c. 
PC3 tumors 16 h p.i. A clear and significant difference between uptake of 111In-TF12 
(4.9 ± 0.6% ID/g) and 125I-TF12 (0.7 ± 0.2% ID/g, P<0.0001) in the tumor was 
observed 16 h after injection of the radiolabeled TF12, which could be explained by 
the internalizing characteristics of TF12. The biodistribution of the 111In-labeled TF12 
indicated that the bsAb accumulated preferentially in the tumor (4.9 ± 0.6% ID/g, 16 
h p.i.), while the blood level at that time did not exceed 0.4 ± 0.1% ID/g. The optimal 
interval between injection of TF12 and 111In-IMP288 was assessed by examining 
seven intervals: 12, 14, 16, 18, 20, 24 and 36 hours (3-5 mice/group, Figure 2). 
Extension of the time interval between injection of TF12 and injection of 111In-IMP288 
from 16 to 36 hours significantly decreased tumor uptake of the radiolabeled hapten, 
from 9.6 ± 1.3% ID/g to 1.0 ± 0.5% ID/g (P<0.0001). Shortening the interval from 
16 to 14 or 12 h did not improve tumor uptake significantly (P=0.81 and P=0.14, 
respectively), while tumor-to-blood ratios where lower at the shorter intervals. Based on 
these observations an interval of 16 h between injection of TF12 and radiolabeled 
IMP288 was used.
Retention of radiolabeled IMP288 in the tumor over time is particularly important 
in pretargeted radioimmunotherapy. Retention was determined at the optimal TF12 
and 111In-IMP288 dose (16-h interval) during 3 days p.i. (5 mice/group). Figure 3 
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Figure 2. Biodistribution of 111In-IMP288 (0.1 nmol, 0.4 MBq) in BALB/c nude mice with a subcutaneous PC3 xenograft 
measured 2 h after injection (n=3-5). Mice were pre-injected i.v. with 2.5 nmol of TF12 at increasing time interval before 
injection of 111In-IMP288 (12, 14, 16, 18, 20, 24, and 36 h). 
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shows that >50% of the 111In-label 
was still present in the tumor at 48 
h after injection (5.8 ± 0.7% ID/g, 
t½ = 50 h).
At the optimized conditions determined 
in the experiments described above, 
111In-IMP288 showed a rapid and 
high uptake in the tumor (20.4 ± 
0.6% ID/g, 2 h p.i.) while concen-
trations in blood (0.9 ± 0.2% ID/g) 
and normal tissues were low (Figure 
4). 111In-IMP288 cleared very rapidly 
from the blood via the kidneys. The 
kidneys were the normal organs with 
the highest uptake (2.2 ± 0.1% ID/g). 
Pretargeted immunoPET
With the same dosing schedule, similar results were obtained with TF12 and 
68Ga-IMP288, with slightly lower tumor uptake (12.2 ± 2.3% ID/g). To determine 
the potential of pretargeted immunoPET to detect TROP-2-expressing tumors, microPET 
imaging of 68Ga-IMP288 was performed in nude mice with s.c. PC3 tumors of 
Figure 4. Biodistribution of 111In-IMP288 (0.1 nmol, 0.4 MBq) injected i.v. 16 h after i.v. injection of TF12 (2.5 nmol) in 
BALB/c nude mice with a subcutaneous PC3 xenograft at 2 h after injection (n=5).
Figure 3. Tumor uptake at increasing time points (1, 2, 4, 24, 
48, 70 h) after injection of TF12/111In-IMP288 (2.5 nmol/0.1 
nmol, 0.4 MBq, 16-h interval, n=5). 
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approximately 0.1 g. Images acquired as early 
as 1 h p.i. clearly showed the PC3 tumors 
(Figure 5). No accumulation of radioactivity in 
the other normal organs was observed, except 
for the kidneys and the bladder.
Pretargeted radioimmunotherapy
The potential of PRIT using the bsAb TF12 and 
177Lu-labeled IMP288 was determined in a 
therapy experiment and compared to RIT with 
177Lu-hRS7 (11.1 MBq, 13.8 µg). PRIT with 
2.5 nmol TF12 and 13.7 MBq 177Lu-IMP288 
significantly improved the median survival of 
mice with s.c. PC3 tumors from 67 days to 90 
days (P<0.0001, Figure 6). The control groups 
received either 177Lu-IMP288 without TF12 or 
vehicle. Median survival of the mice in both control groups was similar, indicating that 
there is no effect of administration of a high activity dose of 177Lu-IMP288 alone. At 
the end of the experiment (120 d), all mice treated with 177Lu-hRS7 IgG were still alive. 
Figure 5. Anterior 3D volume-rendering projection of a microPET/
CT scan of a BALB/c nude mouse with a subcutaneous PC3 tumor 
on the shoulder injected with TF12 and 68Ga-IMP288 (0.1 nmol, 5 
MBq) acquired 1 h after injection. 
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Figure 6. Survival of BALB/c nude mice with a subcutaneous PC3 xenograft treated with TF12/177Lu-IMP288 
(2.5 nmol/11.1 MBq, 0.1 nmol), 177Lu-hRS7 (13.7 MBq, 30 µg), 177Lu-IMP288 without pretargeting (11.1 MBq, 0.1 
nmol) or vehicle (n=10).
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However, this increase in survival (median survival >120 d) was accompanied by a 
significant decrease in platelets (from 1110 ± 230 x 109/L at t= -3 d to 430 ± 250 
x 109/L at t= 14 d, P=0.0005) and leukocytes (from 3.2 ± 0.8 x 109/L at t= -3 d 
to 0.6 ± 0.3 x 109/L at t= 14 d, P<0.0001), which was not observed in the mice 
treated with PRIT. Thus, treatment with 177Lu-hRS7 IgG appeared to be more effective, 
but also clearly more toxic. 
In PRIT, the kidney could also be the organ at risk. Therefore, creatinine and urea 
levels were examined in the experimental groups and the kidneys were examined 
histologically after completion of the experiment (120 d). Creatinine and urea levels, 
and histologic analysis of the kidneys compared to age-matched control mice, did not 
show any indication of renal toxicity. 
Discussion
The present study shows the potential of pretargeted immunoPET and PRIT of PC with 
the bsAb TF12 and the radiolabeled hapten peptide IMP288. The dose optimization 
studies in mice with s.c. PC3 tumors revealed that the highest uptake of the radiolabeled 
hapten peptide in the tumor was obtained at bsAb doses ≥2.5 nmol, and at lower 
IMP288 doses (≤0.1 nmol). The optimal time interval between injection of TF12 and 
111In-IMP288 was 16 h. Most importantly, these experiments showed that internal-
ization does not disqualify bsAbs for pretargeting as long as the dosage interval is 
carefully tuned, as shown previously by Sharkey et al. [6]. Retention of the radiolabel in 
the tumor was high: more than 50% of the radiolabel that was present in the tumor at 
1 h p.i. was still present after 48 h. In the TF2/IMP288 pretargeting system using the 
non-internalizing anti-CEA x anti-HSG bsAb in mice with LS174T tumors only 32% of 
the radiolabeled IMP288 was retained in the tumor [9], suggesting that the internalizing 
characteristics of TF12 could cause better retention of the radiolabel in the tumor due 
to internalization of the TF12-IMP288 complex by the tumor cells.
Retention in the tumor and rapid clearance from the blood enabled clear visualization of 
the tumor with PET as early as 1 h after injection. Some 68Ga activity in the kidneys and 
bladder was observed, due to the renal clearance of IMP288. Renal clearance might 
be a disadvantage when imaging PC, since physiological uptake in the urinary tract 
might conceal pathological uptake in the lower abdomen. However, renal clearance 
of radiolabeled IMP288 is very efficient, which may enable the distinction between 
physiological and pathological uptake.
The pretargeted RIT experiment showed that TF12/177Lu-IMP288 significantly improved 
the median survival of mice with s.c. PC3 tumors without significant hematological 
or renal toxicity. The improved median survival in the group of mice treated with 
177Lu-hRS7 IgG was achieved at the expense of severe hematological toxicity. In the 
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therapy experiments, the maximum activity dose of 177Lu-IMP288 was used, which 
necessarily was below the maximum tolerated dose (MTD), due to the limited specific 
activity of the 177Lu-chloride used for labeling of the peptide. Currently, carrier free 177Lu-
chloride has become available with improved specific activity. In future studies, we will 
determine the safety and efficacy of PRIT with higher activity doses of 177Lu-IMP288 
and of multiple cycles of TF12/177Lu/90Y-IMP288, as accomplished by Schoffelen et 
al with anti-CEA x anti-HSG bsAb TF2 [13].
Conclusion
The dosing of the pretargeting agents TF12 and IMP288 was optimized in mice with 
s.c. PC3 tumors. At optimized conditions, TROP-2-expressing PC3 tumors could be 
targeted efficiently and very rapidly with the radiolabeled hapten peptide IMP288. This 
pretargeting system allows rapid and sensitive PET imaging of PC using 68Ga-labeled 
hapten peptide. TF12 in concert with 177Lu-labeled IMP288 could also be a promising 
candidate for pretargeted radioimmunotherapy of TROP-2-expressing prostate tumors. 
Further PRIT studies at MTD with higher activity doses and/or multiple dosing are 
necessary to determine its application in the future.
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Abstract
Purpose
Pretargeting with bispecific antibodies and radiolabeled hapten-peptides could 
be used to specifically target tumors with high target-to-background ratios. TF12 
is a trivalent bispecific antibody that consists of two anti-TROP-2 Fab fragments 
and one anti-HSG (histamine-succinyl-glycine) Fab fragment. The TROP-2 antigen 
is expressed in many epithelial cancers, including prostate cancer (PC), and 
therefore this bispecific antibody can be used for pretargeting of PC. In this study, 
the potential for pretargeted radioimmunoPET with TF12 and the 68Ga-labeled 
di-HSG peptide IMP288 in mice with human PC xenografts was investigated 
using 2-deoxy-2-18F-fluorodeoxyglucose (18F-FDG) as a reference.
Procedures 
The potential of pretargeted immunoPET with TF12 and the 68Ga-labeled di-HSG 
hapten peptide, IMP288, was studied in mice with subcutaneous PC3 tumors 
using 18F-FDG as a reference. Furthermore, the use of this pretargeting system for 
imaging PC lesions was evaluated in mice with intraperitoneally growing tumors 
with 18F-FDG as a reference.
Results
68Ga-IMP288 showed rapid accumulation in the TF12 pretargeted subcutaneous 
tumor (7.2 ± 1.1% ID/g) with low uptake in the kidneys (1.8 ± 0.5% ID/g) and 
high tumor-to-blood ratios (17.4 ± 11.2) at 1 h p.i. Accumulation of 18F-FDG in 
the s.c. tumors was significantly lower (3.4 ± 0.9% ID/g, P=0.008), with lower 
tumor-to-blood ratios (3.0 ± 1.9, P=0.011). ImmunoPET/CT images clearly 
visualized both subcutaneous and intraperitoneal tumors as small as 5 mm3 with 
low blood levels and kidney uptake as early as 1 h p.i.
Conclusion
Pretargeted immunoPET with TF12 in combination with a 68Ga-labeled hapten 
peptide is an efficient system for rapid, sensitive and specific imaging of prostate 
cancer.
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Introduction
In most cancers, it is essential to differentiate between metastatic and non-metastatic 
disease to predict disease outcome and to determine treatment options. Especially in 
prostate cancer (PC), an accurate imaging method to determine the location, extent and 
biological potential of PC could improve patient outcome by fine-tuning the treatment 
based on the characteristics of the tumor both in surgery and during radiation therapy. 
Trans-rectal ultrasound (TRUS) and conventional magnetic resonance imaging (MRI) 
are effective for diagnosis of the primary tumor, but adequate detection of metastatic 
spread needs further improvement [1, 2, 3]. Positron emission tomography (PET) imaging 
is a widely used imaging modality to detect metastatic disease in several cancers. 
However, 18F-FDG-PET is not suited for staging patients with PC, since sensitivity is 
low due to artifacts related to its renal excretion and due to the relatively low avidity 
of differentiated prostate cancer for 2-deoxy-2-18F-fluorodeoxyglucose (18F-FDG) [2, 4]. 
Several other radiotracers have been developed for imaging metastatic PC, such as 
radiolabeled bombesin-analogues (targeting the gastrin-releasing peptide receptor), 
11C- and 18F-choline and 11C-acetate, each with specific advantages and limitations [5]. 
A new class of promising tracers currently under clinical development are radiolabeled 
PSMA-ligands targeting prostate specific membrane antigen (PSMA) expressed on the 
vast majority of PC, such as 99mTc-MIP1404 [6] and 68Ga-HBED-CC-PSMA [7]. The first 
clinical studies indicate that this tracer may have considerable advantages in detecting 
PC lesions, even in patients with low PSA levels. 
Antibody imaging in humans has been reported with several radiolabeled monoclonal 
antibodies (mAbs), such as capromab pendetide (Prostascint®) and J591 [2]. Due to 
the long circulatory half-lives of imaging agents based on intact antibody molecules, 
lesions can only be depicted several days after injection.
For more rapid imaging, we developed a pretargeting approach using the bispecific 
monoclonal antibody (bsAb) TF12, a trivalent bsAb that consists of two anti-TROP-2 
Fab fragments and one anti-HSG (histamine-succinyl-glycine) Fab fragment [8]. The 
target antigen TROP-2, also known as EGP-1 (epithelial glycoprotein-1), GA733-1, 
gp50/T16 and TACSTD2 (tumor-associated calcium signal transducer 2), is a 46 
kDa transmembrane glycoprotein expressed in carcinomas of the lung, bladder, 
breast, cervix, ovary, stomach and prostate [9]. Most normal human tissues do not 
express TROP-2, although it is found at low levels in several normal glandular cells, 
including glands in the bronchus, breast, prostate and skin, and ducts and acini of the 
pancreas [10].
In pretargeting, unlabeled TF12 is injected intravenously, and when it has cleared 
from the blood, an HSG-substituted radiolabeled hapten-peptide is injected. This hap-
ten-peptide will be trapped in the tumor by the anti-HSG arm of the bsAb or is rapidly 
cleared via the kidneys [8].
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In this study, the potential of pretargeted radioimmunoimaging with TF12 and the 
radiolabeled di-HSG peptide IMP288 in mice with subcutaneous and intraperitoneal 
human PC xenografts was investigated.
Materials and methods
The anti-TROP-2 x anti-HSG bsAb TF12 (Mw 168 kDa) was produced using the 
Dock-and-Lock technology as described previously [11], and made available from IBC 
Pharmaceuticals, Inc., a subsidiary of Immunomedics, Inc. The DOTA-conjugated hap-
ten-peptide IMP288 (DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2) was prepared as 
described previously [12].
Cell culture
The human prostate cancer cell line, PC3, is an androgen-independent cell line, originally 
derived from a PC bone metastasis. Cells were obtained from ATCC (CRL 1435; 
Manassas, VA) and were grown in RPMI 1640 medium (GIBCO®, Life Technologies 
Corporation, Carlsbad, CA, USA), supplemented with 10% fetal calf serum (FCS, 
Life Technologies, Grand Island, NY) and 2 mM glutamine. For inoculation of the 
mice to induce growth of PC3 xenografts, tumor cells were washed with 0.9% NaCl, 
disaggregated with trypsin and resuspended in 67% complete RPMI 1640 medium 
and 33% Matrigel (BD Biosciences, San Jose, CA) to the appropriate concentration (3 
x 106 cells/200 µL (s.c. model) and 2 x 106 cell/200 µL (i.p. model)). 
Tumor models
All experiments were approved by the institutional Animal Welfare Committee of the 
Radboud University Medical Center (Nijmegen, The Netherlands), and were conducted 
in accordance with the principles set forth by the Revised Dutch Act on Animal Experi-
mentation.
Male BALB/c nude mice (Janvier SAS, Le Genest Saint Isle, France), 8–9 weeks old, 
were adapted to laboratory conditions for at least one week before experimental use. 
They were housed under non-sterile standard conditions in individually ventilated cages 
(Tecniplast®, 5 mice per cage), with free access to animal chow (Sniff Voer®) and water.
The mice were inoculated s.c. in the flank with 200 µL of PC3 cell suspension (3 x 106 
cells). The s.c. PC3 tumors grew to approximately 0.1 g in 10 days after tumor cell 
inoculation, as determined by caliper measurements in 3 dimensions using the formula 
V = 4/3π (length/2 x width/2 x height/2), assuming that the density of tumor tissue 
is 1 g/cm3.
For the studies in mice with intraperitoneally-growing PC3 tumor lesions, male BALB/c 
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nude mice were also used. Using a 23-G needle and a 1 ml syringe, 5 x 200 µL 
of a cell suspension containing 2 × 106 PC3 cells in Matrigel was injected into the 
peritoneal cavity of the mice. After 7 days, palpable tumors developed intraperitoneal-
ly. All radiolabeled preparations (0.2 mL) were injected intravenously via the tail vein.
Radiolabeling of IMP288 
The DOTA-conjugated IMP288 was radiolabeled with 68Ga from a TiO2-based 
IGG100 68Ge/68Ga generator (Eckert & Ziegler, Berlin, Germany). Radiolabeling was 
performed essentially as described previously by Schoffelen et al. [13]. The generator was 
eluted with 0.1 M HCl and the pH of the 68Ga-containing fraction was adjusted to 3.5 
with 2.5 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, Sigma-Aldrich, 
St. Louis, MO, USA). 148-185 MBq of 68Ga-eluate was added to 1 µg of IMP288 in 
2.5 M HEPES buffer (at a ratio HEPES buffer:eluate of 1:8). After incubation at 95°C 
for 20 minutes, 50 mM ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich,) was 
added to a final concentration of 1 mM. The 68Ga-IMP288 preparation was loaded 
on an Oasis® HLB cartridge (Waters, Milford, MA, USA), that was activated with 1 ml 
100% ethanol and washed with 1 ml water. The cartridge was subsequently washed 
with 2 ml water and then eluted with 0.2 ml 30% ethanol, essentially as described 
previously [14].
Before i.v. injection, the preparation was diluted at least 2.5 times in 0.5% bovine 
serum albumin (BSA, Sigma-Aldrich) in PBS. Radiochemical purity of the preparations 
was determined by ITLC and RP-HPLC. ITLC was performed to determine the fraction 
of unbound 68Ga (mobile phase 0.1 M ammonium acetate and 0.1 M EDTA 1:1, pH 
5.5), and the fraction of colloid (mobile phase DMF and 1.25 M ammonium acetate 
pH 5.5, 1:1). For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 µm, 4.6 × 250 mm; 
Agilent Technologies, Amstelveen, The Netherlands) was eluted with 0.1% trifluoro-
acetic acid in water (TFA, Lab-scan, Analytical Sciences, Brussels, Belgium) and 0.1% 
TFA in acetonitrile solution (Lab-scan, Analytical Sciences, Brussels, Belgium) for 5 min 
with a linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 
1 mL/min. Radiochemical purity (RCP) of all labeled preparations used in these studies 
exceeded 97%, radiochemical yield always exceeded 95%.
Pretargeted ImmunoPET/CT
The potential of pretargeted immunoPET with TF12 and the 68Ga-labeled di-HSG 
peptide IMP288 was studied in mice with subcutaneous PC3 tumors using 18F-FDG as 
a reference. Each mouse was injected with both tracers (with a 48 h interval), enabling 
a direct comparison of the agents in the same mouse. One group of 5 mice with s.c. 
PC3 tumors was injected i.v. with 2.5 nmol (462 µg) of TF12 and 16 h later with 3.5-8 
MBq (0.1 nmol) of 68Ga-IMP288. One hour after injection of 68Ga-IMP288, mice 
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were scanned in a small-animal PET/CT scanner, while warmed and anesthetized 
with a mixture of isoflurane and oxygen. After 48 h, the same mice were injected 
with 18F-FDG, and microPET/CT images were acquired 45 min after injection. Mice 
were euthanized by O2/CO2 asphyxiation. After imaging, tumors and organs were 
dissected, weighed and counted in a gamma counter to determine biodistribution of 
the 18F-FDG. Tissue uptake (% ID/g) was calculated against an injection standard. A 
second group of 5 mice received the same agents in reversed order, to be able to 
determine biodistribution of the 68Ga-IMP288 after dissection. An additional control 
group of 5 mice received 68Ga-IMP288 without pretargeting with TF12 to determine 
the nonspecific uptake of the radiolabeled hapten peptide without the bsAb.
To investigate the potential of pretargeted immunoPET for detecting i.p. lesions, a group 
of 7 mice with intraperitoneally-growing PC3 tumors was injected i.v. with 2.5 nmol of 
TF12 and 16 h later with 5 MBq (0.1 nmol) of 68Ga-IMP288. A second group of 6 
mice with intraperitoneal tumors was injected i.v. with 10 MBq of 18F-FDG. A control 
group (n=4) had no intraperitoneal tumors and received the same agents as the first 
group, to determine the physiological uptake of 68Ga-IMP288 in the abdomen. One 
hour after injection of 68Ga-IMP288, or 45 min after injection of 18F-FDG, mice were 
euthanized and PET/CT images were acquired. After imaging, mice were dissected, 
and tumors and normal tissues were weighed and counted in a gamma counter to 
determine the concentration of the radiolabel. The uptake of 68Ga-IMP288 (% ID/g) 
was calculated against an injection standard.
MicroPET/CT imaging
PET/CT images were acquired with an Inveon® animal PET/CT scanner (Siemens 
Preclinical Solutions, Siemens Healthcare Molecular Imaging, Knoxville, TN), having 
an intrinsic spatial resolution of 1.5 mm. The animals were scanned in a prone (s.c. 
model) or a supine (i.p. model) position. PET emission scans were acquired for 20-30 
min, preceded by CT scans for anatomic reference (spatial resolution, 113 µm; 80 kV; 
500 µA; exposure time, 300 ms). Scans were reconstructed using Inveon Acquisition 
Workplace software (version 1.2; Siemens Preclinical Solutions), with an ordered set 
expectation maximization-3D/maximum a posteriori (OSEM3D/MAP) algorithm with 
the following parameters: matrix 256 x 256 x 159, pixel size 0.43 x 0.43 x 0.8 mm3 
and a beta-value of 0.1.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows®. 
Differences in uptake were tested for significance using the nonparametric Mann 
Whitney test for two groups. A P-value below 0.05 was considered significant.
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Results
Pretargeted immunoPET in mice with s.c. tumors
The pretargeting system revealed high uptake of 68Ga-IMP288 in all s.c. PC3 tumors 
(7.2 ± 1.1% ID/g) and rapid blood clearance, resulting in excellent tumor-to-blood 
ratios (17.4 ± 11.2) as early as 1 h after injection (Figure 1). The organ with the 
highest uptake was the kidney, with an uptake of 1.8 ± 0.5% ID/g at 1 h p.i. Tumor 
uptake of 18F-FDG was significantly lower than that of 68Ga-IMP288 (3.4 ± 0.9% 
vs 7.2 ± 1.1% ID/g, P=0.008), with much lower tumor-to-blood ratios (3.0 ± 1.9, 
P=0.011) and higher kidney uptake (5.9 ± 0.9% ID/g, P=0.004). 68Ga-IMP288 not 
proceeded by injection of the bsAb showed virtually no tumor uptake (0.3 ± 0.1% 
ID/g, P=0.016), resulting in low tumor-to-blood ratios (2.4 ± 0.4, P=0.016). Kidney 
uptake of 68Ga-IMP288 was not affected by the presence of TF12 (1.7 ± 0.3% ID/g 
vs 1.8 ± 0.5, P>0.99), indicating that renal uptake of the peptide was nonspecific. 
The blood level of 68Ga-IMP288 in the mice that received TF12 (0.60 ± 0.39% ID/g) 
was significantly higher than blood level of 68Ga-IMP288 in the mice that did not 
receive TF12 (0.13 ± 0.2% ID/g, P=0.016), indicating that some complexation of 
TF12 with IMP288 occurred in the circulation.
Figure 1. Biodistribution of 68Ga-IMP288 (0.1 nmol, 5 MBq, injected intravenously 16 h after injection of TF12 (2.5 
nmol)), 18F-FDG (10 MBq) or 68Ga-IMP288 without TF12 (0.1 nmol, 5 MBq) in BALB/c nude mice with a subcutaneous 
PC3 xenograft 45 min (18F-FDG) or 1h (68Ga-IMP288) after injection (n=5).
Blo
od
Mu
scle Tum
or Lun
g
Spl
een
Kid
ney Live
r
Inte
stin
e
Pro
sta
te
Fem
ur
0
1
2
3
4
5
6
7
8
9 TF12 / 68Ga-IMP288
68Ga-IMP288
18F-FDG
% 
ID
/g
112 Chapter 6
Figure 3. Biodistribution of 68Ga-IMP288 (0.1 nmol, 5 MBq), injected intravenously 16 h after injection of TF12 (2.5 
nmol) in BALB/c nude mice with intraperitoneal PC3 xenografts 1 h p.i. (n=7), 18F-FDG (10 MBq, n=6) 45 min p.i. or 
TF12/68Ga-IMP288 in tumorless mice (control group, 5 MBq, n=4) 1 h p.i. 
Blo
od
Mu
scle Tum
or
Lun
g
Spl
een
Sto
ma
ch
Kid
ney Live
r
Inte
stin
e
Pro
sta
te
Fem
ur
0
1
2
3
4
5
6
7
8
9
10
11
%
 ID
/g
TF12 / 68Ga-IMP288
TF12 / 68Ga-IMP288, no tumor
18F-FDG
Figure 2. Anterior 3D volume-rendering projection of microPET/CT scan of a BALB/c nude mouse with a subcutaneous 
PC3 tumor on the flank injected with either TF12 and 68Ga-IMP288 (0.1 nmol, 5 MBq, A) or 18F-FDG (10 MBq, B, same 
mouse) or 68Ga-IMP288 without TF12 (0.1 nmol, 5 MBq, C, different mouse) acquired 45 min 18F-FDG) or 1 h 68Ga-
IMP288) after injection. The location of the s.c. tumor is indicated by the white circle.
A B C
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Figure 4. Anterior 3D volume-rendering projection of a microPET/CT scan of a BALB/c nude mouse with intraperitoneal 
PC3 tumors injected with either TF12 and 68Ga-IMP288 (0.1 nmol, 5 MBq, A) at 1 h after injection or 18F-FDG (10 MBq, 
B) at 45 min after injection and a control mouse (TF12 and 68Ga-IMP288, no tumor, C), acquired 1 h after injection. The 
location of the i.p. tumors is indicated by the white circles. 
A B C
Pretargeted immunoPET/CT images of 68Ga-IMP288 clearly visualized the s.c. tumor 
with minimal activity in the kidneys (Figure 2A). The 18F-FDG PET/CT images in the 
same mouse showed typical 18F-FDG distribution with lower activity in the tumor and 
physiologic uptake in brain, heart and intestines (Figure 2B). Tumor-to-liver ratios were 
determined by ROI analysis and showed a significant difference between pretargeted 
68Ga-IMP288 (10.8 ± 4.8) and 18F-FDG (3.4 ± 1.2, P<0.0001). Images acquired 
1 h after injection of 68Ga-IMP288 without prior administration of TF12 showed no 
tumor uptake, minimal activity in the kidneys, and excretion of the radiolabel via the 
urine (Figure 2C).
Pretargeted immunoPET in mice with i.p. tumors
To assess the potential of pretargeted immunoPET to image small PC lesions, the 
pretargeting approach was tested in mice with intraperitoneally-growing PC3 tumors. 
On average, in each mouse 5 lesions were found in the peritoneal cavity (range 3-7). 
Mice that received both TF12 and 16 h later 68Ga-IMP288, showed specific uptake 
of the radiolabeled DOTA-conjugated di-HSG-peptide (4.1 ± 1.2% ID/g) in the intra-
peritoneal tumors (Figure 3). Uptake of the pretargeted 68Ga-labeled di-HSG peptide in 
other tissues was comparable to that of the mice with s.c. tumors. Blood clearance was 
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Figure 6. Anterior 3D volume-rendering projection of a microPET/CT scan of a BALB/c nude mouse with intraperitoneal 
PC3 tumors injected with 18F-FDG (10 MBq), acquired 45 min after injection (A) and the same mouse at dissection (B). 
The location of the i.p. tumors is indicated by the white circles, arrows indicate kidneys and urine bladder.
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Figure 5. Anterior 3D volume-rendering projection of a microPET/CT scan of a BALB/c nude mouse with intraperitoneal 
PC3 tumors injected with TF12 and 68Ga-IMP288 (0.1 nmol, 5 MBq), acquired 1 h after injection (A) and the same 
mouse at dissection (B). The location of the i.p. tumors is indicated by the white circles, arrows indicate kidneys and urine 
bladder.
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rapid, resulting in high tumor-to-blood ratios (8.4 ± 3.8) as early as 1 h after injection. 
Tumor uptake of 18F-FDG in this model was lower than that of the radiolabeled hap-
ten-peptide (3.4 ± 1.5% ID/g, P=0.01), and tumor-to-blood ratios were significantly 
lower than that of 68Ga-IMP288 (4.1 ± 3.4, P<0.0001).
Pretargeted immunoPET/CT images acquired 1 h after injection of 68Ga-IMP288 
clearly visualized the intraperitoneally-growing tumors in the mice with minimal activity 
in the kidneys and the bladder (Figure 4A). The conventional 18F-FDG PET/CT images 
showed typical 18F-FDG distribution with limited activity in the tumors (Figure 4B). 
Images of control mice without i.p. PC3 tumors injected with TF12/68Ga-IMP288 
showed some activity in the kidneys and excretion of the radiolabel via the urine (Figure 
4C), but without any additional residual activity in the abdomen.
Figures 5 and 6 show the intraperitoneal tumors both on PET/CT images and at 
dissection. The smallest lesions clearly visualized with TF12/68Ga-IMP288 were as 
small as 5 mm3.
Discussion
The present study shows the potential of pretargeted immunoPET of PC with the bsAb 
TF12 and the 68Ga-labeled di-HSG hapten peptide, IMP288. The studies in mice 
with s.c. PC3 tumors revealed high uptake of the radiolabeled hapten-peptide in the 
tumor together with low background levels shortly after injection (t = 1 h). Compared 
to TF12/68Ga-IMP288, 18F-FDG showed significantly lower tumor and higher kidney 
uptake. Tumor uptake was TF12-mediated, since tumor uptake was extremely low in 
mice that were not pretargeted and only received 68Ga-IMP288. A significant difference 
between blood levels of pretargeted 68Ga-IMP288 and 68Ga-IMP288 without prior 
injection of TF12 was observed, indicating that circulating TF12 binds 68Ga-IMP288, 
thereby elevating blood levels of the radiolabeled compound. Earlier studies have 
shown that increasing or decreasing the time interval between TF12 and IMP288 
injection does not further improve tumor-to-blood ratios [8]. In the intraperitoneal model, 
tumor uptake of the radiolabeled hapten was lower, which might be due to the reduced 
vascularization of the small i.p. tumors. This is supported by earlier observations that 
tumor uptake in the intraperitoneal tumors was higher in mice imaged >7 days after 
tumor inoculation, and increased blood vessel formation in the i.p. tumors after 7 days. 
However, imaging of the mice >7 days after tumor cell inoculation was impossible due 
to the fast deterioration of the condition of the mice after 7 days. As a result, tumor-to-
blood ratios (7.8 ± 4.1) in the i.p. model were lower than in the subcutaneous model 
(17.4 ± 11.2).
The pretargeting system of TF12 and 68Ga-labeled IMP288 was able to clearly 
visualize s.c. or i.p. tumors, with only some background activity in the kidneys and the 
urinary bladder. In the i.p. model, tumors as small as 5 mm3 were clearly visible on the 
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PET/CT images, indicating that pretargeted immunoPET with TF12 and 68Ga-labeled 
IMP288 is a sensitive and rapid imaging method. These results suggest opportunities 
for clinical evaluation of this pretargeting approach in imaging of metastasized PC.
Currently, several radiotracers are used or developed for imaging of PC. 18F-choline is 
clinically the most widely used imaging agent, with fair sensitivity (86%) and specificity 
(93%) for detection of lymph node metastases and recurrent disease in patients with 
PSA > 2ng/ml [5, 15]. 68Ga- and 99mTc-PSMA ligands are promising new agents for 
imaging of advanced PC [6, 7, 16]; currenly, phase II trials with these agents are ongoing.
Pretargeted immunoPET using TF12/68Ga-IMP288, with its specific target on PC 
lesions and metastases may become a valuable addition to this imaging arsenal for 
metastatic PC.
Conclusion
Pretargeting with TF12 in combination with 68Ga-labeled hapten peptides is a promising 
and efficient system for rapid, sensitive, and specific imaging of prostate cancer. Further 
studies are necessary to determine its application also in pretargeted immunotherapy.
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Abstract 
TROP-2 is a pancarcinoma marker that is expressed at high levels in many epithelial 
cancers, including prostate cancer (PC). The trivalent bispecific antibody TF12 
(anti-TROP-2 x anti-HSG (histamine-succinyl-glycine)) has shown to effectively 
target PC. In this study, the efficacy of pretargeted radioimmunotherapy (PRIT) 
with multiple cycles of TF12 and 177Lu-labeled di-HSG-peptide (IMP288) in mice 
with s.c. PC3 tumors was investigated and compared to that of conventional RIT 
with 177Lu-labeled anti-TROP-2 mAb hRS7.
Methods 
The potential of one, two and three cycles of PRIT using the TF12 pretargeted 
177Lu-IMP288 (41 MBq per cycle) was determined in mice with s.c. PC3 tumors, 
and compared to the efficacy and toxicity of RIT with 177Lu-hRS7 dosed at the 
maximum tolerated dose (11 MBq).
Results
PRIT with two and three cycles of PRIT showed significantly higher median survival 
(>150 days) compared to PRIT with one cycle of TF12 and 177Lu-IMP288 (111 
days, P<0.001) or the controls (76 days, P<0.0001). All mice treated with the 
mAb 177Lu-hRS7 survived at the end of the experiment (150 days), compared to 
80% in the mice that were treated with three cycles of PRIT and 70% in the group 
that received two cycles of PRIT. Clinically significant hematologic toxicity was 
found only in the groups that received either three cycles of PRIT (P<0.0009) or 
RIT (P<0.0001).
Conclusion
TROP-2-expressing prostate cancer can be targeted efficiently with TF12 and 
radiolabeled IMP288. 177Lu-IMP288 accumulated rapidly in the tumors. 
Pretargeted radioimmunotherapy with multiple cycles of PRIT inhibited the growth 
of s.c. PC3 tumors. Clinically relevant hematological toxicity was observed in the 
group that received three cycles of PRIT, however, conventional RIT with the parent 
mAb 177Lu-hRS7 was at least as effective with similar toxicity.
121Pretargeted radioimmunotherapy of Prostate Cancer
Introduction
Treatment options for metastatic castrate resistant prostate cancer (CRPC) are increasing. 
As current therapeutic agents have only limited efficacy, there remains a great need to 
develop effective treatments of PC, once it has advanced to the hormone-independent 
stage. Radioimmunotherapy (RIT) with the use of radiolabeled monoclonal antibodies in 
prostate cancer patients has been reported with the 177Lu-labeled anti-PSMA antibody 
J591[1, 2]. However, due to the long circulatory half-life of agents based on intact antibody 
molecules, clinically relevant myelotoxicity limits the activity dose that can be safely 
administered. To avoid toxicity related to slow clearance of radiolabeled antibodies 
from the circulation, a pretargeting approach can be applied. In pretargeting, tumors 
are targeted by a non-radiolabeled bispecific antibody, allowing the unbound antibody 
to clear from the circulation, followed by injection of a radiolabeled small molecule 
that is recognized by the bispecific antibody. The unbound radiolabeled compound 
then rapidly accumulates in the tumor or clears quickly from the circulation [3]. A new 
and potent pretargeting strategy consists of administration of a trivalent bispecific 
monoclonal antibody followed by administration of a radiolabeled di-HSG hapten 
peptide. In a phase I/II clinical trial Schoffelen et al. have demonstrated the potential 
of such an approach to target colorectal carcinoma in patients [4].
For pretargeting of prostate cancer, the bispecific monoclonal antibody (bsAb) TF12 
was developed, based on the monoclonal antibody hRS7 [5]. hRS7 is a humanized 
IgG1 monoclonal antibody directed against TROP-2, also known as EGP-1 (epithe-
lial-glycoprotein-1), GA733-1, gp50/T16 and TACSTD2 (tumor-associated calcium 
signal transducer 2). TROP-2 is a 46 kDa transmembrane glycoprotein overexpressed 
in carcinomas of the lung, bladder, breast, cervix, ovary, stomach and prostate [6]. 
Most normal human tissues do not express TROP-2, but low levels are present in several 
normal glandular cells, including glands in the bronchus, breast, prostate and skin, 
and ducts and acini of the pancreas [7]. Given its overexpression in prostate cancer, 
we studied the potential targeting ability of hRS7 IgG in a nude mouse-human prostate 
cancer model [8], showing excellent in vivo targeting of PC3 xenografts with 89Zr- and 
111In-hRS7 IgG within 3 days. The slow clearance from the circulation results in low 
tumor-to-background ratios, especially at earlier time points after i.v. injection.
The bsAb TF12, is a trivalent bsAb that consists of two anti-TROP-2 Fab fragments and 
one anti-HSG (histamine-succinyl-glycine) Fab fragment [9]. In this approach, unlabeled 
TF12 is injected intravenously, and when it has localized in the tumor and cleared 
from the blood, a di-HSG-substituted radiolabeled hapten-peptide is injected. This 
hapten-peptide will be trapped in the tumor by the anti-HSG arm of the bsAb or is 
rapidly cleared from the body. Previous feasibility studies have shown the potential of 
pretargeted radioimmunotherapy (PRIT) using TF12 and 177Lu-IMP288 [5]. Due to the 
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unavailability of carrier-free 177LuCl3, studies were performed with a 
177Lu-dose that was 
below MTD (Maximum Tolerated Dose). Since then, 177LuCl3 with high specific activity 
(>3,000 GBq/mg) has become available, enabling labeling of the low peptide dose 
of IMP288 with a higher activity dose.
In this study, the potential of different regimens of pretargeted radioimmunotherapy 
with TF12 and the radiolabeled di-HSG peptide, IMP288, in mice with human PC 
xenografts was investigated. 
Materials and methods
The anti-TROP-2 x anti-HSG bsAb TF12 was produced using the Dock-and-Lock 
technology (DNL®) as described by Rossi et al. [10], and made available from IBC 
Pharmaceuticals, Inc., a subsidiary of Immunomedics, Inc. The production and charac-
terization of the anti-TROP-2 mAb hRS7 have been described previously [6]. The DO-
TA-conjugated hapten-peptide IMP288 (DOTA-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2) 
was prepared as described by McBride et al. [11].
Cell culture
The human prostate cancer cell line, PC3, is an androgen-independent cell line, 
originally derived from a PC bone metastasis. Cells were obtained from ATCC 
(CRL 1435; Manassas, VA) and were grown in RPMI 1640 medium (GIBCO, Life 
Technologies Corporation, Carlsbad, CA, USA), supplemented with 10% FCS (fetal 
calf serum, Life Technologies, Grand Island, NY). For subcutaneous inoculation, PC3 
cells were washed with 0.9% NaCl, disaggregated with trypsin and resuspended in 
67% complete RPMI 1640 medium and 33% Matrigel (BD Biosciences, San Jose, CA) 
to the appropriate concentration (3 x 106 cells/200 µL).
Tumor model
All experiments were approved by the institutional Animal Welfare Committee of the 
Radboud University Medical Center (Nijmegen, Te Netherlands), and were conducted 
in accordance with the principles set forth by the Revised Dutch Act on Animal Experi-
mentation.
Male BALB/c nude mice (Janvier SAS, Le Genest Saint Isle, France), 8–9 weeks old, 
were adapted to laboratory conditions for at least one week before experimental use. 
They were housed under non-sterile standard conditions in individually ventilated cages 
(Tecniplast, 5 mice per cage), with free access to animal chow (Sniff Voer®) and water.
The mice were inoculated s.c. in the flank with 200 µL of PC3 cell suspension (3 x 106 
cells in 67 % complete RPMI 1640 medium and 33 % Matrigel (BD Biosciences,
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San Jose, CA, USA)). The s.c. PC3 tumors grew to approximately 0.1 g in 10 days 
after tumor cell inoculation, as determined by caliper measurements in 3 dimensions 
using the formula V = 4/3π (length/2 x width/2 x height/2), assuming that the density 
of tumor tissue is 1 g/cm3. The radiolabeled preparations (0.2 mL) were injected 
intravenously via the tail vein. 
Radiolabeling of IMP288 and hRS7
The DOTA-conjugated IMP288 was radiolabeled with 177Lu (177LuCl3, non-carrier 
added, ITG Isotopen Technologien Garching AG, Garching, Germany). Radiolabeling 
was performed essentially as described previously by Schoffelen et al. [12]. Prior to 
i.v. injection, the preparation was diluted at least 2.5 times with 0.5% bovine serum 
albumin (BSA, Sigma-Aldrich) in PBS.
DTPA conjugation and subsequent labeling of hRS7 IgG with 177Lu were performed 
essentially as described previously [6, 8, 13]. The radiochemical purity of the labeled 
IMP288 and hRS7 preparations was determined using instant thin-layer chromatogra-
phy (ITLC), and reversed-phase high-performance liquid chromatography for IMP288 
as described previously [12]. ITLC using silicagel strips (Biodex, Shirley, NY, USA) was 
performed to determine the fraction of unbound 177Lu (mobile phase: 0.1 M citrate pH 
6.0 (Merck, Darmstadt, Germany). 
For RP-HPLC, the C18 column (Zorbax Rx-C18; 5 µm, 4.6 × 250 mm; Agilent 
Technologies, Amstelveen, The Netherlands) was eluted with a mixture of 97% of a 
0.1% trifluoroacetic acid in H2O solution (TFA, Sigma-Aldrich) with 3% of a 0.1% 
TFA in acetonitrile solution (Lab-scan, Analytical Sciences, Brussels, Belgium) with a 
linear gradient to 100% of the latter solution over 10 minutes at a flow rate of 1 mL/
min. Radiochemical purity (RCP) of all labeled IMP288 preparations always exceeded 
97%; the RCP of 177Lu-hRS7 exceeded 98%.
Immunoreactivity
The anti-TROP-2 reactivity of radiolabeled TF12 and hRS7 was determined using freshly 
trypsinized PC3 cells, as described by Lindmo et al. [14] with minor modifications. The 
bispecific immunoreactivity of TF12 was demonstrated by incubating PC3 cells with 
TF12 (10 µg/mL) during 30 min at 37°C, washing and subsequent incubation with 
111In-IMP288 (40,000 cpm). After 1 h at 37°C, the total activity and activity in the 
cell pellet was determined in a γ-counter. 88% of the added hapten-peptide specifically 
bound to the pretargeted PC3 cells.
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The therapeutic effect of a single or multiple cycles of PRIT with TF12 and 177Lu-IMP288 was 
assessed in mice with PC3 xenografts (10 mice/group) and compared to the efficacy of 
conventional RIT using the radiolabeled parent mAb, 177Lu-hRS7. Mice were treated with 
the first cycle of TF12/177Lu-IMP288 or 177Lu-hRS7, 10 days after PC3 cell inoculation, 
when tumors weighed approximately 0.1 g.
In the mice that were treated with PRIT, tumors were pretargeted with 2.5 nmol TF12 (462 
µg) 16 h before administration of the 177Lu-IMP288 [5]. The next day, mice received the 
maximum activity dose of 177Lu activity that could be labeled onto 0.1 nmol (160 ng) 
IMP288 (41 MBq, specific activity 410 MBq/nmol). Two additional groups of 10 mice 
received a second or a second and third cycle of TF12/177Lu-IMP288, respectively. Time 
interval between cycles was 48 h, as determined in earlier experiments [5]. Another group 
was treated with one cycle of 177Lu-hRS7 at the maximum tolerated dose (MTD, 11 MBq, 
15 µg (0.1 nmol), specific activity 110 MBq/nmol). 
One control group of PC3 tumor-bearing mice was injected i.v. with vehicle (200 µL PBS, 
0.5% BSA) twice instead of TF12 and IMP288. The second control group received vehicle 
instead of TF12 and was injected 16 h later with 41 MBq of 177Lu-IMP288. A third control 
group was neither inoculated with PC3 cells, nor received any radioimmunotherapy. The 
latter group was included to determine whether effects seen in the kidneys were attributable 
to the radioimmunotherapy, or to regular ageing processes.
Tumor size was measured in three dimensions with a caliper and body weight was 
determined twice weekly, starting 7 days after tumor cell inoculation. Blood samples of 
0.1 mL of all mice were collected via submandibular bleeding before therapy, and 26, 
33, 47 and 60 days after administration of the agents to determine hemoglobin levels, 
and leukocyte and platelet counts. When the humane endpoint was reached (tumor size 
>2 cm3 or animal discomfort level >3 as judged by a blinded biotechnician), mice were 
euthanized by O2/CO2-asphyxiation and dissected. At dissection, the tumor and kidneys 
were excised, weighed, fixed in 4% formalin and processed for paraffin sectioning. The 
experiment was terminated 150 days after injection of the radiolabeled compounds and 
the remaining mice were euthanized and dissected. Sections of the kidneys were HE 
(Hematoxylin and Eosin) and PAS (Periodic Acid Schiff) stained and evaluated by a nephro-
pathologist to determine potential (chronic) kidney damage caused by the (P)RIT.
Biodistribution studies 
The effect of the multiple cycles of TF12 and 177Lu-labeled IMP288 on tumor uptake 
in mice with s.c. PC3 tumors was determined by administering one, two or three 
cycles of TF12/177Lu-IMP288 (0.4 MBq/cycle) to groups of 5 mice, as described 
above. Two hours later, mice were dissected and tissue uptake was determined in a 
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gamma counter. Biodistribution of the 177Lu-hRS7 (0.4 MBq) 3 days after injection of the 
radiolabeled antibody was also determined in this mouse model. Tumor uptake, blood 
levels and uptake in relevant tissues (muscle tissue, lung, spleen, kidney, liver, intestine, 
prostate, femur and bone marrow) were determined. The uptake as percentage of 
injected dose per gram tissue (% ID/g) in each tissue sample was calculated.
SPECT/CT imaging
To visualize the in vivo distribution of the radiolabeled compounds, SPECT/CT scans 
were acquired 7 hours (TF12/177Lu-IMP288) or 3 days (177Lu-hRS7) after injection 
of the 177Lu-labeled agent, respectively. Mice were scanned using a U-SPECT II 
microSPECT/CT scanner (Milabs, Utrecht, The Netherlands). Mice were anesthetized 
using isoflurane/O2 (5% induction, 2.5% maintenance) and scanned for 30 min using 
the 1.0-mm diameter pinhole collimator tube. Scans were reconstructed with MILabs 
reconstruction software, which uses an ordered-subset expectation maximization 
algorithm, with a voxel size of 0.375 mm.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.0 for Windows®. 
Survival curves were compared using the log-rank test. The level of significance was 
set at a P-value of less than 0.05. Differences in uptake were tested for significance 
using the nonparametric Mann Whitney test, differences in survival were calculated 
using the Log-rank test.
Results
Biodistribution studies
The in vivo distribution of 177Lu-IMP288 (0.1 nmol, 0.4 MBq) in mice that were pretargeted 
16 h earlier with TF12 was determined 2 h after injection of the radiolabeled di-HSG 
peptide. Uptake of 177Lu-IMP288 in the PC3 tumors after one (8.5 ± 1.4% ID/g), two 
(9.0 ± 2.2% ID/g) or three (8.2 ± 1.4% ID/g) cycles of PRIT showed no significant 
differences (P>0.9, Figure 1A). Two hours after injection, blood levels (<1% ID/g), and 
uptake in normal tissues were low in all groups. Organ distribution of the radiolabel 
did not show any significant differences among the three groups, nor obvious trends. 
177Lu-labeled parental mAb hRS7 showed high tumor uptake at 3 days after injection 
(62.0 ± 11.0% ID/g, Figure 1B), along with high blood levels (10.0 ± 1.6% ID/g).
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The potential of multiple cycles of PRIT using the bsAb TF12 and 177Lu-labeled IMP288 
was determined in mice with s.c. PC3 tumors and was compared to that of RIT with 
177Lu-hRS7 (11 MBq, 15 µg). PRIT with 2.5 nmol TF12 and 41 MBq 177Lu-IMP288 
significantly improved the median survival of mice with s.c. PC3 tumors from 76 days 
to 111 days (P<0.0001, Figure 2). The median survival in the groups that received 
multiple cycles of PRIT or the group that was treated with 177Lu-hRS7 (>150 days) 
Figure 1A. Biodistribution of 177Lu-IMP288 after one, two or three cycles of 177Lu-IMP288 (0.1 nmol, 0.4 MBq ) injected 
i.v. 16 h after the bsAb TF12 (2.5 nmol) in BALB/c nude mice with a subcutaneous PC3 xenograft at 2 h after injection 
(n=5).
Figure 1B. Biodistribution of 177Lu-hRS7 (15 µg, 0.4 MBq) in BALB/c nude mice with a subcutaneous PC3 xenograft 
measured 3 d after injection (n=5).
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was significantly higher (P<0.0001). The control groups received either 177Lu-IMP288 
without TF12 or vehicle. Median survival of mice in both control groups was similar 
(76 days vs 72 days), indicating that there was no effect of administration of a high 
activity dose of 177Lu-IMP288 alone. At the end of the experiment (150 d), all mice 
treated with 177Lu-hRS7 IgG were still alive. Of the groups that received either two or 
three cycles of TF12/177Lu-IMP288, 70% and 80% of mice survived, respectively. The 
difference in survival between the groups that were treated with two or three cycles of 
TF12/177Lu-IMP288 and the group that was treated with 177Lu-hRS7 was not significant 
(P=0.067 and 0.146, respectively). At the end of the experiment, the average tumor 
size of the treated groups was significantly smaller than tumor size in the control groups 
(Figure 3). In the control groups and the group that received one cycle of PRIT, tumor 
(re)growth was seen, while the surviving mice in the other groups showed stabilization 
of tumor growth or a reduced tumor size. 
There was no significant decrease in hemoglobin levels, platelets and body weight 
in either of the groups after treatment (Figure 4ABC). However, leukocyte counts 
decreased significantly (Figure 4D) in the groups that received either two (-39%, from 
4.4 ± 1.5 x 109/L at t= -2 d to 2.7 ± 1.0 x 109/L at t= 26 d, P=0.01) or three cycles 
of PRIT (-66%, from 7.4 ± 2.0 x 109/L at t= -2 d to 2.5 ± 1.3 x 109/L at t= 26 d, 
P<0.0009) or RIT (-69%, from 4.5 ± 0.9 x 109/L at t= -2 d to 1.4 ± 0.6 x 109/L at 
t= 26 d, P<0.0001). Thus, treatment with two or three cycles of TF12/177Lu-IMP288 
or with 177Lu-hRS7 IgG was more effective, but also more toxic. 
In PRIT, the kidney could also be the organ at risk. Therefore, the kidneys of mice that 
were treated with PRIT were examined histologically after completion of the experiment 
(150 d). The kidneys of the treated mice were compared to the kidneys of the 
age-matched control mice: at this analysis no indication of renal toxicity was observed. 
Figure 3. Tumor size of subcutaneous PC3 xenografts in BALB/c nude mice treated with one, two or three cycles of 
TF12/177Lu-IMP288 (2.5 nmol/0.1 nmol, 41 MBq per cycle), 177Lu-hRS7 (15 µg, 11 MBq), 177Lu-IMP288 without 
pretargeting (0.1 nmol, 41 MBq) or vehicle (PBS, n=10).
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Figure 4. Body weight (A), Haemoglobin levels (B), Platelets (C) and Leukocyte counts (D) of BALB/c nude mice with a 
subcutaneous PC3 xenograft treated with one, two or three cycles of TF12/177Lu-IMP288 (2.5 nmol/0.1 nmol, 41 MBq 
per cycle), 177Lu-hRS7 (15 µg, 11 MBq), 177Lu-IMP288 without pretargeting (0.1 nmol, 41 MBq) or vehicle (PBS, n=10).
Figure 5. Anterior projections of SPECT/CT scans of BALB/c nude 
mice with an s.c. PC3 tumor in the right flank injected with (A) 
TF12 (2.5 nmol) and 177Lu-IMP288 (0.1 nmol, 41 MBq) or with 
(B) 177Lu-hRS7 (15 µg, 11 MBq). Circles indicate tumor. Images 
were acquired 7 h (TF12/177Lu-IMP288) or 3 days (177Lu-hRS7) 
after injection of the radiolabel.
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SPECT/CT imaging
To visualize distribution of the radiolabel in the tumor bearing mice, SPECT/CT images 
were acquired. In mice treated with TF12 and 177Lu-IMP288, images acquired 7 h p.i. 
clearly showed uptake of 177Lu-IMP288 in the PC3 tumors (Figure 5A), without retention 
of the radiolabeled hapten in other tissues. Due to its longer circulating half-life, images 
of 177Lu-hRS7 distribution were acquired at 3 days p.i. (figure 5B). The images of the 
mice that received 177Lu-hRS7 IgG showed the preferential uptake of the radiolabeled 
antibody in the tumor and low levels of the radiolabel in normal organs.
Discussion
In the present study the potential of multiple cycles of pretargeted radioimmunother-
apy of PC with the bsAb TF12 and the 177Lu-labeled hapten-peptide IMP288 was 
compared to that of conventional RIT with the parental mAb 177Lu-hRS7. Biodistribution 
studies showed that tumor uptake of radiolabeled IMP288 was similar in the groups 
that received either one, two or three cycles of PRIT (8.2 - 9.0% ID/g), indicating tumors 
were targeted as efficiently with subsequent pretargeting cycles. Apparently, within 48 
h sufficient TROP-2 epitopes in the tumor were available for another pretargeting cycle.
Two hours after injection of the radiolabeled hapten-peptide, almost all activity had 
cleared form the blood via the kidneys (<1% ID/g). Tumor uptake of the 177Lu-labeled 
parental mAb hRS7 was much higher (62.0 ± 11.0% ID/g), at the expense of higher 
blood levels (10.0 ± 1.6% ID/g), even at 3 days after injection of the radiolabel. 
Images of mice 7 h after PRIT and 3 d after RIT clearly showed uptake of the radiolabel 
in the PC3 tumor, with very low background activity levels.
The pretargeted RIT experiment showed that one cycle TF12/177Lu-IMP288 significantly 
improved the median survival of mice with s.c. PC3 tumors without significant 
hematological or renal toxicity. However, a marked improvement of the median survival 
was observed in the groups that received multiple cycles of PRIT, or RIT. The improved 
median survival especially in the groups of mice that received RIT or three cycles of PRIT 
was achieved at the expense of hematological toxicity, resulting in significant decrease 
of leukocyte levels after treatment. Two cycles of PRIT showed less hematological toxicity, 
but was also less effective. At the end of the experiment, 70% of animals in the group 
with two PRIT cycles was still alive, vs 80% in the three cycle PRIT group and 100% of 
animals in the conventional RIT group, although these differences were not significant. 
This indicates that RIT with one dose of 177Lu-hRS7 is at least as effective as three 
cycles of TF12/177Lu-IMP288, with similar toxicity despite lower tumor/blood ratios of 
the 177Lu-hRS7 as compared to TF12/177Lu-IMP288. Furthermore, tumor growth curves 
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show regrowth of tumors after PRIT and stabilization of tumor size after RIT, underlining 
the long term effectiveness of RIT compared to multiple cycles of PRIT. Most likely this is 
due to the much higher tumor uptake of the 177Lu-hRS7 (62.0% ID/g) compared to the 
tumor uptake of TF12/177Lu-IMP288 (8.0-9.2% ID/g). These results are not in line with 
earlier studies comparing PRIT and RIT [15], and with an earlier study with comparable 
bsAb-hapten combinations by Frampas et al. [16], that showed higher efficacy and 
similar toxicity of PRIT compared to RIT. However, in this study the tumor uptake of 
the direct labeled mAb was much lower (20.4% ID/g in s.c. tumors) than that of the 
radiolabeled hRS7, whilst tumor uptake of the bsAb TF2 was comparable to that of 
TF12 (9.1% ID/g vs 8.5% ID/g).
In the present study, it is shown that additional therapy cycles improve the therapeutic 
efficacy of PRIT, but also increase hematological toxicity. In future studies, other 
therapeutic regimens should be investigated. Whilst a dose of 3 times 41 MBq is the 
MTD for 3 cycles of PRIT, a higher activity dose in one cycle might improve therapeutic 
efficacy of PRIT. However, higher radioactivity dose can only be achieved by increasing 
the amount of peptide (due to the maximum specific activity of 0.4 GBq/nmol that can 
be reached), resulting in decreased tumor uptake [5]. Perhaps a hapten-peptide with 
multiple DOTA moieties could be developed to further enhance the specific activity of 
the hapten-peptide. Also repetition of two cycles of PRIT two months after the initial 
therapy might increase survival, especially since tumor size has decreased dramatically 
which could enable improved access of the therapeutic agent to the deeper layers of 
the tumor. 
Conclusion
PRIT could be particularly suited to treat PC in an adjuvant setting, either after 
prostatectomy or in case of biochemical recurrence as indicated by a rising PSA.
The pretargeting system consisting of the bsAb TF12 and the radiolabeled hapten-pep-
tide IMP288 showed efficient and very rapid targeting of TROP-2-expressing PC3 
tumors in mice. Pretargeted radioimmunotherapy with multiple cycles of PRIT showed 
improved median survival, accompanied by hematological toxicity in the groups that 
received two or three cycles of PRIT. However, conventional RIT with the parent mAb 
177Lu-hRS7 resulted in at least as effective treatment of the PC3 tumors, with similar 
toxicity.
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General discussion
In this thesis, the potential of (pre)targeted radioimmunoimaging and radioimmuno-
therapy of prostate cancer with a radiolabeled humanized anti-TROP-2 monoclonal 
antibody (hRS7) and an anti-TROP-2 x anti-HSG bispecific monoclonal antibody (TF12) 
in combination with a radiolabeled hapten peptide (IMP288) was investigated.
Despite effective diagnostic and treatment options for primary prostate cancer (PC), 
treatment options for advanced, hormone independent disease are limited. Once the 
cancer has spread beyond the prostate gland, survival rates drop dramatically [1]. At 
present, extensive research is aimed at the development of new molecular imaging 
techniques to improve detection and staging of PC, together with the development of 
new therapeutic options.
For both applications, radiolabeled monoclonal antibodies (mAbs) are of interest. The 
advantage of these pharmaceuticals is their potential for specific in vivo targeting. 
Radiolabeled mAbs that target prostate cancer-associated cell surface antigens, are of 
particular interest in PC. Promising developments are seen with J591, that is directed 
against the extracellular domain of the PSMA receptor. This monoclonal antibody has 
been labeled with 111In and 89Zr for immunoSPECT/PET [2], or with 177Lu and 90Y for 
radioimmunotherapy [3].
Another potential target for PC is TROP-2, a transmembrane glycoprotein that is 
overexpressed in several adenocarcinomas. We evaluated the characteristics of the 
anti-TROP-2 mAb humanized RS7 (hRS7) in a subcutaneous and in an orthotopic 
PC3 mouse model. Our studies revealed excellent immunoPET (using 89Zr-hRS7) and 
immunoSPECT (using 111In-hRS7) images of PC3 xenografts in mice, indicating that 
hRS7 has potential as a prostate cancer imaging agent.
However, there are several drawbacks to the use of mAbs in radioimmunoimaging 
and -therapy. Due to the long circulatory half-life of intact antibodies (IgG), lesions can 
only be depicted several days after injection when the antibody has cleared from the 
background. This is inconvenient for patients and for clinical practice. Besides this, 
sensitivity of mAb-based imaging may be hampered due to nonspecific accumulation 
in (inflamed) tissues caused by the enhanced permeability and retention (EPR) effect [4].
Furthermore, in radioimmunotherapy, the long circulatory half-life of mAbs causes 
relatively high radiation doses to well-perfused tissues, such as the (radiosensitive) bone 
marrow. The long exposure to the therapeutic radionuclide results in clinically relevant 
myelotoxicity limiting the activity dose that can be administered safely. To avoid toxicity 
related to slow clearance of radiolabeled antibodies from the circulation, various 
approaches can be applied. One of these approaches consists of the use of antibody 
fragments. However, due to their rapid clearance, tumor uptake of antibody fragments 
is lower and kidney uptake is higher. 
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An alternative strategy to exploit the excellent in vivo targeting capabilities of mAbs 
and to circumvent their disadvantages in imaging and RIT is pretargeting with bispecific 
anti-tumor x anti-hapten antibodies. In pretargeting, tumors are pretargeted by a non-ra-
diolabeled bispecific antibody (bsAb). When the bsAb has cleared from the circulation, 
a radiolabeled small molecule (hapten-peptide) with affinity for the other binding arm 
of the bsAb is injected. The radiolabeled hapten-peptide rapidly accumulates in the 
tumor or clears quickly from the circulation. The potential of pretargeted imaging and 
radioimmunotherapy (PRIT) to target CEA-expressing colorectal carcinoma (CRC) has 
been demonstrated by Schoffelen et al. in a phase I/II clinical trial. The results showed 
rapid and specific tumor targeting of the 111In- or 177Lu-labeled hapten-peptide IMP288 
after pretargeting with the anti-CEA x anti-hapten bispecific monoclonal antibody TF2. 
The study demonstrated that specific targeting in CEA expressing CRC is feasible and 
safe [5].
We investigated the potential of pretargeting of prostate cancer using the anti-TROP-2 x 
anti-HSG bsAb TF12 as targeting agent, together with the radiolabeled di-HSG-hapten-
peptide IMP288. As opposed to TF2, TF12 has internalizing properties. Theoretically, 
internalization of a bsAb might limit subsequent binding of the radiolabeled hapten-
peptide to the bsAb, since the bsAb would be no longer available on the cell surface to 
trap the di-HSG-peptide IMP288. We showed that TF12 indeed is slowly internalized 
by the target cell after binding to the TROP-2 antigen, while a substantial fraction (60%) 
remained accessible on the tumor cell surface to capture the hapten peptide after 24 
h. We optimized the TF12 dose, the dose of the radiolabeled hapten-peptide and the 
interval between injection of the bsAb and IMP288 and determined the in vivo targeting 
characteristics of TF12/111In-IMP288 in mice with subcutaneous PC3 tumors. Under 
these optimized conditions, immunoPET using TF12/68Ga-IMP288 was performed. 
Retention in the tumor and rapid clearance from the blood enabled clear visualization 
of the tumor with PET as early as 1 h after injection. Tumor uptake was TF12-mediated, 
since tumor uptake was extremely low in mice that were not pretargeted and only 
received 68Ga-IMP288. The pretargeting system of TF12 and 68Ga-labeled IMP288 
clearly visualized intraperitoneal tumors as small as 5 mm3 within 1 h after injection 
of the radiolabeled peptide, indicating that immunoPET with TF12 and 68Ga-labeled 
IMP288 is a sensitive and rapid imaging method.
Next to its potential as imaging approach, we investigated the potential of pretargeted 
radioimmunotherapy of PC with the bsAb TF12 and the 177Lu-labeled hapten-peptide 
IMP288, and compared the efficacy to that of conventional RIT with the parental mAb 
hRS7 directly labeled with 177Lu. In pretargeting, the amount of the radiolabeled peptide 
that can be targeted to the tumor cells is limited. In mice with PC3 tumors the maximum 
dose of IMP288 that results in optimal tumor uptake is 0.1 nmol. Therefore, the amount 
of 177Lu activity that can be administrated is limited by the maximum specific activity 
of 177Lu-IMP288 (14 MBq/0.1 nmol). After the introduction of carrier-free 177Lu to the 
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market, it was possible to label 0.1 nmol of IMP288 with higher doses of 177Lu, up to 
41 MBq. However, mice tolerated even higher doses of 177Lu-IMP288. To determine 
the maximum therapeutic effect of the PRIT in mice with PC3 tumors, multiple cycles of 
TF12/177Lu-IMP288 were administered. The results of these PRIT studies showed that 
the growth of PC3 tumors could be inhibited significantly by repetitive cycles of PRIT.
In our studies we demonstrated the feasibility of pretargeting of prostate cancer using 
the radiolabeled humanized anti-TROP-2 monoclonal antibody (hRS7) or an anti-TROP-2 
bispecific monoclonal antibody (TF12) in combination with a radiolabeled hapten 
peptide (IMP288).
Future prospects
Schoffelen et al. demonstrated fast clearance of the bsAb TF2 from serum in a phase I 
clinical trial [5]. Of the injected bsAb, 86% was cleared within 6 h after injection, and 
99% within 24 h. This clearance rate is much higher than expected for such a large 
(168 kDa) protein. This may be caused by the lack of an Fc-part that is recognized 
by the neonatal Fc receptor (FcRn) , thus excluding the unique recirculation process for 
intact mAbs, responsible for the long circulation half life of IgG mAbs. Alternatively, 
the unexpectedly rapid clearance could be due to the limited stability of bsAbs in 
vivo: bsAbs manufactured by means of the Dock-and-Lock (DNL) method are based 
on disulfide bridges between the Fab fragments, that are prone to oxidation in vivo. 
However, Fab fragments have not been detected in blood samples after injection of 
bsAbs, although this could be due to the rapid clearance of the Fab fragments.
Furthermore, retention of the TF12/IMP288 complex in the tumor is limited: in mice 
of the radiolabeled IMP288 in the tumor is cleared from the tumor within 2 days. To 
optimize the efficacy of PRIT tumor retention of IMP288 should be further improved. 
Recently, Rossin et al. developed a novel method of pretargeting, making use of 
bioorthogonal chemistry revealing a covalent binding of the radiolabeled agent to 
the (TCO-modified) anti-tumor antibody [6]. Due to the covalent nature of the interaction 
between Ab and radiolabeled agent, tumor retention may be improved. Another 
possibility to enhance the efficacy of PRIT is the use of α-emitting radionuclides such 
as Astatine-211 (211At) and Bismuth-213 (213Bi), with high linear energy transfer (LET), 
allowing for effective delivery of radiation within short distance of the targeted lesions, 
preserving non-targeted tissues. The relatively short half-lives of these α-emitters (7.2 h 
and 45 min, respectively), matches with the tumor targeting kinetics of radiolabeled 
hapten-peptide [7].
Currently, several radiotracers based on PSMA are under clinical development. Due to 
its excellent expression in PC, that increases with increasing Gleason scores, PSMA is a 
very promising target for both PC imaging and treatment. In view of this, developing a 
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bsAb against PSMA would have clinical potential. Furthermore, dual modality imaging 
in combination with an IRDye, as demonstrated by Lütje et al. [8], may be of particular 
interest. While radionuclide imaging may allow pre-operative detection and intra-op-
erative localization of tumor lesions, near infrared fluorescense (NIRF) imaging would 
enable real time intra-operative visualization of tumor lesions.
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Summary
The aim of the studies described in this thesis was to investigate the potential of (pre)
targeted radioimmunoimaging and radioimmunotherapy of prostate cancer with a 
humanized anti-TROP-2 monoclonal antibody (hRS7) and an anti-TROP-2 x anti-HSG 
bispecific monoclonal antibody (TF12).
Chapter 1 gives an overview of current diagnostic and treatment options in patients with 
prostate cancer (PC), and explores the advantages and disadvantages of radionuclide 
imaging and therapeutic techniques that are currently developed. Different novel 
radionuclide imaging techniques, using radiolabeled metabolic tracers (11C/18F-flu-
orocholine, 11C-acetate), receptor-binding ligands (PSMA ligands, gastrin releasing 
peptide receptor ligands) and antibodies are reviewed. 
In Chapter 2 a review of the literature on conventional (US, CT, MRI) and radionuclide 
imaging (PET, SPECT) techniques of prostate cancer is presented. Sensitivity of 
18F-FDG-PET for imaging PC is limited, presumably due to low FDG avidity of most 
PC lesions. In addition, 18F-FDG is excreted mainly via the urinary tract, obscuring 
the prostate gland, and restricting the identification of lymph node metastases. Thus, 
18F-FDG uptake in PC cells is insufficient to enable clear visualization of PC lesions, 
leaving room for other radiotracers to be developed for staging and follow up of PC. 
The monoclonal antibody hRS7, a humanized antibody against TROP-2, an epithelial 
glycoprotein expressed in PC, was investigated. The studies described in Chapter 3 
show abundant expression of TROP-2 in human PC tumors and metastases, and in human 
PC3 tumors in mice. High and specific uptake of radiolabeled hRS7 in PC3 tumors was 
demonstrated in subcutaneous and intraprostatic mouse tumor models. Tumor-to-blood 
ratios increased with time, due to continuous accumulation of the radiolabeled hRS7 
in the tumor and clearance of the agent from the blood. PET imaging with 89Zr-labeled 
hRS7 clearly visualized the PC3 tumors in the mice with low background activity, 
especially at later time points (3-7 days after injection). The results of these studies 
indicated that hRS7 is a promising candidate for imaging of TROP-2 expressing tumors, 
and led to the development of a bispecific monoclonal antibody aimed at TROP-2 for 
pretargeted radionuclide imaging of PC.
TF12 is a trivalent bispecific monoclonal antibody (bsAb) composed of the anti-TROP-2 
Fab-fragments and one anti-histidinesuccinylglycine (HSG) hapten Fab-fragment, 
covalently linked via the Dock-and-Lock (DNL) technology. TF12 was developed to 
overcome the disadvantages associated with the use of radiolabeled mAbs, mainly 
related to their relatively long circulatory half-life. In pretargeting, a bispecific mAb 
(bsAb) aimed at both an epitope typically overexpressed on prostate cancer cells 
and a hapten peptide that does not naturally occur is injected intravenously. After 
several hours/days, when the unlabeled bsAb has accumulated in the tumor (and has 
cleared from the blood), the radiolabeled hapten peptide is injected. The radiolabeled 
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hapten peptide is bound by the bsAb in the tumor or is rapidly cleared from the 
circulation. In Chapter 4, the possible internalizing properties of the bsAb TF12 were 
investigated in vitro and in vivo, to determine whether its internalizing properties would 
limit its application in pretargeting. In theory internalization of a bsAb might hamper 
subsequent binding of the radiolabeled hapten peptide to the bsAb, since it is no 
longer available on the cell surface to trap the di-HSG substituted peptide IMP288. 
We showed that TF12 indeed was slowly internalized by the target cell after binding 
to the TROP-2 antigen, but a substantial fraction remained accessible on the tumor cell 
surface. Approximately 60% of the TF12 remained available at the cell membrane after 
24 h, leaving sufficient amounts of TF12 available to capture the hapten peptide. In 
vivo studies showed excellent tumor uptake of the 111In-labeled hapten peptide IMP288.
In the studies described in Chapter 5, the dose of the pretargeting agent TF12 and 
the hapten peptide IMP288 were optimized in a nude mouse human tumor model. In 
addition, the effect of the length of the time interval between administration of the two 
agents on tumor targeting was studied in detail. The optimal interval between TF12 
and IMP288 was determined to be 16 h, while the optimal dose of TF12 was 2.5 
nmol (462 µg) and 0.1 mmol (160 ng) for IMP288. Under these optimized conditions, 
the characteristics of TF12 in combination with radiolabeled IMP288 and its potential 
for pretargeted radioimmunoimaging and radioimmunotherapy were assessed. After 
pretargeting with TF12, 111In-IMP288 showed high accumulation in s.c. PC3 tumors 
(20.4 ± 0.6% ID/g) as early as 2 h after injection, with low activity in normal organs. 
The organs with the highest uptake of 111In-IMP288 were the kidneys (2.2 ± 0.1% 
ID/g), due to the renal excretion of the radiolabeled peptide. Blood levels were low 
(0.9 ± 0.2% ID/g), indicating rapid clearance of the unbound hapten peptide from the 
blood. Pretargeted immunoPET with TF12 and 68Ga-labeled IMP288 rapidly visualized 
the PC3 tumors in the same mouse model, indicating this may be an efficient imaging 
method for PC. Pretargeted radioimmunotherapy (PRIT) with TF12 and 177Lu-IMP288 
showed a significant increase in survival, when compared to groups of mice that 
were injected with either PBS or 177Lu-IMP288 without TF12. Mice that were treated 
with conventional radioimmunotherapy (RIT) with 177Lu-hRS7 showed a significantly 
better survival, although these mice showed more hematological toxicity. Because PRIT 
was not given at the maximum tolerated dose and hematological and renal toxicity 
were absent, there was room for improvement of this therapy by further increasing the 
radioactivity dose.
The potential for imaging small metastatic prostate cancer lesions with pretargeted 
immunoPET was assessed in Chapter 6. In mice with intraperitoneally-growing PC3 
tumors, pretargeted immunoPET was performed with TF12 and 68Ga-IMP288, using 
18F-FDG PET as a reference. Tumors as small as 5 mm3 could be clearly visualized after 
pretargeting with high tumor-to-blood ratios of 68Ga-IMP288 (8.4 ± 3.8). Tumor-to-
blood ratios for 18F-FDG were significantly lower (4.1 ± 3.4), together with decreased 
tumor visualization due to physiologic 18F-FDG uptake in the intestines. 
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In Chapter 7, the potential of PRIT for the treatment of prostate cancer was further 
explored in mice with s.c. PC3 tumors. PRIT with one, two or three cycles of TF12/177Lu-
IMP288, using a high activity dose (41 MBq/mouse/cycle), was compared to RIT 
with directly labeled 177Lu-hRS7 (11 MBq). Three cycles of PRIT significantly improved 
survival compared to one or two cycles of PRIT, but was accompanied with significantly 
more hematological toxicity. This toxicity was similar to the hematological toxicity seen 
in RIT with 177Lu-hRS7; RIT was at least as effective as 3 cycles of PRIT. 
The studies described in this thesis show potential for the use of pretargeting for imaging 
and therapy of prostate cancer. Clinical studies are indicated to determine the value of 
pretargeted immunoPET of prostate cancer in patients.
Summary
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Samenvatting
In dit proefschrift worden studies beschreven waarin de mogelijkheden worden 
onderzocht van (pre)targeted radioimmunoimaging en radioimmunotherapie van pros-
taatkanker, met behulp van een anti-TROP-2 monoklonaal antilichaam, hRS7, en een 
anti-TROP-2 x anti-HSG bispecifiek monoclonaal antilichaam, TF12.
In Hoofdstuk 1 wordt een overzicht gegeven van de huidige diagnostiek en behandeling 
van patiënten met prostaatkanker. Daarnaast worden de mogelijkheden, voordelen en 
nadelen van imaging en therapie met behulp van nieuw ontwikkelde, radioactieve 
tracers behandeld. Verschillende radiofarmaca die in klinisch onderzoek en in de 
klinische praktijk worden toegepast, zoals radioactieve metabole tracers (11C/18F-fluo-
rocholine, 11C-acetaat), receptor bindende liganden (PSMA liganden, bombesine-ana-
loga) en antilichamen worden besproken.
Hoofdstuk 2 bevat een overzicht van de literatuur van conventionele imaging technieken 
bij prostaatkanker (echografie, CT, MRI) en imaging met behulp van radiotracers (PET, 
SPECT). De sensitiviteit van 18F-FDG-PET, een veelgebruikte techniek in de oncologische 
diagnostiek, in patiënten met prostaatkanker is beperkt. Dit wordt veroorzaakt doordat 
de meeste prostaattumoren en met name lymfekliermetastasen slechts een geringe 18F-
FDG-opname vertonen. Daarnaast wordt 18F-FDG voornamelijk uitgescheiden via de 
nieren, waardoor tumoren in de urogenitale zone minder goed afgebeeld worden. 
Daarom is er een grote behoefte aan betere radiofarmaca voor met name stadiëring 
en follow-up van patiënten met prostaatkanker.
In Hoofdstuk 3 wordt het gehumaniseerde monoklonale antilichaam hRS7 onderzocht, 
dat gericht is tegen TROP-2, een geglycosyleerd transmembraan eiwit. De studies 
beschreven in dit hoofdstuk tonen een goede expressie van TROP-2 in zowel primaire 
humane prostaattumoren als in metastasen. TROP-2 komt ook tot expressie in de 
experimentele PC3 tumor die in naakte muizen getransplanteerd kan worden. Hoge 
en specifieke opname van radioactief gelabeld hRS7 in PC3 tumoren werd gevonden 
in zowel subcutane als orthotope PC3 tumoren in immunodeficiënte muizen. Doordat 
het gelabelde antilichaam efficiënt in de PC3 tumoren accumuleerde en langzaam 
klaarde uit het bloed en de normale weefsels, konden de tumoren na 3-7 dagen 
duidelijk worden afgebeeld met PET met 89Zr-gelabeled hRS7 als tracer. De resultaten 
van deze studies laten zien dat radioactief gelabeld hRS7 een veelbelovende tracer is 
voor de imaging van tumoren die TROP-2 tot expressie brengen.
Echter, het gebruik van intacte monoklonale antilichamen voor imaging heeft een 
aantal nadelen, die voornamelijk worden veroorzaakt door de lange halfwaardetijd 
van IgG antilichamen in het bloed. Daarom is een bispecifiek antilichaam ontwikkeld 
dat eveneens gericht is tegen TROP-2, voor pretargeted imaging van prostaatkanker. 
Dit antilichaam, TF12, bestaat uit twee anti-TROP-2 Fab-fragmenten en één anti-histi-
dinesuccinylglycine (HSG) hapteen Fab-fragment, die covalent aan elkaar gebonden 
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zijn middels de Dock-and-Lock (DNL) technologie. Bij pretargeting wordt eerst het 
bispecifieke antilichaam, gericht tegen zowel het target op de tumorcellen als tegen 
een hapteen-peptide , intraveneus geïnjecteerd. Nadat het niet-gelabelde bispecifieke 
antilichaam zich heeft opgehoopt in de tumor en het niet-gebonden deel uit het bloed 
is geklaard, wordt het bijbehorende, radioactief gelabelde hapteen-peptide (IMP288) 
intraveneus toegediend. Dit hapteen-peptide wordt vervolgens gebonden door het 
bispecifieke antilichaam op de tumorcellen, of snel uitgescheiden via de nieren. 
In Hoofdstuk 4 wordt de internalisatie van het bispecifieke antilichaam TF12 door 
prostaatkankercellen zowel in vitro als in vivo onderzocht, om te bepalen of deze 
eventuele internalisatie gebruik van TF12 bij pretargeting in de weg staat. In feite kan 
binding van het hapteen-peptide aan het bispecifieke antilichaam alleen plaatsvinden 
zolang het TF12 nog niet door de tumorcel is geïnternaliseerd. De internalisatie studies 
lieten zien dat TF12 inderdaad langzaam wordt geïnternaliseerd door de tumorcellen 
na binding aan TROP-2, maar dat een substantieel deel beschikbaar blijft op de 
celmembraan. Na 24 uur is nog ongeveer 60% van het TF12 beschikbaar op het 
celoppervlak, wat voldoende is voor binding van het hapteen-peptide. De in vivo 
studies lieten uitstekende accumulatie van het 111In-gelabelde hapteen-peptide in de 
tumor zien, wat bevestigt dat het langzaam internaliserende TF12 gebruikt kan worden 
voor pretargeting van prostaatkankercellen.
In de studies die zijn beschreven in Hoofdstuk 5, werden de optimale doses van het 
bispecifieke antilichaam TF12 en het hapteen peptide IMP288 voor pretargeting in 
muizen met subcutane PC3 tumoren bepaald. Verder werd het effect van de tijd tussen 
toediening van TF12 en het IMP288 op de tumor targeting in detail bestudeerd. Het 
optimale interval tussen toediening van TF12 en het IMP288 bleek 16 uur, de optimale 
dosering was 2.5 nmol (462 µg) TF12 and 0.1 mmol (160 ng) IMP288. Onder deze 
optimale omstandigheden werd de pretargeted imaging van de PC3 tumoren in muizen 
met TF12 en gelabeld IMP288 uitgevoerd. Na pretargeting met 2.5 nmol TF12 werd 
2 uur na intraveneuze injectie van 111In-IMP288 een hoge concentratie in subcutane 
PC3 tumoren gemeten (20.4 ± 0.6% ID/g), met zeer lage achtergrondactiviteit in 
de normale organen: de activiteit in het bloed was laag (0.9 ± 0.2% ID/g) en de 
hoogste concentratie werd gemeten in de nieren (2.2 ± 0.1% ID/g). Met pretargeted 
immunoPET met TF12 en 68Ga-gelabeld IMP288 kon de PC3 tumor duidelijk worden 
afgebeeld. Pretargeted radioimmunotherapie (PRIT) met TF12 en 177Lu-IMP288 bleek 
de groei van de PC3 tumoren significant te remmen. Bij muizen die werden behandeld 
met behulp van conventionele radioimmunotherapie (RIT) met 177Lu-gelabeld hRS7 werd 
de groei van de tumoren ook significant geremd, maar dat ging gepaard met hema-
tologische toxiciteit (daling van het aantal leukocyten in het bloed). In de muizen kon 
PRIT niet worden uitgevoerd op het maximale 177Lu-IMP288 dosisniveau. Er werd nog 
geen hematologische en renale toxiciteit gezien, en dus was er ruimte om PRIT verder 
te verbeteren.
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In Hoofdstuk 6 is een studie beschreven waarin is onderzocht of kleine intraperitoneale 
prostaat tumoren met behulp van pretargeted immunoPET konden worden afgebeeld. 
In muizen met intraperitoneaal groeiende PC3 tumoren werd pretargeted immunoPET 
met TF12 en 68Ga-IMP288 onderzocht, waarbij 18F-FDG PET als referentie methode 
werd toegepast. Zeer kleine tumoren vanaf 5 mm3 konden duidelijk afgebeeld worden 
met pretargeted immunoPET, met hoge tumor-bloed ratio’s van het 68Ga-IMP288 (8.4 
± 3.8). De tumor-bloed ratio’s met 18F-FDG PET waren significant lager (4.1 ± 3.4).
In Hoofdstuk 7 wordt een studie beschreven waarin de mogelijkheden van PRIT voor de 
behandeling van prostaatkanker verder onderzocht zijn in muizen met een subcutane 
PC3 tumor. PRIT met één, twee of drie cycli TF12/177Lu-IMP288 (41 MBq/muis/
cyclus) werd vergeleken met RIT met direct gelabeld 177Lu-hRS7. Drie cycli PRIT gaf 
een significant betere overleving dan één of twee cycli. Na drie cycli werd echter wel 
meer hematologische toxiciteit gezien. Deze toxiciteit was vergelijkbaar met die van 
177Lu-hRS7; één cyclus RIT was minstens zo effectief als drie cycli PRIT. 
De studies beschreven in dit proefschrift tonen de mogelijkheden voor (pre)targeted 
imaging en therapie van prostaatkanker. Studies in patiënten zullen de waarde van 
pretargeted immunoPET moeten uitwijzen.
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Dankwoord
Geachte prof. dr. Boerman, beste Otto, met wie zou ik dit dankwoord anders kunnen 
en willen starten dan met jou? Ik wil je danken voor al je steun; door je inspirerende 
begeleiding, hartelijkheid, humor en bijzonder indrukwekkende wetenschappelijke 
inbreng heb ik dit proefschrift kunnen volbrengen. En ik ken maar weinig mensen die 
in snelheid van beantwoorden van e-mails regelmatig de automatische beantwoording 
van Outlook verslaan… Daarnaast ben ik zeer onder de indruk van je vermogen om 
van “rol” te wisselen, van promotor naar collega en weer terug. Ik hoop nog lang met 
je te mogen samenwerken.
Geachte prof. dr. Oyen, beste Wim, dank voor je steun deze jaren, je suggesties, je 
fenomenale brede kennis en op zijn tijd een klein schouderklopje zijn me zeer tot steun 
geweest. 
Beste Remco, aan jou ook een bijzonder woord van dank. Je onvoorwaardelijke 
geloof in de goede afloop van dit proefschrift en je volle vertrouwen zijn voor mij een 
belangrijke factor geweest voor de mogelijkheid dit proefschrift te schrijven en tevens 
voor het plezier dat ik heb in mijn ‘gewone’ werk. Daarnaast heb ik veel van je geleerd 
de afgelopen jaren, van je manier van out-of-the-box denken en van je visie op de 
farmaceutische zorg. Ik ben ervan overtuigd dat deze daadwerkelijk een verschil kan 
gaan maken voor de individuele patiënt.
Graag wil ik de leden van de manuscriptcommissie, prof. dr. Peter Mulders, prof. dr. 
Harry Hendrikse en prof. dr. Winald Gerritsen, bedanken voor het beoordelen van de 
wetenschappelijke waarde van dit proefschrift.
Mijn paranimfen, Cathelijne, Marieke en Tinka. 
Cathelijne, lieve, betrouwbare, hardwerkende steun-en-toeverlaat, jij weet beter dan 
wie dan ook dat dit proefschrift zonder jou nooit tot stand was gekomen. Niets was je 
teveel om de studies tot een goed einde te helpen brengen, zelfs voor middernachte-
lijke activiteiten op het dierenlab draaide jij je hand niet om. En dan ben je daarnaast 
ook nog een ontzettend fijn mens! Met veel plezier en respect kijk ik terug op onze 
samenwerking, heel veel dank. 
Tinka, lieve, eindeloos betrouwbare, intelligente, gezellige vriendin, wat heerlijk dat 
ik al zo lang zoveel met jou mag delen. Ik hoop nog lang regelmatig een glaasje 
bubbels met je te mogen heffen op alle goede dingen in het leven, te beginnen met het 
vervolmaken van dit proefschrift! Cheers!
Lieve Marieke, lieve Colleegaa , wat heb ik toch een respect voor jou. Ik ken 
niemand die zo’n ongelofelijke doorzetter is als jij. Jij geeft nooit op, werkt harder dan 
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eigenlijk mogelijk is en probeert daarnaast ook nog anderen te steunen. Dank voor je 
interesse, ontelbare fijne telefoongesprekken en onvoorwaardelijke vriendschap. De 
Kwakel – Groningen is gelukkig helemaal niet zo ver!
Bianca, Henk, Iris en Kitty, heel veel dank voor jullie onmisbare hulp in PRIME! Dankzij 
jullie goede en professionele ondersteuning is het mogelijk geweest deze onderzoeken 
uit te voeren. Jullie zijn het levende bewijs dat diepe liefde voor dieren en dierexperi-
menteel onderzoek samen kunnen gaan, sterker nog, niet zonder elkaar kunnen. Een 
bijzonder woord van dank voor Bianca, ook jij was altijd bereid om op de meest 
onmogelijke tijdstippen naar PRIME te komen. Heel veel dank! 
A special thanks to our colleagues from Immunomedics (New Jersey, USA), who 
provided the antibodies and peptide and therefore made this research possible.
Janine, lieve collega, wat leer ik toch veel van je! Je bent echt een kei in je vak en ook 
nog een enorm gezellig kamergenootje. Dank voor al die jaren delen van lief-en-leed, 
ik hoop nog lang met je te mogen samenwerken. 
Jolande, voor jou uiteraard ook een bijzonder woord van dank. Al jaren werken we 
samen op het domein van de radiofarmacie en ik vind het geweldig om te zien hoe jij 
je hierin hebt ontwikkeld. Je enthousiasme is aanstekelijk en het is een fijn gevoel om 
met een gerust hart afwezig te kunnen zijn als jij er bent. Ik hoop ooit zo relaxed in het 
leven te kunnen staan als jij…
Lieve collega’s van de Apotheek, Martijn, Marjolein, Nicole, Dirk, Karin, Monique, 
Anna, collega-(ziekenhuis)apothekers, collega’s van het lab, collega’s van bereidingen, 
collega’s van de CTU, collega’s van de Vakgroep, collega’s van het secretariaat en 
van logistiek/magazijn… wat zijn we inmiddels groot geworden! Jullie maken het, 
naast uiteraard het uitdagende werk zelf, voor mij meer dan de moeite waard iedere 
keer naar Nijmegen te komen. Dank voor jullie collegialiteit!
Rian, Peter en Maichel, dank voor jullie eeuwige optimisme en de fijne samenwerking. 
Dankzij jullie inzet (en uiteraard die van ons hele team), is het mogelijk radiofarmaca 
die in ons eigen lab zijn ontwikkeld, geschikt te maken om toe te passen in klinisch 
onderzoek en in de klinische praktijk. From Mouse to Man. Fantastisch!
Michel, Sandra, Danny, Gerben, Janneke, Wim en Natascha, fijne collega’s, jullie 
zijn de “stille kracht” op de afdeling. Jullie treden niet vaak op de voorgrond, maar 
zijn wel de basis van de activiteiten die we dagelijks uitvoeren. Dank voor de fijne 
samenwerking.
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Alle collega’s van Radiologie en Nucleaire Geneeskunde, laboranten, AIOS, nucleair 
geneeskundigen, onderzoekers, research analisten, secretariaat, dank voor de fijne 
samenwerking en jullie oprechte interesse in dit onderzoek.
Beste Eric Franssen, zonder jou zou ik wellicht nooit in de radiofarmacie zijn beland. 
Dankzij je aanstekelijke enthousiasme als opleider radiofarmacie ben ik me voor dit 
fantastische en uitdagende vakgebied gaan interesseren en zie waartoe dat heeft 
geleid!
Marinke, Vivienne, Tinka, Nanda, Willemijn, Daphne en Saskia, kortom: jaarclub 
Tiramisu. Sinds 1994 zijn we bij elkaar en hebben nog steeds zoveel pret samen! Op 
naar de volgende 20 jaar, en de daarop volgende, en de daarop volgende… 
Lieve Mirella, wat hebben we al veel meegemaakt samen! Dank voor je vriendschap, 
en vooral ook voor je heerlijk relativerende gevoel voor humor!
Edward, Astrid, Dennis, Marc, Maykel, Ingrid, lieve vrienden, jullie zijn er altijd. Dat is 
makkelijk op te schrijven, maar betekent voor mij meer dan woorden kunnen uitdrukken. 
Jullie zijn geweldig, en zo gezellig, dank!
Lieve Hennie, voor jou ook graag een bijzonder woord van dank. Je hebt vast geen 
idee hoe inspirerend jouw levensvisie kan zijn voor anderen, graag maak ik van 
deze gelegenheid gebruik om je te laten weten hoeveel bewondering ik heb voor je 
benadering van het leven. Ik wens je alle goeds.
Lieve Martine, ook jij hebt zoveel geholpen de laatste jaren, zodat ik ruimte had om 
aan dit proefschrift te werken. Onze rots in de branding, dankjewel voor alles!
Lieve Oma, voor u uiteraard ook een bijzonder woord van dank. WOII heeft u veel 
kansen ontnomen, maar dit heeft u nooit uit het veld doen slaan. Integendeel, u heeft 
dit aangegrepen om mij en mijn broertje altijd van het belang van doorzetten te 
doordringen. Dank voor uw geloof en vertrouwen in ons.
Lieve schoonouders, Rick, Corinne, Yara en Finn. Wat heb ik het getroffen met zo’n 
fijne schoonfamilie! Veel dank ook voor alle steun bij de opvang van onze meisjes om 
tijd te kunnen maken voor dit proefschrift.
Lieve Mark, Nicole en Alexander, onze wereldreizigers. Schotland, Engeland en nu 
Australië… what’s next? Uit het oog betekent zeker niet uit het hart, we komen graag 
langs!
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Lieve pap en mam, wat een heerlijk gevoel te weten dat jullie altijd achter me staan en 
me altijd steunen. Het is fijn om jullie na een lange dag te kunnen spreken als ik weer 
eens in de auto zit en het is fantastisch om te zien wat een lieve opa en oma jullie zijn 
voor onze meisjes. Dank! 
Lieve Marc, je bent er altijd voor me. Rotsvast, lief, sterk, humoristisch en een 
ongelofelijk lieve papa voor onze meisjes… wat hebben we het goed samen. Ons 
leven is één grote chaotische puzzel en toch weten we het elke keer weer samen te 
redden. Misschien komt er nu weer wat rust en wordt de puzzel eenvoudiger… of 
misschien ook niet !
Lieve Dana, lieve Suus, mijn kleine vrolijke vrouwtjes, jullie maken elke dag mooier en 
elk moment intenser. Jullie zijn mijn alles.
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inflammatie bij Reflex Sympatische Dystrofie en heeft zij een HPLC methode opgezet 
voor het analyseren van midazolam glucuronides in bloed. In haar laatste studiejaar 
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